0001144204-13-007330.txt : 20130211 0001144204-13-007330.hdr.sgml : 20130211 20130211140830 ACCESSION NUMBER: 0001144204-13-007330 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20121231 FILED AS OF DATE: 20130211 DATE AS OF CHANGE: 20130211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALLIED HEALTHCARE PRODUCTS INC CENTRAL INDEX KEY: 0000874710 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 231370721 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19266 FILM NUMBER: 13590783 BUSINESS ADDRESS: STREET 1: 1720 SUBLETTE AVE CITY: ST LOUIS STATE: MO ZIP: 63110 BUSINESS PHONE: 3147712400 MAIL ADDRESS: STREET 1: 1720 SUBLETTE AVENUE CITY: ST LOUIS STATE: MO ZIP: 63110 10-Q 1 v332497_10q.htm 10-Q

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

xQuarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the quarterly period ended December 31, 2012

 

¨Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

For the transition period from________ to ________

 

Commission File Number: 0-19266

 

ALLIED HEALTHCARE PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware   25-1370721
(State or other jurisdiction of   (I.R.S. Employer
Incorporation or organization)   Identification No.)

 

1720 Sublette Avenue, St. Louis, Missouri 63110

(Address of principal executive offices, including zip code)

 

(314) 771-2400

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter periods that the registrant was required to file such reports, and (2) has been subject to such filing requirements for the past ninety days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer,” “accelerated filer" and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated filer ¨
       
Non-accelerated filer ¨ (Do not check if smaller reporting company) Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

 

The number of shares of common stock outstanding at January 31, 2013 is 8,030,247 shares.

 

 
 

 

INDEX

 

        Page
        Number
Part I – Financial Information     
  Item 1. Financial Statements    
    Statement of Operations -    
    Three and six months ended December 31,    
    2012 and 2011 (Unaudited)   3
         
    Balance Sheet -    
    December 31, 2012 (Unaudited) and    
    June 30, 2012   4 - 5
         
    Statement of Cash Flows -    
    Six months ended December 31, 2012 and 2011    
    (Unaudited)   6
         
    Notes to Financial Statements   7 – 11
         
  Item 2. Management’s Discussion and Analysis of    
    Financial Condition and Results of Operations   11 – 16
         
  Item 3. Quantitative and Qualitative Disclosure    
    about Market Risk   16
         
  Item 4. Controls and Procedures   16
         
Part II - Other Information    
         
  Item 1. Legal Proceedings   16-17
         
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   17
         
  Item 6. Exhibits   18
         
    Signature   19

 

SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

Statements contained in this Report, which are not historical facts or information, are "forward-looking statements." Words such as "believe," "expect," "intend," "will," "should," and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, which could cause the outcome and future results of operations, and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for economic factors affecting the delivery of health care services, impacts of the U.S. Affordable Care Act, such as the expected impact on the Company of the excise tax commencing in 2013 on the sale of certain medical devices and specific matters which relate directly to the Company's operations and properties as discussed in the Company’s annual report on Form 10-K for the year ended June 30, 2012. The Company cautions that any forward-looking statements contained in this report reflect only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.

 

2
 

 

PART I.     FINANCIAL INFORMATION

 

Item 1.     Financial Statements

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF OPERATIONS

(UNAUDITED)

  

   Three months ended   Six months ended 
   December 31,   December 31, 
   2012   2011   2012   2011 
                 
Net sales  $9,921,422   $10,681,395   $19,208,513   $22,076,403 
Cost of sales   7,815,489    7,946,458    15,123,605    16,935,449 
Gross profit   2,105,933    2,734,937    4,084,908    5,140,954 
                     
Selling, general and                    
administrative expenses   2,857,065    2,693,894    5,495,640    5,327,983 
Income (loss) from operations   (751,132)   41,043    (1,410,732)   (187,029)
                     
Other (income) expenses:                    
Interest income   (2,821)   (7,297)   (7,047)   (16,292)
Interest expense   -    -    -    336 
Other, net   7,645    11,743    15,226    26,149 
    4,824    4,446    8,179    10,193 
                     
Income (loss) before provision for (benefit from) income taxes   (755,956)   36,597    (1,418,911)   (197,222)
Provision for (benefit from) income taxes   (287,263)   13,907    (539,186)   (74,944)
Net income (loss)  $(468,693)  $22,690   $(879,725)  $(122,278)
                     
Basic earnings (loss) per share  $(0.06)  $0.00   $(0.11)  $(0.02)
                     
Diluted earnings (loss) per share  $(0.06)  $0.00   $(0.11)  $(0.02)
                     
Weighted average shares                    
outstanding - basic   8,100,593    8,124,386    8,112,490    8,124,386 
                     
Weighted average shares                    
outstanding - diluted   8,100,593    8,124,834    8,112,490    8,124,386 

 

See accompanying Notes to Financial Statements.

 

3
 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

ASSETS

 

   (Unaudited)     
   December 31,   June 30, 
   2012   2012 
         
Current assets:          
Cash and cash equivalents  $4,586,331   $5,284,543 
Accounts receivable, net of allowances          
of $300,000   3,551,587    4,843,593 
Inventories, net   10,049,584    10,001,226 
Income tax receivable   583,706    46,042 
Other current assets   590,082    400,677 
           
Total current assets   19,361,290    20,576,081 
           
Property, plant and equipment, net   9,628,935    9,603,556 
Other assets, net   1,137,908    1,167,432 
           
Total assets  $30,128,133   $31,347,069 

 

See accompanying Notes to Financial Statements.

 

(CONTINUED)

 

4
 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

(CONTINUED)

LIABILITIES AND STOCKHOLDERS' EQUITY

 

   (Unaudited)     
   December 31,   June 30, 
   2012   2012 
         
Current liabilities:          
Accounts payable  $1,693,881   $1,797,144 
Other accrued liabilities   1,961,826    1,855,579 
Deferred income taxes   793,990    802,961 
Deferred revenue   -    114,700 
Total current liabilities   4,449,697    4,570,384 
           
Commitments and contingencies          
           
Stockholders' equity:          
Preferred stock; $0.01 par value; 1,500,000 shares          
authorized; no shares issued and outstanding   -    - 
Series A preferred stock; $0.01 par value; 200,000 shares          
authorized; no shares issued and outstanding   -    - 
Common stock; $0.01 par value; 30,000,000 shares          
authorized; 10,427,878 shares issued at December 31,          
2012 and June 30, 2012; 8,030,247 and 8,124,386 shares          
outstanding at December 31, 2012 and June 30, 2012, respectively   104,279    104,279 
Additional paid-in capital   48,563,230    48,540,802 
Accumulated deficit   (2,016,693)   (1,136,968)
Less treasury stock, at cost; 2,397,631 and 2,303,492 shares at          
December 31, 2012 and June 30, 2012, respectively   (20,972,380)   (20,731,428)
Total stockholders' equity   25,678,436    26,776,685 
Total liabilities and stockholders' equity  $30,128,133   $31,347,069 

 

See accompanying Notes to Financial Statements.

 

5
 

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF CASH FLOWS

(UNAUDITED)

 

   Six months ended 
   December 31, 
   2012   2011 
         
Cash flows from operating activities:          
Net loss  $(879,725)  $(122,278)
Adjustments to reconcile net loss to net          
cash provided by operating activities:          
           
Depreciation and amortization   650,379    627,378 
Stock based compensation   22,428    21,695 
Provision for doubtful accounts and sales          
returns and allowances   17,054    17,030 
Deferred taxes   (8,971)   (8,678)
           
Changes in operating assets and liabilities:          
Accounts receivable   1,274,952    1,138,044 
Inventories   (48,358)   (519,444)
Income tax receivable   (537,664)   (73,929)
Other current assets   (189,405)   (290,234)
Accounts payable   (103,263)   383,071 
Deferred revenue   (114,700)   (344,100)
Other accrued liabilities   106,246    (177,084)
Net cash provided by operating activities   188,973    651,471 
           
Cash flows from investing activities:          
Capital expenditures   (646,233)   (912,994)
Net cash used in investing activities   (646,233)   (912,994)
           
Cash flows from financing activities:          
Purchases of treasury stock   (240,952)   - 
Net cash used in financing activities   (240,952)   - 
           
Net increase (decrease) in cash and cash equivalents   (698,212)   (261,523)
Cash and cash equivalents at beginning of period   5,284,543    6,512,887 
Cash and cash equivalents at end of period  $4,586,331   $6,251,364 

 

See accompanying Notes to Financial Statements.

 

6
 

 

ALLIED HEALTHCARE PRODUCTS, INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

1. Summary of Significant Accounting and Reporting Policies

 

Basis of Presentation

 

The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2012.

 

Recently Issued Accounting Pronouncements

 

We have reviewed accounting pronouncements and interpretations thereof issued by the FASB, AICPA and the SEC that have effective dates during the periods reported and in future periods. Management does not believe that any of those pronouncements will have a material impact on the Company’s present or future financial statements.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.

 

2. Inventories

 

Inventories are comprised as follows:

 

   December 31, 2012   June 30, 2012 
         
Work-in progress  $689,645   $654,677 
Component parts   7,799,890    7,495,333 
Finished goods   2,849,782    3,178,507 
Reserve for obsolete and excess inventory   (1,289,733)   (1,327,291)
   $10,049,584   $10,001,226 

 

7
 

 

3. Earnings per share

 

Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,386, respectively. The number of diluted shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,834, respectively. The number of basic shares outstanding for the six months ended December 31, 2012 and 2011 was 8,112,490 and 8,124,386, respectively. The number of diluted shares outstanding for the six months ended December 31, 2012 and 2011 was 8,112,490 and 8,124,386, respectively.

 

4. Commitments and Contingencies

 

Legal Claims

 

The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.

 

The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient and that it is not reasonably possible at this time that any additional liabilities will result from the resolution of these matters that would have a material adverse effect on the Company’s results of operations, financial position, or cash flows.

 

Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”) and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara’s claims. Among other things, Niagara seeks approximately $469,000, which it alleges represents the value of electricity provided prior to the commencement of litigation going back to 2003. The Company has posted a $250,000 bond which Niagara could draw against for electricity provided and not collected since the December 2010 temporary restraining order in the event Niagara prevails in its lawsuit. The amount of the bond exceeds the cumulative invoiced electricity charges generated by Niagara since the issuance of the temporary restraining order. As of December 31, 2012, the Company has not recorded a provision for this matter as management intends to vigorously defend this litigation and believes it is not probable that the Company will be required to pay for electricity as Niagara claims. The Company believes, however, that any liability it may incur should it not prevail in the litigation would not have a material adverse effect on its financial condition, its result of operations, or its cash flows.

 

8
 

 

Employment Contract

 

In March 2007, the Company entered into a three year employment contract with its chief executive officer. The contract is subject to annual renewals after the initial term. The contract was amended and restated in December 2009 without extending its term. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.

 

5. Financing

 

The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”) pursuant to which the Company obtained a secured revolving credit facility with borrowing availability of up to $7,500,000 (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.

 

The Credit Facility was amended on November 12, 2012 extending the maturity date to November 12, 2013, reducing the borrowing availability from $7,500,000 to $5,000,000, and removing all financial covenants. The Credit Facility will be available on a revolving basis until it expires on November 12, 2013, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 3.50% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.

 

9
 

 

Under the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.

 

The 30-day LIBOR rate was 0.21% on December 31, 2012.

 

At December 31, 2012 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.

 

6. Baralyme® Agreement

 

A reconciliation of deferred revenue resulting from the agreement with Abbott Laboratories (“Abbott”), with the amounts received under the agreement, and amounts recognized as net sales is as follows:

 

   Three Months ended   Six Months ended 
   December 31,   December 31, 
   2012   2011   2012   2011 
                 
Beginning balance  $-   $630,850   $114,700   $802,900 
                     
Revenue recognized                    
as net sales   0    (172,050)   (114,700)   (344,100)
    0    458,800    0    458,800 
Less - Current portion                    
of deferred revenue   0    (458,800)   0    (458,800)
   $0   $0   $0   $0 

 

10
 

 

In addition to the provisions of the agreement relating to the withdrawal of the Baralyme® product, Abbott agreed to pay Allied up to $2,150,000 in product development costs to pursue development of a new carbon dioxide absorption product for use in connection with inhalation anesthetics that does not contain potassium hydroxide and does not produce a significant exothermic reaction with currently available inhalation agents. As of December 31, 2012, $2,150,000 has been received as a result of product development activities.

 

7. Share Repurchases

 

On November 21, 2012 the Company’s Board of Directors approved the purchase of up to 100,000 shares of the Company’s common stock. This authority terminates on February 19th, 2013. Pursuant to this authorization, the Company repurchased 94,139 shares of stock at an average price of $2.54 for an aggregate total purchase price of $240,952.

 

8. Subsequent Events

 

The Company’s product liability insurer, Medmarc Insurance Group, demutualized and was acquired by ProAssurance Corporation on January 1, 2013. As a policyholder of a mutual insurance company, Allied was entitled to receive a portion of the proceeds received by Medmarc. In January 2013 the Company received a cash payment of approximately $516,000 and will reflect a gain of this amount in the quarter ended March 31, 2013.

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Medical Device Excise Tax

 

Under the Health Care Education Reconciliation Act of 2010, beginning on January 1, 2013, a Medical Device Excise Tax (“MDET”) will be imposed on all U.S. sales of certain medical devices. The tax is 2.3% of the selling price of the taxable product, subject to certain exceptions. The MDET will represent an additional cost burden on the Company’s operations. If the excise tax were applied to 2012 revenues, it would have reduced net profits by approximately $200,000, reducing earnings per share by approximately 2 cents per share. The Company intends to mitigate the effect of the MDET through a combination of anticipated increases in market prices, by improving operational efficiency, and the increased access to healthcare anticipated by the Act. However, the Company does not have any assurance that these strategies will be successful in entirely offsetting the cost of the MDET.

 

11
 

 

Results of Operations

 

Three months ended December 31, 2012 compared to three months ended December 31, 2011

 

Allied had net sales of $9.9 million for the three months ended December 31, 2012, down $0.8 million from net sales of $10.7 million in the prior year same quarter. Domestic sales were down 18.0% while international sales, which represented 31.2% of second quarter sales, were up 31.6% from the prior year same quarter.

 

Sales for the three months ended December 31, 2012 and 2011 included $0, and $172,050 respectively for the recognition of income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Income from the agreement was recognized at $57,350 per month until the expiration of the agreement in August 2012. Allied continues to sell Carbolime®, a carbon dioxide absorbent with a different formulation than Baralyme®, as well as Litholyme®, a new premium carbon dioxide absorbent. The Company ceased the sale of Baralyme® on August 27, 2004.

 

Orders for the Company’s products for the three months ended December 31, 2012 of $9.3 million were $0.2 million or 2.1% lower than orders for the prior year same quarter of $9.5 million. Domestic orders are down 3.8% over the prior year same quarter while international orders, which represented 26.7% of second quarter orders, were 3.3% higher than orders for the prior year same quarter. The decrease in domestic orders during the three months ended December 31, 2012 was primarily for items for the construction market. The Company does not believe that this indicates a decrease in aggregate market demand. The Company has improved its systems and processes to be more effective in this market. The Company also continues to believe that the purchase of equipment and durable goods and the purchase of equipment by hospitals and municipalities have been cut to meet budgets and conserve cash due to the slow recovery of the economy since the recession in 2008. Orders and sales remain below pre-recession levels.

 

Gross profit for the three months ended December 31, 2012 was $2.1 million, or 21.2% of net sales, compared to $2.7 million, or 25.2% of net sales, for the three months ended December 31, 2011. The $0.6 million reduction in gross profit is primarily attributable to the decrease in sales and production. Gross profit, as a percentage of sales, was negatively impacted by the $172,050 reduction in payments resulting from the Abbott agreement recognized in sales and income. In addition, lower sales have led to lower utilization of fixed expenses in the Company’s manufacturing operations.

 

Selling, general and administrative expenses for the three months ended December 31, 2012 were $2.9 million compared to selling, general and administrative expenses of $2.7 million for the three months ended December 31, 2011. Salaries and benefits are approximately $216,000 higher than in the prior year and travel expenses are approximately $80,000 higher than in the prior year. These increases have been offset by decreases in other expense accounts including a $48,000 decrease in legal expenses, $36,000 reduction in sample expenses, and a $30,000 reduction in recruiting expenses.

 

Loss from operations was $751,132 for the three months ended December 31, 2012 compared to income from operations of $41,043 for the three months ended December 31, 2011. Allied had loss before benefit from income taxes in the second quarter of fiscal 2013 of $755,956 compared to income before provision for income taxes in the second quarter of fiscal 2012 of $36,597.

 

12
 

 

Net loss for the second quarter of fiscal 2013 was $468,693 or $0.06 per basic and diluted share compared to net income of $22,690 or $0.00 per basic and diluted share for the second quarter of fiscal 2012. The weighted average number of common shares outstanding, used in the calculation of basic earnings per share for the second quarters of fiscal 2013 and 2012 were 8,100,593 and 8,124,386, respectively. The number of diluted shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,834, respectively.

 

Six months ended December 31, 2012 compared to six months ended December 31, 2011

 

Allied had net sales of $19.2 million for the six months ended December 31, 2012, down $2.9 million, or 13.1% from net sales of $22.1 million in the prior year same period resulting from lower order levels. Domestic sales were down 20.6% from the prior year same period while international sales were up 17.3% from the prior year same period. International business represented 27.1% of sales for the first six months of fiscal 2013.

 

Sales for the six months ended December 31, 2012 and 2011 included $114,700 and $344,100 respectively for the recognition of income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of Baralyme®. Income from the agreement was recognized at $57,350 per month until the expiration of the agreement in August 2012. Allied continues to sell Carbolime®, a carbon dioxide absorbent with a different formulation than Baralyme®, as well as Litholyme®, a new premium carbon dioxide absorbent. The Company ceased the sale of Baralyme® on August 27, 2004.

 

Orders for the Company’s products for the six months ended December 31, 2012 of $18.9 million were $1.8 million or 8.7% lower than orders for the prior year same period of $20.7 million. Domestic orders are down 13.6% over the prior year same period while international orders, which represented 27.4% of orders for the first six months of fiscal 2013, were 7.6% higher than orders for the prior year same period. The drop in domestic orders is primarily in the construction market and does not reflect a further drop in aggregate demand in that market. The Company is improving its systems and processes to be effective in this market. The decrease in domestic orders is also partially the result of a decrease in government orders from the prior year. The Company believes this is a fluctuation in government orders generally and does not represent a decrease in the Company’s market share.

 

13
 

 

Gross profit for the six months ended December 31, 2012 was $4.1 million, or 21.4% of net sales, compared to $5.1 million, or 23.1% of net sales, for the six months ended December 31, 2011. The decrease in gross profit is primarily the result of lower sales and production levels, including the decrease in income recognized from the agreement with Abbott Laboratories, than in the prior year. Gross profit during the first six months was favorably impacted from the prior year by an approximately $0.4 million reduction in shipping and other startup cost at its Stuyvesant Falls facility. Gross Profit during the first six months of fiscal 2013 was also favorably impacted by approximately $0.2 million in cost reductions for purchased materials and manufacturing processes at the Company’s St. Louis facility.

 

Selling, general and administrative expenses for the six months ended December 31, 2012 were $5.5 million compared to selling, general and administrative expenses of $5.3 million for the six months ended December 31, 2011. Salaries and benefits are approximately $273,000 higher than in the prior year. In addition travel expense is approximately $108,000 higher. These increases have been partially offset by decreases in other expense accounts including a $91,000 decrease in legal expenses and a $59,000 decrease in recruiting expenses.

 

Loss from operations was $1.4 million for the six months ended December 31, 2012 compared to loss from operations of $0.2 million for the six months ended December 31, 2011. Allied had loss before benefit from income taxes in the first six months of fiscal 2013 of $1.4 million, compared to loss before benefit from income taxes in the first six months of fiscal 2012 of $197,222. The Company recorded a tax benefit of $539,186 for the six months ended December 31, 2012 compared to a tax benefit of $74,944 for the six months ended December 31, 2011.

 

Net loss for the six months ended December 31, 2012 was $879,725 or $0.11 per basic and diluted share compared to net loss of $122,278 or $0.02 per basic and diluted share for the first six months of fiscal 2012. The weighted average number of common shares outstanding, used in the calculation of basic earnings per share for the first six months of fiscal 2013 and 2012 were 8,112,490 and 8,124,386, respectively. The weighted average number of common shares outstanding, used in the calculation of diluted earnings per share for the first six months of fiscal 2013 and 2012 were 8,112,490 and 8,124,386, respectively.

 

Liquidity and Capital Resources

 

The Company believes that available resources, including availability under a credit facility described below, are sufficient to meet operating requirements in the coming year.

 

The Company’s working capital was $14.9 million at December 31, 2012 compared to $16.0 million at June 30, 2012. The decrease in working capital was primarily a result of accounts receivable which decreased by $1.3 million largely due to a decrease in sales. Accounts receivable as measured in days of sales outstanding (“DSO”) was 36 DSO at December 31, 2012; down from 44 DSO at June 30, 2012. In addition cash and cash equivalents decreased by $0.7 million. At December 31, 2012 these decreases in working capital were offset by an increase in other current assets of $0.2 million and an increase in income tax receivable of $0.5 million. The increase in other current assets is a result of prepayment of the Company’s insurance premiums for the fiscal year.

 

14
 

 

The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”) pursuant to which the Company has a secured revolving credit facility with borrowing availability of up to $5,000,000 (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement. See Note 5 – Financing to the Company’s consolidated unaudited financial statements for more information concerning the Credit Facility.

 

Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to the 30-day LIBOR rate plus 3.50%. Advances may be prepaid in whole or in part without premium or penalty. The 30-day LIBOR rate was 0.21% on December 31, 2012.

 

At December 31, 2012 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.

 

In the event that economic conditions were to severely worsen for a protracted period of time, we believe that we will have borrowing capacity under credit facilities that will provide sufficient financial flexibility. The Company would have options available to ensure liquidity in addition to increased borrowing. Capital expenditures, which are budgeted at $1.5 million for the fiscal year ended June 30, 2013, could be postponed.

 

Inflation has not had a material effect on the Company’s business or results of operations during the first six months of fiscal 2013.

 

Litigation and Contingencies

 

The Company becomes, from time to time, a party to personal injury litigation arising out of incidents involving the use of its products. The Company believes that any potential judgments resulting from these claims over its self-insured retention will be covered by the Company’s product liability insurance.

 

Recently Issued Accounting Guidance

 

The impact and any associated risks related to the Company’s critical accounting policies on business operations are discussed throughout “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” where such policies affect the Company’s reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see the Company’s Annual Report on Form 10-K for the year ended June 30, 2012.

 

15
 

 

See Note 1 – Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements and their impact, if any, on the Company’s financial statements. Management believes there have been no material changes to our critical accounting policies.

 

Item 3.    Quantitative and Qualitative Disclosure about Market Risk

 

At December 31, 2012, the Company did not have any debt outstanding. The revolving credit facility bears an interest rate using the 30-day LIBOR rate as the basis, as defined in the loan agreement, and therefore is subject to additional expense should there be an increase in market interest rates while borrowing on the revolving credit facility.

 

The Company had no holdings of derivative financial or commodity instruments at December 31, 2012. The Company has international sales; however these sales are denominated in U.S. dollars, mitigating foreign exchange rate fluctuation risk.

 

Item 4.    Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of those controls and procedures performed as of December 31, 2012, the Chief Executive Officer and Chief Financial Officer of the Company concluded that its disclosure controls and procedures were effective.

 

Changes in internal control over financial reporting

 

There were no changes in the Company’s internal control over financial reporting during the quarter ended December 31, 2012 that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

Part II.     OTHER INFORMATION

 

Item 1.  Legal Proceedings

 

Product liability lawsuits are filed against the Company from time to time for various injuries alleged to have resulted from defects in the manufacture and/or design of the Company’s products. Any such proceedings that are currently pending are not expected to have a material adverse effect on the Company. The Company maintains comprehensive general liability insurance coverage which it believes to be adequate for the continued operation of its business, including coverage of product liability claims.

 

16
 

 

In addition, from time to time the Company’s products may be subject to product recalls in order to correct design or manufacturing flaws in such products. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.

 

However, for these matters, management does not believe, based on currently available information, that the outcomes of these proceedings will have a material adverse effect on the Company’s financial condition as a whole, though the outcomes could be material to the Company’s operating results for a particular period, depending, in part, upon the operating results for such period.

 

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

 

During the quarter ended December 31, 2012 the Company repurchased common stock as follows:

 

           (c) Total Number of   (d) Maximum Number 
   (a) Total       Shares Purchased   of Shares that May 
   Number of   (b) Average   as Part of Publicly   Yet Be Purchased 
   shares   Price Paid   Announced Plans   Under the Plans 
Period  Purchased   per Share   or Programs   or Programs 
                 
October 2012                    
October 1, 2012 through October 31, 2012   -    -    -    - 
                     
November 2012                    
November 1, 2012 through November 30, 2012   18,100   $2.54    -    81,900 
                     
December 2012                    
December 1, 2012 through December 31, 2012   76,039   $2.54    -    5,861 
                     
Total   94,139   $2.54    -    5,861 

 

On November 21, 2012 the Company’s Board of Directors approved the purchase of up to 100,000 shares of the Company’s common stock. This authority terminates on February 19, 2013. During the months of November 2012 and December 2012 the Company repurchased on the open-market 94,139 shares for an aggregate total purchase price of $240,952.

 

17
 

 

Item 6. Exhibits

 

(a) Exhibits:
     
  31.1 Certification of Chief Executive Officer (filed herewith)
     
  31.2 Certification of Chief Financial Officer (filed herewith)
     
  32.1 Sarbanes-Oxley Certification of Chief Executive Officer (furnished herewith)*
     
  32.2 Sarbanes-Oxley Certification of Chief Financial Officer (furnished herewith)*
     
  99.1 Press Release dated February 11, 2013 announcing second quarter earnings*
     
  101 Pursuant to Rule 405 of Regulation S-T, the following financial information from the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2012, is formatted in XBRL interactive data files: (i) Statement of Operations for the three and six months ended December 31, 2012 and 2011; (ii) Balance Sheet at December 31, 2012 and June 30, 2012; (iii) Statement of Cash Flows for the six months ended December 31, 2012 and 2011; and (iv) Notes to Financial Statements.**

 

*Notwithstanding any incorporation of this Quarterly Report on Form 10-Q in any other filing by the Registrant, Exhibits furnished herewith and designated with an asterisk (*) shall not be deemed incorporated by reference to any other filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 unless specifically otherwise set forth therein.

 

** As provided in Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

 

18
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ALLIED HEALTHCARE PRODUCTS, INC.

 

  /s/ Daniel C. Dunn
 

Daniel C. Dunn

  Chief Financial Officer

 

  Date: February 11, 2013

 

19

 EX-31.1 2 v332497_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION

 

I, EARL R. REFSLAND, certify that:

 

1. I have reviewed this Form 10-Q of ALLIED HEALTHCARE PRODUCTS, INC.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: February 11, 2013

  /s/ EARL R. REFSLAND
     Earl. R. Refsland
     President & Chief Executive Officer

 

 

 EX-31.2 3 v332497_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

CERTIFICATION

 

I, DANIEL C. DUNN, certify that:

 

1. I have reviewed this Form 10-Q of ALLIED HEALTHCARE PRODUCTS, INC.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: February 11, 2013

 

  /s/ DANIEL C. DUNN
     Daniel C. Dunn
     Vice President, Chief Financial Officer & Secretary

 

 

 EX-32.1 4 v332497_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION Pursuant to 18 U.S.C. § 1350

 

The undersigned officer of ALLIED HEALTHCARE PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the Company’s fiscal quarter ended December 31, 2012 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Earl R. Refsland
     Earl R. Refsland
     President & Chief Executive Officer

February 11, 2013

 

 

 EX-32.2 5 v332497_ex32-2.htm EXHIBIT 32.2

 

Exhibit 32.2

 

CERTIFICATION Pursuant to 18 U.S.C. § 1350

 

The undersigned officer of ALLIED HEALTHCARE PRODUCTS, INC. (the "Company"), hereby certifies, to such officer's knowledge, that the Company's Quarterly Report on Form 10-Q for the Company’s fiscal quarter ended December 31, 2012 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ Daniel C. Dunn
     Daniel C. Dunn
     Vice President, Chief Financial Officer & Secretary

February 11, 2013

 

 

 

 EX-99.1 6 v332497_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Contact: Daniel C. Dunn
  Chief Financial Officer
  314/771-2400

 

Allied Healthcare Products Reports Second Quarter Loss

 

ST. LOUIS, February 11, 2013 – With governmental markets at all levels coping with severe budget constraints, and hospital equipment markets also in recession, Allied Healthcare Products (NASDAQ: AHPI) reported a loss for the second quarter of fiscal year 2013.

 

Net income for the quarter ending December 3, 2012 represented a loss of about $469,000, or a negative 6 cents per basic and diluted share, versus about $23,000, or zero cents per basic and diluted share for the prior year. Sales for the quarter declined from about $10.7 million to $9.9 million, or about 7.5 percent, from the previous year.

 

For the first two quarters of fiscal 2013, net income was a negative $880,000, or a negative 11 cents per basic and diluted share, compared to negative net income of $123,000 or negative 2 cents per basic and diluted share, for the prior year. Sales for the first two quarters slipped from about $22.1 million to $19.2 million, or about 13.1 percent, from the previous year.

 

A bright spot in Allied sales came from international markets. For the first half of the year, international sales increased almost 19 percent over the previous year.

 

Increases in global markets, however, could not offset continued decline in Allied’s domestic hospital construction business. Sales in the domestic construction market fell about 36 percent compared to the prior year.

 

 
 

 

Sales of Allied’s new carbon dioxide absorbent Litholyme®, used in anesthesia procedures, were hindered by product introduction delays, Allied reported. However, those problems have been resolved, and U.S. hospitals are adopting the advanced product.

 

“Overall, our domestic carbon dioxide absorbent sales are up nearly 17 percent in the first half,” said Earl Refsland, Allied Healthcare Products president and chief executive officer. “We expect that sales growth to increase as we steadily build the base of hospitals that we have converted to Litholyme.”

 

Allied Healthcare Products manufactures a variety of respiratory products used in the healthcare industry in a range of hospital and alternate care settings including sub-acute facilities, home healthcare and emergency medical care. Allied product lines include respiratory care products, medical gas equipment and emergency medical products. Allied products are marketed to hospitals, hospital equipment dealers, hospital construction contractors, home healthcare dealers and emergency medical product dealers.

 

“SAFE HARBOR” STATEMENT: Statements contained in this release that are not historical facts or information are “forward-looking statements.” Words such as “believe,” “expect,” “intend,” “will,” “should,” and other expressions that indicate future events and trends identify such forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome and future results of operations and financial condition to be materially different than stated or anticipated based on the forward-looking statements. Such risks and uncertainties include both general economic risks and uncertainties, risks and uncertainties affecting the demand for and economic factors affecting the delivery of health care services, and specific matters which relate directly to the Company’s operations and properties as discussed in its periodic filings with the Securities and Exchange Commission. The Company cautions that any forward-looking statement contained in this report reflects only the belief of the Company or its management at the time the statement was made. Although the Company believes such forward-looking statements are based upon reasonable assumptions, such assumptions may ultimately prove inaccurate or incomplete. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement was made.

 

##

 

2
 

 

ALLIED HEALTHCARE PRODUCTS, INC.

STATEMENT OF OPERATIONS

(UNAUDITED)

 

   Three months ended,   Six months ended, 
   December 31,   December 31, 
   2012   2011   2012   2011 
                 
Net sales  $9,921,422   $10,681,395   $19,208,513   $22,076,403 
Cost of sales   7,815,489    7,946,458    15,123,605    16,935,449 
Gross profit   2,105,933    2,734,937    4,084,908    5,140,954 
                     
Selling General and administrative expenses   2,857,065    2,693,894    5,495,640    5,327,983 
Income (loss) from operations   (751,132)   41,043    (1,410,732)   (187,029)
                     
Interest income   (2,821)   (7,297)   (7,047)   (16,292)
Interest expense   -    -    0    336 
Other, net   7,645    11,743    15,226    26,149 
    4,824    4,446    8,179    10,193 
Income (loss) before provision for                    
(benefit from) income taxes   (755,956)   36,597    (1,418,911)   (197,222)
                     
Provision for (benefit from) income taxes   (287,263)   13,907    (539,186)   (74,944)
Net income (loss)  $(468,693)  $22,690   $

 (879,725

)  $(122,278)
                     
Net income (loss) per share - Basic  $(0.06)  $0.00   $0.11)  $(0.02)
                     
Net income (loss) per share - Diluted  $(0.06)  $0.00   $0.11)  $(0.02)
                     
Weighted average common shares outstanding - Basic   8,100,593    8,124,386    8,112,490    8,124,386 
                     
Weighted average common shares outstanding - Diluted   8,100,593    8,124,834    8,112,490    8,124,386 

 

3
 

 

ALLIED HEALTHCARE PRODUCTS, INC.

BALANCE SHEET

(UNAUDITED)

 

   December 31, 2012   June 30, 2012 
ASSETS          
Current assets:          
Cash and cash equivalents  $4,586,331   $5,284,543 
Accounts receivable, net of allowances of $300,000   3,551,587    4,843,593 
Inventories, net   10,049,584    10,001,226 
Income tax receivable   583,706    46,042 
Other current assets   590,082    400,677 
Total current assets   19,361,290    20,576,081 
Property, plant and equipment, net   9,628,935    9,603,556 
Other assets, net   1,137,908    1,167,432 
Total assets  $30,128,133   $31,347,069 
           
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current liabilities:          
Accounts payable  $1,693,881   $1,797,144 
Other accrued liabilities   1,961,826    1,855,579 
Deferred income taxes   793,990    802,961 
Deferred revenue   -    114,700 
Total current liabilities   4,449,697    4,570,384 
           
Commitments and contingencies          
           
Stockholders' equity:          
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding   -    - 
Series A preferred stock; $0.01 par value; 200,000 shares authorized; no shares issued and outstanding   -    - 
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878 shares issued at December 31, 2012 and June 30, 2012; 8,030,247 and 8,124,386 shares outstanding at December 31, 2012 and June 30, 2012, respectively   104,279    104,279 
Additional paid-in capital   48,563,230    48,540,802 
Accumulated deficit   (2,016,693)   (1,136,968)
Less treasury stock, at cost; 2,397,631 and 2,303,492 shares at December 31, 2012 and June 30, 2012, respectively   (20,972,380)   (20,731,428)
Total stockholders' equity   25,678,436    26,776,685 
Total liabilities and stockholders' equity  $30,128,133   $31,347,069 

 

4

 GRAPHIC 7 tlogo.jpg GRAPHIC begin 644 tlogo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`>P#4`P$1``(1`0,1`?_$`:(````&`@,!```````` M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+ M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7 M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8 MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R'EZ>W MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7AS[]U[KL MBWU]^Z]UU[]U[KWOW7NO>_=>Z][]U[KHD#Z^]$TI@FIIC_5PZ]0GAU#K,C08 MZEJ:[(5E+0T-%$\]96UD\--1TL,:EY):FIG>.&"*-`2S.P`'U/MJXN+>TC\6 MZD2.,FE6-!7KT'^-/X5M62:M-*C4U3P%!YGR'5CV!1[ABII-2$'SR1`$6)]DMSS)MR?I6PENY M2::849\^52.T5\B3Z]37R?\`=U]ZN>0K['R]?BPDH?&G46T5"*A@\Q0.OJ4U M4J*TJ.JH=_\`_"I7X?8#)U5%L+HWO??U+!+XX,KE'V3L2DK8[K^]34>0SN5R MZQ?T\D$;V'*CVFEWCF%U\"RVZ!)R>,L^A`!QU&-)'#>@"D5P2.I^V/\`N_O< MZY"-OFY;1MVM:Z=4TSC&`5TB(_,AZ>:UZ0FV_P#A5?T%5YJFI=V_%#M?`82: MJC1\O@=_;)W1D*>D9XQ+5O@JBFVX9WA5F;QQU+%E46-R/?HMTWZV(@GLX&!J M6,,MIS35WT/D,`5/ M'SZV+/BI\M>A_F?U30=Q_'S>L&\MG5-7+BL@LE%58C/;:S]+#!45NW=SX&OC MBK\-F*2&KB2)EWWEO>0%H%,;JQUH11E;SJ/0D&A&#Y=8:< M]\@VG,4O*G.ELUMO,0#`&A62)O@EC<=KQM0@,IX@@T((!D_:[H&]>]^Z] MU[W[KW7O?NO=>]^Z]UQD98D>65ECBC1Y)))&"1QHBEG=W8A455%R20`/?NM] M!QU_W-T_VS4;FH^J^UNM^RZO962CP^\Z7K_?&V-Y5&TZJK!JT\NA)]^ZWU[W[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW5??\UKY)U?Q#_EQ?,KY#XK(U&(W)U]T5O(;)RE'.::MQW8 M.[*5-D=?5M%4*R20U=)O/M?D!VSOCN+M_HGNNBRPW=V3NO-;QWA5]==K[3J:# M&[GVIFXX59V6%'55LI51X=:B:I*XH.%/SZVRO?NG>O>_=>Z]_C_3WNG6P*FG M1;/DI\O/CC\0MFS;[^17;6U.LL'I<8VGS%6]3N/<-0@8K1;8VGC$K-R;DK)6 M4@)1TLMCRQ4`D(+G<+2S)69P9/)5^+]G$GTZ%7)G(O.7N%NR;-RAMUS>7;N! M5%[%'K)(:)&*9!<@4!X]:O7RH_X4^;@W'62]??`_H2KJLMDJJ;&8GL3N*BFK M\YE9Y-<-')LGIW:U565E96O)9XAD*YW8>EZ*_'LGNKK=;T+%:AK8.`:!=LY>1/N-PVEJ=\]WMXM8;"$%I+>"414XX>YE5D[>!1%JY^% MAT7?;7\M_P#G=?S.WH=Q_+ON/='4?6V49O MHJ.*BE,;?LC-Q8ER%-V-[E7'L2K-XK][.@5C)WD@"GP_`,>@KZYZ%5][U?=7 M]DI/H?;'9X=VY@@%#)$O!P`06NKCQ`PU`$Z!2O`#JW;XY?\`":/X'=5TN-K> MY\AV'\D-QT\<#UD6XT4/^EI4^A-:>74`\[??2]V^:%DMMF^DV>R8]O@H)9T'D%FEUJG MS\!(PWXJT6EMG7?\O[X/]3TU/3=>_$WX_;;%,J+%51=5;.R.4/C'H:7-9G$Y M++S2KP=;SLY(Y/M4'(4+B@_;^WB?SZQXW;W(]PM\F\?==[W29\\;B0"I^0(_ ME3KCWY\0_AAV%U;O'']W="]-5_7V,V[FLSG:^?8FV<16[=Q6+Q=3793.8K<. M*QU!F=O5N/H:9YEJJ6HAEB,8(;CW20(\;)(H92I!KY@]*>4^?OV]M=24V9FFDDRD/7U#N`9?-^M(8:FH@H=RX['5%5&@6:KHY4X\.E45E M&I4W;5-Q(`"QI4JM0@QB@!-//K*C[\N^;?=]^Z]U#R,=;-CZ^'&U$-)D M9:*KBH*JHA^X@IJV2"1*2HGI[KYX8)RK,EQJ4$?GW[K1!(('&G7RR?YY>/\` M^%"_QZJ9L3_,&^0W9^^_COOS-U.%V_O3I'=XV_\`&O>%46J9J/;V6V[L##[' M;;^7J:"*22+%[DQ\DFB55H3_`)?]@_L'5RW_``B&DITZ MS_F)4L95)%[`^.D_B47(A?;/:J(68*`;.K"U[@W_`-<^'3T!.C))/S^T];UG MO?3W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:L/_``K.WOOS,_!# MJ#X@=1X?(;H[0^7OR$PN)HMHXET_B.>V1TIMS-=M[L$,+,OEBHLQAL-+(+VT MBW/`/NFY"/A/'C_J_;UJ_P#_``D#^3$?3_\`-!R?2>3R!I]O_*KH_=^S*2GG MJA#3R[YZZFB[/VE,T)D6)ZI<#A\[20"Q<&MTJ/4??NFH:AFU8%>OJ/>_=*>D M%V5V;U[U#LK/]B=H[TVWU_L;:]$^1S^Z]VY6EPN"QE+&&-ZFNK)(XS-,PTQ0 MIJFFD(1%9B`6Y[B"TC,URP6-1GS/[!4_RZ7[9LV[\P7L>T[%;27>ZRL`D2*S ML3_I5!/YF@IDFG6H=_,"_P"%+U=D:G,=4?R_-NO303U$^%E^1&^,.TN0KI)= M5&)>KNNZ^(-"U3(?\DR&:1I6)!3'WTL0VU]=70U6ZO!`2"I6C._]$@F@#<*U MJ!\^NA?M+]R$PPQ'JM:)8J/20T5YB,]PU5S5L],G\W_`++^07\B26DZ>_EZ?#G% M].=;;OVAAJ*K_F@[ZP$7='<.\]TYW'U46X-H[K\:ST4$0TR$]C584\.(!4.33S/J?4GKG3[C^\'N)[GWQN^;=QFEM:]MNA\. MW0`U4"-:`Z>"E@6IQ;I&?\(\NX>U>ZOY@OSCWQV_V5OSM'>>YOC;B(@,S04E*A#U>1KY MRE/2P+ZIJB9$'+>VY9/"A:;%5'^K_5_/H_Y=Y=W/FK?K+EO9(C+N=[<+#$@( M%'?@QK@*M*L>`&3PZUD>IO\`A4CUAN[O'$[1[*^.&=ZSZ7SV>IL-!V4N_:?< MNY-JTE75)34NY=Y;3@V_1X\X:'6)*Y*"NFFHX=3I]QH((?&\;G'*'N5MA8EJ M'3J\15/F:]O;^*A/RKUG'S-]POF;:.4'WC9=[CON9K>`RRVHM1&K^&I:1(Y_ M%;42!VDQJ&S4KU81_,][%WU\I,OLG^5[\7L[;?\`\BL1C-Y?)#LO$2+58KHC MXGC(4_\`%LUFJF%O"V:[4D3[#$4)D23(4PE3B.H23V8W$BWL@L(2:-1V9>`0 M$'C_`$^``/"I/GU"7L?8[=R!:7/OQS@D36&U2&+:[:2G^.;FZE4\/R9+.HF= MLJ&50#J%.K7^A>D>O_C=TUUQT5U;B5PNP^L-KX[:NWJ0B(U4U/0H34Y3)S0Q MQ)5YG-U\LM96SZ09ZN>20\L?9D:<%%%\AZ=09S'S!N?->_7?,F].9-UO)VDD M8^98UH*\`."CR``Z%SW[HEZ][]U[KWOW7NO>_=>Z][]U[JCO_A2+LW";T_DK M?.2'-4L50=M[*V-O7#RO$DDM#G=J]L["RF/JZ9F4M#-:-XBZV/CE8?0D'W6F MH1GJ@'_A$/6+_=3^8MC3"WD&Y/C97B?R*4:*3$]OTPB5!Z@4>$DG_&WU'O2_ MRZ36^34972!^8)_V.M\+WOI5U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[ MW[KW6NOVY00_*7_A2%\:]AU$!R6ROY=/P3[-[VSU-4I#/C%[3^36:/5N'QLM M.WD5JK^XKP5JB0*;1\`K?W[ATT1K>I_U?ZJCKY\V^:/*?RB?YYV4^WC&-Q?Q M+^_?9U4C2U*@+ZG@/M`S M^SKZB'\P+^:C\9OY?_6]!N7>N=AWWV+O+!?QKJOI[:5=!-NG>U+41JV/SM;4 MVEIMJ[&9Y%,N6JUT,NI:>.HF'B]E]YN*6K"!%9[H\`.%?F?+[>II]GO9#G7W MFW,0\O1>%L,;`W%[("(84XFGG))3(1:D^=`:]:5NZ>ROYEG\^7O^GVGAJ6?. M[9P-;+FJ+8F%J*_:GQYZ'Q50S0TN:W9E)ONH:S.FFA]P/=F63;8I9=LY+9V(M(W.J4>37$OQ/49,?P"NFAH#T M8W_A/O\`SU/F!_-A^=GR3Z_[PQ?6.R^G=I=`UG9O7?6W7NUIHYMKY>#LG8^U MJ=^V<7N_;F;^,_=1JL!EZ.&MI*JMQO7FX,KAJF..8$0 MY'%YFBIZJDG0K+354,QP-GBLJFH:&OW+MO-XC=N'PE?6#]NFH\_68):)WD!BC\X=_2I]UEA%S M`]N30,./V9'\^/RZE7V6YWL_;CW3V;G+:HMZM+JT$6J&.!U:=V(H(]!-#J!*N#P!->'7T9/A#\+-K?#_K23%R;BR'9 M7<^^%P.7[Q[NW%&K[G[,W1@\+1X/%PAWO+B-C[/Q%(F-V_B(R(,=CX@+--)/ M)(=6L%O8IX5N@`I0GS.*5/']G`>77%_W)]PKWW#WE;N."+;^6[4.EA80K2"S MB=RYTH?BE_=>Z][]U[KWOW7NJ9 M/^%#0O\`R7/Y@(O;_C#^*/UM].QMD&W^Q]^ZJQIC_5Q'6M]_PB$E)IOYCD1F MU?Y3\89&B!%E/K[T.F;8:4IY5ZWW/>^E'7O?NO=>]^Z] MU[W[KW7O?NO=>]^Z]U[W[KW7A]1_B0/]N;>_=>ZU[OY+D2]Y_*3^<5\_JHBN MH.[OFQ/\<>KLY/*T_P!UU+\0-M0;!QE5B99?5#ALOF,M,^E3XWEIB0/3[\2! MGIE2H!D;"`5).!GS)_9UJO\`_"HWH'J#?_\`-@AWUM3>^V\N^8Z+Z^H^]L!M M:KIZO/8+LK:=?F\#C<'GY*/=6_MX;<^.^"J,=M#-]F9S-'='8O9+;)IJ/"C8?7 M@RM76R8RDVYC:..AERE>II,;I$=-!42*ZQL6MM<&LDV":&OXC3&?]5>LO?=_ M[PO)'L#LX]O?;2UM+CFJ"(1J$"K;VE1_;2!`-=SFK1_C/=(>%=]GX]?'#I3X ML]9X7J+H?KS`==;$PB!X\7AJ;_*LGD'C1:K-[CR]09[M*Q[Y&+$"O!0<(HX!5HJC` M'57W\[W^6!\1_G;\0N\NP>X.OL?0]U=(=(]E;_ZM[RVO1T6,[)VW6["VCF]W M4&W*[-+#KW-L;)UF.,=5B:_S4P29Y(/!4:9E]T'2!0]:=W_"+2H,7\QKY%Q. M0O\`$?A5N&6-2VE7,/=73TC%%L#*T08K<\CGZ^_=-II!TGXP33KZ'GR\&KXF M?*)1]6^.O=H%K?GK3GREI2@)J/AHM7Y+%2HI M^Y>M(Q&-0]0<55R1QQ_MM#SZ3PFK-_IC_DZ^E'8'@B_O?2CJM;'?S,.H]Q_S M0*S^5WM#"ON?L3:/QSSG??9V^J'/T@PW7V3I<_M&@P'6%7@Q02U%?N;,;NGB234\>N_]]P"3_L`.3[]UKKNQM>QY_P`"3_MOJ/?NO==>_=>Z][]U[KWO MW7NO>_=>ZIO_`.%!M,:O^3%_,$B$BQZ>E(:G4U[$46^=H5ACXN=4H@TK_B1[ M]U5N(_U>8ZUH?^$0$H2H_F.TKQ,DIC^,4X+BS&-3W=$0Q)OJU_X`>_=-19.. M%/Y];]WOW3_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW17?FWW]1_%?X??) MSY&UE3#2'I?HWLOL''25"&2*7/[?VIDZK;-&4!!D;(;B%+3JHY9I`![]U5V* M*7H2!Z<2?3K3)P'\TBG_`)0B#;V`K\3')'] M$#U/D:X\QUF_]V?[JUUSND/N)[@P/'R+"PDA@DHOU6DDK)]MZ+#$BKI\"T`'PHH$8<4T&@752HO-_X M1:?)M]X_&KY:?%K.99ZO-=5=OX/N?;T%4SRU+[:[AP0P6;"3.6,D5%NSKYY9 M`3<2Y#5_;]K@*"GEUS7>>:ZFDNKAVDGD;4[L279CQ9V)JQ.,_P"?K=A][ZUT M6CYITYJ_AO\`+:E"AS4_&3OJG"E7<,9NK-U1Z2D8+L#J^B@D_CW[JK?"?LZ^ M<_\`\(R:ME_FA=ITJJ`LOPL[&\C7&IA#VKTPZJ0!]-3\?GCW[II5K(7]">OH M[_+"$U'Q8^2T`-C-\?NYH0>.#)UQN5`>2!P6][Z>=J`GKYZO_"*APWS[^3O) MX^%M4@U,"W'=O5@8*H)TH&^G]1S[J./3,0`D>GFQ/^#K9/\`Y^_\^^3^5+C, M9T7U)U-G]W?*'MGKL[LZ^W]NW$K'T9L'&5^9RFW?XUD:@5<60WWO+$3XF::+ M!4\<=.FNGEJYQ$WAEWTZS:17K58_X2A]G[Y[5_G:;T[([+W-FM\=A=F_'WY# M;JWMO'/U[5F8W!N3-[FZ_P`SE\KDII%M//55ZMPND1@A5`1`OO5*=)XT_4U_ MZO/_`%?SZ^GU5U=-04M575M33T='14\]75U=7-'34E+2TT335%34U$K+%!3P M0H6=V(55!)X'O?2DF@)ZT@.XOYD_\Q#^>U\RNPO@_P#RB.SIOC/\/.I%D3N; MYAT/W^,W+NC$+D*K#_WDQ^XL2H*BFVQA,'+19?-00RUE;54]+Y M(Z?1.<=)C))(.S'_`!7^H_RSFBD["_X2J?)GJ;;&0[A^'W\V/Y-5'RVV[1S[ MAPM7O?+[AV7@M\[HAU5D^+?>6W=\Y#<.U'S4C[D&-F9?4/KU< MB31DBN/+_9_R=&C_`.$]'\[3N;Y:[W[+_EW_`#_@_@_S;Z%BW)#B-SY'&T&` MS':.(Z\RIV[OW;F\\3CC#B8^V.OZ]`]5+0PQ09;&AZKQK)3U$DV^MQ,2=!-: M#C_J_P!7EUM?D@`DFP'))^@'OW3W6NA_.+_X42?'[^6-FY.@.N-JO\DOF5D* M+'U$75.(R-Y32130R MR>.!7III-/EY]5F8#N/_`(61?(7:4?=6Q^J_CET+MC<%*V_\*&?E-N+X<_-W^6/_`#5_BWD^I?E-NWJ6KV?M3?.RL!-M:*7<4];C,UB( M>Q.OLKF:R@I\/N"DHU>DW!MROJ<94(RE:303(-UZ;7Q`:R_=>Z][]U[KWOW7NN+&P_QMQ_OA[V!7CPZW@=S?"./6G5 M_P`*&_YJ_5V^.NNPOYGAS;%_M:.)7H],L[R"`JN[N9G,,&E47#,>/RTCS/J!]G6>7W8?N ML#FFWB]R/=`K#RVI\2WLV73]0HX23LV([I!J M2D-,_:6RQN)G'ZA''_5YGI[[S_WGAO23>V'M<_@\NQ#P[FX1\2%1H,5NZ4!@ M``4TPP`TT&3?G_-2^.?^S8_RY/F=T#!`*G,;]Z#WZVUHS3FJ9M[[7QC[SV,4 M@`+O)_>[;U%;3Z@?IS[7$UZP#95"^M*'\QY_RZ^>)VM-4OF=C28^#Z,LN0TCEB#KIE" M1)2II_+_`%<*=?5L_P!;W[I3T`7RN75\6ODJOTU=`=RK?^E^N=R#\%3_`+R/ M?NM-\)^SKYNO_"-&:.G_`)IO84;L===\,NT8(0?$GKB[+Z9JVX>3R.%CC-M` M/')`M[]TVC+K*XK7KZ3OR3@BJOCIW]33W$%3TGVK!-I.EO%-L3/1R:6YTG2Q ML??NG2,&O7SH_P#A%O*L7\Q;Y!T\A17J/A?N/Q!0Q$OV_)_R=?1#^3_`,7.B?F%TSO3HKY#=<[8[(Z]WE@\KC*K M'[AQ-%7U>$JJ^AFI8=Q[7R%1!+6;;W3B'<3T>0HWBJJ:=%='!'O?2B@/'KYK MO_"3#%4V`_G393!4=1+4TN%Z#^2&&IJF9%6:HAQ>>V=1Q2SA+JLLL=.':Q*Z MCQ:]ANA`KY=-)361YX_P'K;P_P"%1'S0+:^SCUJX8K'4?Z MOM^WAUF_X3)_&?KOXH_RF^CMW5<^V\1V)\HQD?D/V+EJN;'8ROJZ?AAY'JT31JN"-7V_;U=IO3Y5_%[ MK=)).Q/DET'L-(E+R-O+N'KW;.@!?)R,SN&C/Z!>WY'OP!K0<>K%DIW$4Z^7 MY\\OF'U)T)_PI(W)\TOB#V%@M[=:[:^2G378.8W=L;-0Y#9^[)"62>;26"W.B"#0\>FC)'K!4BIQ_EZ^D#_,W^ M;N`^`/P-^0?RXGEQ==D]A[`J&ZPQE?*IHMU=H[M:#;_5^&,899:NBK]TY:EF MJECN_P!A%,XX4D>Z<M+#_A*'\$IOF=\GN__P":I\JS5]LYCK+L M*>@ZYR^]%CS2;I^2.]*=MX;Y[-R0K8YXJK*]?8/*T7\-!&FEKM57_A67\!.M_D)_+PW5\NZ7;] M%2=\_$!]O9[$;MHZ:G@RF?ZCW'N[#[:WQL//51C\F1PV,DW"F=H%G\QE/&4U;6^,L@8CZ_[EN[+K?_"XM_K^_=4C M^.AXTZ^@E[]T_P!>]^Z]U[W[KW7O?NO=>]^Z]UT2%%R;#W[_``=:)H"5_.D3HNDW5\./B=N8/W=74DF'[F[4PLZ21=.XK*4;+-M':]?&Y5NTTW"K0-; M)CMMZ"CT-6QI(''Z,JBP`_-A<\FYM]23""./>NO4KCKXS_R?Q.>_E;?SGNS1MF+^%2_%/YO#LO9,:J8VEV+1;_Q M_9VT(D@C6.-H,EU[EJ:%E`!:*4J+?3WZN>DI'=3SIY?ZOEU]D3:VY<-O3;&W M-X[;B`10OJ+,386YO[]UIOA/V=?-6_X1TRB'^;% MFD2%Y%JOB%V_$\S.5$+INWJ:?]$9TOJ$04:^+?3GW[_-TF']N">.>OIC=^J& MZ)[I1A=7ZD[)5A_JE.R\V"..>??NE;?BZ^;Q_P`(PW8?S,>Y8V5M)^%6]]!9 MOT'_`$M=,N[*H%BSDVO_`$_Q]U'GTD@_M']=1_R4Z^F_)_FY?^64G^/]AOQ^ M?=NE77RU_P#A+%5TU)_/.FII-:R5_6GRKHJ6R&\DZ5%+7MYN2J(*6@EL1_:` M'NYD!733I,E3*U?4?\=/1V_^%LW4:QH^8ZL?ZH_X1^?"3>G5O66Z= MX_*#YD?QS<77FR<[EJ#"[SZYIL)093+[;QF0R=#AX:KKBNEAPU/5U#1TL;,Q MCA51J)%R_P"/\OY]46`K7N&?ET(5-_PC%_EEB1I-U](*,]'U/!,JL%MZ6'!_UO>F;4:]6T)Z#HI7_"S;M^HZX^(WPB^*N` MK77"[_[1W/O3,478^;D2%H7FR,_9V?V=2M M,&56>6+`[-HHM1_LQ@#@#WOIR"IC);C_`,5UL7^_=.=58_SO<3%F_P"47_,1 MH)4#A?BIVID44OH_>PV$;,4[ZKC_`#=10JUOH2+'Z^_=4?`U>G^K_)UJ5_\` M"(JHF3M/^8;1(L?VC]??'2I9@5U+-%N/MN&-%`9FTLDCZC?D@&PO[U\^FHCJ M?Q/51_+KZ$7O?2CKWOW7NO>_=>Z][]U[KHD*+L0`/J20`/\`8GWZG6B0.)X" MOY>O6N/_`#Q/YP'^RA[4K_C5\=MQ4K?)K>F(5]S[MQU52U*]#[0RM.!'DW#B M6!>Q=P4LI;&P2`_P^E/WL@!-.'+[Z[,;"VMZB=AZ5H/4\>.*#USUF;]U;[N$ M_N1>#W!YTMV_UN[26D,9J@OY1^%B2"8(S5IBG&@2OQ=$._D1_P`G>IW?DMM? M/KY?;WH'K?=]-4U-9NC*U%0:V+O+L6FRS35%?'/6/]UM^GJP\E M5,QR<]U^UU/6=FEM#I8U-2:5KQ-2?MZD#[U?WD(I2WM+[?.N6J7)X+:/96Q?A#U3DHE M6:BEVSU2L])NPXZK!8-#55&P\+5D*?4:S4?K[5$D_8.N=R#)/'T_XOSX#K:* M]^Z=Z][]U[AU\P[_`(6/?'?_`$9?S(NO.^,90+3X?Y,?'W;U9E*N.FT)4;ZZ MERU7L3/O+)I\_E`_#W< M^0R#5^Z.M=F5W0.[6DD\D\64Z4RU7LC#_<,26:>MV3C\35DGDBH!^GOW3PH1 MCAU:C\AXC4?'_O2``$S=.=G1`-PI,FR> M67JGL2.*&,%I)I)-H9A$BC5;L7D9K`"Y)/OW3QX&OIU\VG_A&46C_F==L(\P M0R?"SL%5@8JKR&/M;IABH1@6;Q#GTD6_/O0Z20$>*]/XCU].L`$V(!!!!!Y! M!!%B/R#[WTKZ^6;_`,)CPU-_/RIZ84B4H3`?,*G,2QZ$B6.BS!$$49+&$4[0 MA=/X7CWZ@Z96GB&G''^`]*7_`(61PUZ?S5=CO5-JI*GX=]5MBTTW58TW_P!P M0U(8!"&;[R[W)_2/?N&>JOAZ^6.OHS_!SLG']Q_"[XE]JXNIBJZ/L'XW]*[K M6>'2$,^9ZZV]5UD5D6-5:GK))(V4*NEE(L+6]^Z>C.J,,>/1I??NK=>]^Z]U M\\;_`(6W25![U_E_Q2?<"B3JCO.1"TNBE-1+O'KX3^(%K?<)%#'Y"!?24N?I M;1Z377P#UKZ5\NMF;_A-34T%5_).^#YH`0(-N]J4M6"#QD*?O+LN.LL2S%E\ MHX)^H]['#IV`@QFGKU>G[]TYU7'_`#@,?#E/Y5_\PRCJ(S)"_P`/N^YG4/XR M11]>YNL%FL>0U."!:QM8_7W[JKYC(\^M-[_A$:R'O'Y\:0%+=/\`1+,`P8$_ MWU[&-^.!96'O0K3/3,`H"#Q!/^3KZ'OO?2CKWOW7NO>_=>Z][]U[JG[^*^+?Q-^1'?E3)18^AZ0Z.[&W_0QRJD%"*W:.T,GD,#C4B31'%' M692FIZ:-%L`9`HM[-2S^V?D;N6NELU?DAN?<\NU,!75LOZI6KL!LVGJ4)Y*U%_S[T.'6 MD&E0OIUL6^]]6Z][]U[K3Z_X68_').Q?Y?O2_P`B:&E,F6^.'?-%B\K5)3F7 M[;8W=6(?;&3DJ'`]-.N\\)@$%S8/*`!=O?NFY`::AY=%J_X11?(ELMU-\T?B MGDLC([[)W]L?O?:&-=P8TQ78&'K-D;Q>D5B'6*GRVQL8\@"Z0]6+F[6]^'58 M#1=.:T_U?RZW0._+?Z">Z[_3_1'V3>_TM_+4>O^?KZ@G9T7GZT M[#ATA_+L7=T6@FP?R;>R*:2>;!K^_=*&\^OF:_\`".NHIZ;^:[O:EE9Q45/P M][=AIA%9X7DINQ>HYIC(\ATAM11WKZ]?4$7EA_K_`.]< M^]]+>OEL_P#";&18?^%"#QO+9ZE?FG`B$FS,E#N><*.39M$#L?\``?U]V,9` MU>O29*&9L>G_`!T]'!_X6P=35F&^4OPK[T2@MB=^=%;WZPFKHTD`.:ZOWV-T M*E7(J%"QQG:"F,'U%(W_``/=?+K'56XFB9VE^R^PR%;A$8#3KPC?2] MAX9'5H9`ZT`IC_#UL_\`OW3W4/(Y''XC'UV6RU=1XO%8NCJLCD\GD:J"BQ^. MQ]#!)55M=75E2\5/24='31-)++(RI&BEF(`)]^Z\305ZT8/^%HG6M'V-\;O@ M'\NMD5]+N79&&WGOS8:[CPM;'7X/*X#NS9NV=^[%SN/JZ9FIJO&Y:#KJH>"H M1BDB3QE200?>^'34@#*#\NCA?\(Y?D]@NS?Y=?8/QIGR<1WM\8^[=QU"X5ZB M/[J+K?N-?[Z[:R<%.\AJ&HGWC%N&F+VTJT2CZL+ZZU$:`BG'_5_D_GUMT^_= M/=5[?S:03_*\_F%`$`GX;?(GDWL/^,6[EYXYX]^ZJS!<]:6O_"(ZOBC^1'SJ MQ>@K+6=&=.UZ-]0T>,WWNFFE8'TE0S91>+'Z?7^ONJ)\1_/_`"=?13]^Z=Z] M[]U[KWOW7NBK?,OY:=9_";X^=@?(/M6M"8+:&.,>#P%/4T\.:WOO*NCDCVQL MG;Z37\F5W!D5$>K2RT].LL[VCBI\\MY]J=WY3 M+1]<467Q.XN[MWT!JH,)L_K^&KD.U.C>NJ@HL%)DLI01M1T2)9Z>D6JR4X:9 MKRD\5KXEQ]1)_;C):I/V*!P%!Z>?'KJ/[F<\;G?3;EN$CS M;A<.7D=C5F8FI)/VGRH/EUK/_P#"LKY9T?3/\MA_C-MZN2;MCYJ=A[4ZQV]@ M*6>'^*/L3:VAUI8ZS+;LZ'W MEE]IPO%YC_?G8-*G86QC"H]0F_O9M6C"D6//]"??NO'(H>'7S*O^$XGSIV_\ M%_YH'4>Z^P=P4VV.H>]L3F/COV?F,KD8\5A=OT/8-7BLAM+=6:J:EXZ*#%[< M[%P6,-54U#!*:BFJ'U*`3[]TQ&`&H>OK.=P)'E>F.TDHWAK(LGU=OA:22%DJ M*>KBK-IY0021/&6CG@G64%2I(93Q]??NG6^$_9U\O[_A(;,M-_."VW!*ZQRU M/QL[VI(XGD1&::&+:=08XU9@\LGBI7;0+D*K-:P)'NFXZ%B?.O7U'^P^.O\` M?8_[,W='_NCKO?NGN->OF%_\)`>/[#PNTJ+(9FO>&BQPSFX#3T4HC5F&H7MJ-*>73("B0GS-/\` M!UO2_P#"B/\`ESYK^9#_`"Y]V[?ZKQ:Y[OOHS+0=]='4=!'%49#=U=@,17T> M[>OL54+*NN;?FS,A41T2(VBHRM/0AO3[KU=U4J:\*=?-'_E@_P`R;O+^5#\K M,1WSUA0OF\5XI]B=T=/YRLJ,/C.R]BR5\4V4VMEQXI:O"[IP63IQ4XJM:"27 M&Y&(B2.2"2>"30Z1P%DJ#Q/^K_53KZ)_6'_"KS^3IOGK>CWIN_N'L3J#=38_ MSY7JG>G3^_.H M&0<<>J+_`)=?S<_E5_PH<[TV_P#RPOY9>R=_=-?&7?61B/?O<&X8Q0;WW'U/ M39"&FW/N/L%<+45E!UQU%144VH8<5DV2W-6F"BE95G:B=Q`A4D\>FVD=G&CX M:^G^7_-CY];8'\Q?^6UMCY:?RK]__`3:45%_$-L=*[/V]T#E<\J7PG872>&Q M0ZJKJBJC""A_B,VWH\;6S(OHHZ^H`4@V+?3[#L^SKY?G\K7^8EW3_)M^=LO9 ME;L[.3XS%5N?Z:^3O1.1E7#9K-;5HLWX-S[?9*N.&GQ>_P#8NY<7][C99QH6 MKIFIY#X*F6_AQZ3K514\:#/#KZJWQN_FL?R\OE7UA@.UNI?EKTC)A.%O$&TL/?J&E?+JB%0_=;ZXLVD7/'^-P`/ZDDD``#GWL"IIUJHJ`>)-!]OI^?6@;_-?^4'9_P#- MI^?.S?B#\7X9]X]:[`WK6===5T-,WBV_O+L-5DI.Q>X,W5PF53M3`TM#404] M7):.FPM%-4I9JME)))(UY<^$I%48A,_DQ/IYTIUUD]AN2]@^[E[.W7N=SVC6 M_,.XP++*6IXB0GNMK.%20?%D.AYE.F@<"I*@=;F?P5^'/6OP5^.&R.@.MJ:& M5,-3C,;VW485BR._NPLK!`VZ=X9,Z0ZFOJXA%20'TT>/A@IU],0]FT4(@01C M@/VD^9/7-CW*]Q-[]U.<;SG;?6'U-W(=$:D^'!$"1'#%7@B#`X5))IGH!/YD MGQP_F*_(O%=9X?X%_.G;_P`*:;#-NQ^U:S(=2X;L7-[[->,`NT(\-FK<]O&KPVU\5D)J$ MHM/!2I20M*[^-C?4\K@1Z#D],I!(&U,:FO&OE^RO#''K=_=>Z]?_>/K[]U[K'+%%/%)#-''-#,CQ30RJLD4L4BE)(I$<,KQR(2K`@@@ MV]^Z]UHS=B?\(G^OMT[WWIN7:7S^W#M'`;DW=N;/X?:V23#4=2M+YS!")ECU>--6@>Z9T&M:#^?5R_P#+#_DH=V_RZ*_< M&(S'\SKO[Y'=*9KJW=O75#\>MY;5J,/UEM;(;A&-AQF\=KT.2[+WLF"KMMT5 M'-#%2T<--3RK5-J(``/NO+&1J)I4^G50^U_^$6FR=EYJBW-M7^9CW9M7.K!D<;F<+L+8>*RF-K49F@J\=DBZ<_ZORZ;$(!J*?L/^?K9^_E]_$#>7P>Z"3H_>GRH[P^7U=2;MRV M?Q79O?\`E?XQO7$8*OH,/04&QJ*M>KR56VV\&<7)-3K-42NLU9-IT)I1:=.* MNDGY]:V_9'_",[XH=C]@[_[!KOF+\AL75;^WMNO>U7B:+9W5\E!C:G=F?K\] M4X^B:HQ;S&CI)J]HX]1N54$\^_?+KWA@MJQ7\_\`/U>M_*J_E@TW\K?K#?\` MU+@_E'WU\CMG[OSV#S>VL;W3E*2JH>KHL1CJO'U>)V!C:"22CPN-S[5*35D< M7CC:2FB(0'4S>ZL5TC2*5ZK'_FJ?\);_`(H_S!>RMQ?(;IW?E?\`$OOW=CS9 M'?$^W=I8[=G4G96XY9#++NG<^Q!6[>R&#W=DW-J[(XK(0QUK_OSTDM4TD[^Q MTUX;$4:G^K_5]G5*W7'_``B5[HDW921=M_.OK#&;`2M62OFZTZKW7F=XUM`C M:G@HH-T9W"8/%U52@"ZY)*R.(^K1);2?=>\*IK_J_P``ZW,_Y=W\M#XI?RQ. MF/\`0[\8]F3X\Y>>ER78?96Z*F'-=F]I[@I8#3PYC>FXTI:-)(J.-V2BQU'# M2XO'H[BGIT:25Y/=.**"G1_S:W^'OW5P*]:V?\WG_A-9\6_YFN[LKW[L'==3 M\8/E/E::%=R;^V]MVFW%L'M6HHZ9*:BK.S]B)6X6:?.Z-I:O3$D18$8ZHOZ@_X1+=DUFZ8W^0_SAV!0;)IGU>'IGJ_.YK= MN3A%E-,E?OO*8C#X%F0<2&FR01C?QM^7&E#"A%3_`*OMZ;2!D.#1:YR?\@'6 MS+TM_(C^#?P]^)_R#Z5^)_4F$HNX^Y/C]VUU`_R![5K3NSM3)Y#L#8&?VG2R M9+>[XN27:&WGK,K&]51[?H*&C,::C3RNH)8&.GF0>76OK\7?^$46U*(8O)_, MWYC9C/JG@DRG7OQQVC3X*@F*B-I:?_25V1%G*V:(E2FJ+;E(^DW1HR/;K250 M)GK0C[M1ZW+OB'\3NF?@]\>>O/C!\?\`"Y7`=4=94V8I]M4&0ZHV+5TTTD.0V_M^:A,G9&\Z)X`T\53AMN5`I M*612IBKLC!(&]%O:3<96MX]*FC.=(]<@DGY4'\^LH/NG>UK,#ADC93QZ*-_PG`_E_T73O1M7\R^P<&8NR^_<<:' MJV')4:K5[1Z5IJL219/&M,7GI9^TLC2K6N]E9\5345N)9`U[:!(XQ(!1BH_( M>7S/S]:]#+[YON_-SGSL.0MGG+\N;,3XU/@DNVQ(*?PPBD2+4A"C4X];.7`% MO^1GVH\^L+?D,#T_S=-^0RN,Q*4DF3R%#CTKJ^EQ=$U=5T](*S)US&.BQU*: MB6/[FNJY!IBA35)(W"J3[9GFBA4&5Q&"P`)\R>`_/IR.*24E8U+%02:`F@'$ MFG`#Y],V]\K6839.\,WCF2/(8?:NXLI0/)&DT:5N.Q%95TKR1/Z)46>%25/# M#@^WZ=,DC22IKQSUH5XC_A49V]E_Y;_0-72_(GKJ;^9AGOEWA=K=M['@Z,EC MH(_CED=T;DI!D:"CJ<`O7D-=58EL0/+2ULF0#2L-"L'=;QJK<>-1_ASTG>5Q ME>%#^VE1_.O1Q_@?_.0^7/??\VKN7XT]T?.+XT=>]1=7?*WY+==;?^-&X^A< M]0=L]I=0]54?9V2HLIMKMC;FSJW96#.T,;M9*BLES&9H:RICQE01&_D02-^= M.M0S.RZFX>9\N/V>GS\^E;_*R_G9_-/Y/_-'?6T?D:-I8GXT_*_J#Y7=O_RZ M#C-FX3"Y+^%?'?M+!W>FY._<]NCJ;;TW]\ M^H^OMRYC;>$P'7^U*3;>2VEC]VT]4U*[R5$=)%-%$UY@YL^AD=>5V:/5Y_ZO ME_DZ"C`_SI?Y@_P]I/Y.G;W\PWY+]2Y7X]?.B/M'N;NK.;-Z1QL&1VST96;' MZOFZRP63AVULR+-4>Y]K[DW54561;"4U0]1#.J>218C[WP&>JB;@S<".H6<_ MX4E?(.NZ6_F?]J]"[FVAW+1T?S;Z)^,7\NK,9K85#MC!;9VGWG0=LY&@W;N? M&3XG!YO<\F/PW7WFI8L[IE-7+!]POB$T3>ZWXFHT7%?\E:_X.C^=U?)?^<%_ M*Z_EJ_+KMKYV?(#HCO;Y#YW)=%[`^$VY^L=E8&BCQ7:_;65R.W]U[8W5MX[( MVCBMP2[*=X\G1M-25,%7!1R@MI)C3W#JQ+*I)_R?YNB'[_\`YT'\Q+8?\ION MO);[[GV;UQ_,4^)?\RG;/PZ[[[%JNNM@U^VZ?8V[:K<%=AMVS;1?;DFU8L#4 MT5'4015M/0I)4089Y4;7*Q]Z\NJ+*3%XA^?\O]D>G16.R?Y]W\T/;WPEW+N: M'Y.=05-5L3^9=@OBGA_GGL+HC$9#KCN/IVOZN["W%N;=&$V-EMI5M'E*39V0 MVQ197[K#XV*OJZ&K2G\32V:;WE7I.]RZ-BA6G^KR^6,#CGK:]_E[_(SL+MG^ M5M/\BLI\LMK_`#(WH^S._MQ8#Y(;6Z8R726!W+/LFOWE2X*G7JW'3U+GLALGVSNM?A;T_P!X;3[(V5U>NP<'TG\F^[]W["V3MSX]]FY';.&V MQBLS+M+)[TK&S-)'JGG?"2"CJ45I_&VX"L0.KI(=(XBI\_R^SH\^R_FS_.4^ M`/>?\NO=W\PSY!]*?)GH3^9GN;%]>UW76PNN\!M'R>SI=L9_" M;YMH[4PC--!1 M)-]J'J)5^[ACBJ*:6.1GCLBU-#PZT\A"U''_`&*]&HR/\V/Y[1?RT?Y\_>[= M[S1=N?#KYY5/3OQSW4NPNO:*7KSK:7N78NTJ3`T^&J-K'&YLMM[*U,7ERM/6 M58,A?R%P"NW`5B!PZU%(SQACQQ_,T/3_`+5^8?\`.'_FH?*[LOHWX&_*?KSX MJ;(^$/Q[^,VY=][DWCU[@MP93Y&=T=L=9[>WC7IN85>U]Q'`;>S>;&2IHQ1T M\5+04<"S-!/+4A(&\UQTVAEG6H-,?[&?S!QTUUO9_P#/3P'\Z'/_``D_V?S; M^]-M;-Z5R'SGH>OL=TKU_38'>_5M%O1S0?&.>II]JT>XZ/-YEE."7-I7@>#3 M.-,C^-=]/H6!"MDT_G3H:O\`A/9_,*^3_P`H/D;WIL'YP_-G>&5^1<.T-T9; M_GS?'+X&]S]L=4]O]6]J5F+Z4[!^)FR M>P-_[??;51@\?C?E=M;LK=V,W=08V>OCRU=C^O<5UG4MDZ8K'45)G44HD*E3 MZO7C,%E\,\:8Z#_?_P#PH1ZAI.Q]T]*?'SXL?(OY;=VX;O[LSIW;G6G1\>SL MW7[[V5U!L+8F_P#?/>VWLHN6J*(;`&/[!HJ?%QR6JLE4!B/%'I=O>?6OJ$;" M'/Y_YCU?[@ZT0O^%&VZ*KM+^9=TATGN[+P;;Z^VMUOU3M M],KDJ@4.)Q<':V_LA-O+=596%V2DHJ;&PP)-.0/$E"2>%Y*MTFC@=9IR%@5< MD^=6SY>0'75'[G]A!R[]WG>N;+$.^\7=Q>L-"EB#:6X^G4`9U%F8@>8/6Z_A M-V]+]7];[=I:+>FP-J=:;-VOB<+@*^KW;MS';;QNU=OXV#'8E8,G/D(<>M!2 MXNDC"OKTZ%O[41[A82('BFC9",$'C_L]:9WD`C8N9& M8LU5`)XG[?7JMG?O\V/:'9N\J[HS^75UYE/F[WA$IAR.X-MRU6W?C-UBLQFI MSF^T>\:FG&'%!1LNH4F'^\JJW_-PN)"/:>/6N6W4ND,@#;C>*,:;2V'JVH:'&SX#HGH#[^G6"KP_0G6E1-/'0U_@_9J M-TY=JS@_SU-&Q@]KH875S-<.9)S7R``!R0`/\/&GIPZ`W-'-^VSVK\O@\0U%0B!8UJ11N/1Z-QX@9_;V>P/G^V&;PF4P_P!S MXQ-]O_$J">B\_B8JLOB\VK22`UK7]O\`4=A2$T^=*=:PF*_X3;8:@_EB]0?` MNH[FZWJ>S>K_`)58_P"1M1\C%Z1@BR^>P])O+/[AFV!)0KN8;@CAJ<3F(Z(S MOE)(`(%/@*JJK[JNAJ4Q_J%.@NJ_^$[?S9VKVO\`-;=O1?\`,DZZZJZ^^:'8 M_P`A-Z[NV7/\4=O;LW+B\;WU#O'"UN'H>S,GN:/?.$GQ&U]W/3F3#UV-@GFA M5WA(9@=]5$;\#3_5^72_ZG_X2Y=,?&S=GPP[D^-?R1[-V3WS\:LMCJKLW<6] MFR78.P.W\3E-HUNW>R\+MK8Z#KP1QZ='OJ M_P"2K09+/?R;&MH^^ON]B;1V?#5O%5;CF@V M9'%5;6^[:*1UMZ]RU MV-QOSQ^0_7GR6ZLJM@[(I-K5_P`8.Q.K8-]IM.HQD:YVHQ^^*)COJH@K(1#B MA+1-(D9BF:.HBV,&O6_"!.LCO_XO_/T!NZ/^$\'RL^4FR.L.M?YBG\U'L?Y3 M==[-[QV9V5N7:,6P*S;4^9V9UYLW<.S]N[/VUN9=[.^U9-!55 ME3+,DCM+/"DWN[LK''#JOAMYT_;TE-]_\)2>K(Y.]-A="_)W6;Z5WQM#+=N9+';BZ"S.4R$M4.P\MV%B,IE(MUT>YLQ3@3TYDH4R&D/+' M$B>ZH0IKY=>:WC;-.X@_S%.E'V!_PF9W+E_C_5?%KK+YZ9SKOI#8?S1Z3I-X[@^/M;583=F.FZYQ^?JNQL='N/!0Y+.T5?!-)30>.KH))6BD>LF M(\QU&O5?!*KI2E*?ZN'5[_Q>^+/:O4'Q!J/C7WU\DLW\G=]Y3"]CX'.]Y9O8 MV!V+E,EC=^39E:.E&T,#5U>)@CVQC\J*>,B8M4B+7(0S'W7I0H(4`\>J_P#H M_P#D2]*='_RL.R?Y<.!W?MR3>O:75W:/5^[?EM1],[3PW9V:QO8^\B@H:G.-&\-''9H[*$WCIO2X/E2M>@`Z*_P"$U71W2V%^ M2'4O^GG=>X?BY\N_C7U?T[WWT%%L;&82ER/3GBDDFA6)4\*5ZT$<`?ZO]7_`!?4GXO_`/"?K?/7_?\` M\=.V?F+_`#".X_F_U]\(U9/AGTOO7:E%M+;G6E724U%0[:SVZJZ#<6=FW9D] MITN*HC2)XXM M]/G_`-Z=^?&/J/O:M^1^U/B;2[/QW7/6%=VM-7QY.FS^YI8-W[HDR-ZF)4J_ M#34]14T^N))H4FE5ME@5TC_)U81D_'2E/G]G4WY.?\)C'[[[W^26;VC\_>V> MG?B5\Q^[L9\@/D?\5=O;`PU?0;IW]09F?<4S8G=9W)04=-2MG*ZIJ:)JG%5! MH))4+)4FGB(\K`+0UKU[P]-`E`H^WH=_E1_PGNI^QOD-G?D-\+OG'WK_`"_, MUVIU/L[H[Y!;>ZCH6S6-[3Z\V5MO";+Q)IZV/=.T\AM_<`VCMVCI9)W>L5JB M'[J,0S25!F:(].O+$J8C-!^?^?H\64_E8;7R'S8W;\TJ+O#L/;NY=S_`6;X& M4NW\#C,+393;&#:NDKJ;MS`[YJY*W(1;]QKR:J>-Z1J99U$CE[!?=L=:\-O6 MI]?RI7[>@"^`'\E"L^(?RE7Y>]\?-;NCYP=P;1Z+3XX=+YOM[;^)PM9UEU4, MD*V2CK,K2YK/YC>VXC1I]HE?63(ZPU%2761IE,6NK(I$A8TITK/DQ_)1ZB^4 M?ROW3\G.P.T]PS8_>OF6`+$K"1B'$?17Y]4:!))"[^E.B:]?_P#"9WKGXZUZ;O\` MAK\U>_/B[VO@>[>W=]]>=G[;VKL;>&9V;TUW3MO:.V-S_'NJQ^YA)0[JP>%H M]FTTN&S57:NHIG=WBF<(Z4)J:]6\,@X^'_5\^M@+HSK+LSK&DW_1]D=\;F[W M&Y.PLAN;9%3NK:FU-L5O6VQY=O[]=712HH>AT]^ZMU2A_-7_`)-FQOYDNX=C;?J-GMN/ M^Z\.[MO[PV@]94Y3'X74KJB2DJX*DLJ54L;QR`H8]21"4*=1 M#+7R!!'\)!'#SQ3K)KV`^\WS#[%PWNSQV(W'EV\D#^$9/"*/IT%T8AUHRX== M-20I!%""2#XU_P#"8'X];'S%#F?DWW9O7Y`46,:GEINN-M8R7JSK]ZB*4.?X MO4TN=SV[%B$>-VKL[#46%Q,+6_O M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KK\GZ?\3_L?>^O'AUX?G]/_`"#]?K^??C^?5$XGX?R_R]=^]=7Z M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z] ..[]U[KWOW7NO>_=>Z_]D_ ` end EX-101.INS 8 aphi-20121231.xml XBRL INSTANCE DOCUMENT 0000874710 2009-11-17 0000874710 2011-06-30 0000874710 2011-09-30 0000874710 2011-10-01 2011-12-31 0000874710 2011-07-01 2011-12-31 0000874710 2011-12-31 0000874710 2012-06-30 0000874710 us-gaap:SeriesAPreferredStockMember 2012-06-30 0000874710 2012-09-30 0000874710 2012-11-21 0000874710 2012-11-01 2012-11-30 0000874710 2012-10-01 2012-12-31 0000874710 2012-07-01 2012-12-31 0000874710 aphi:BaralymeMember 2012-07-01 2012-12-31 0000874710 aphi:NiagaraMember 2012-07-01 2012-12-31 0000874710 2012-12-31 0000874710 us-gaap:SeriesAPreferredStockMember 2012-12-31 0000874710 aphi:BaralymeMember 2012-12-31 0000874710 2013-01-31 0000874710 2013-01-01 2013-01-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure ALLIED HEALTHCARE PRODUCTS INC 0000874710 --06-30 Smaller Reporting Company ahpi 8030247 10-Q false 2012-12-31 Q2 2013 10681395 22076403 9921422 19208513 7946458 16935449 7815489 15123605 2734937 5140954 2105933 4084908 2693894 5327983 2857065 5495640 41043 -187029 -751132 -1410732 -7297 -16292 -2821 -7047 0 -336 0 0 11743 26149 7645 15226 4446 10193 4824 8179 36597 -197222 -755956 -1418911 13907 -74944 -287263 -539186 22690 -122278 -468693 -879725 0.00 -0.02 -0.06 -0.11 0.00 -0.02 -0.06 -0.11 8124386 8124386 8100593 8112490 8124834 8124386 8100593 8112490 6512887 6251364 5284543 4586331 4843593 3551587 10001226 10049584 46042 583706 400677 590082 20576081 19361290 9603556 9628935 1167432 1137908 31347069 30128133 1797144 1693881 1855579 1961826 802961 793990 458800 114700 0 4570384 4449697 0 0 0 0 104279 104279 48540802 48563230 1136968 2016693 20731428 20972380 26776685 25678436 31347069 30128133 300000 300000 0.01 0.01 0.01 0.01 1500000 200000 1500000 200000 0 0 0 0 0 0 0 0 0.01 0.01 30000000 30000000 10427878 10427878 8124386 8030247 2303492 2397631 627378 650379 21695 22428 17030 17054 -8678 -8971 -1138044 -1274952 519444 48358 73929 537664 290234 189405 383071 -103263 -344100 -114700 -177084 106246 651471 188973 912994 646233 -912994 -646233 0 -240952 -261523 -698212 <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>1. Summary of Significant Accounting and Reporting Policies</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Basis of Presentation</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2012.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-weight: normal;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Recently Issued Accounting Pronouncements</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We have reviewed accounting pronouncements and interpretations thereof issued by the FASB, AICPA and the SEC that have effective dates during the periods reported and in future periods. Management does not believe that any of those pronouncements will have a material impact on the Company&#8217;s present or future financial statements.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Fair Value of Financial Instruments</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>2. Inventories</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Inventories are comprised as follows:</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: right;">&#160;</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2">December&#160;31,&#160;2012</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2">June&#160;30,&#160;2012</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right;">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 74%; color: black;">Work-in progress</td> <td style="width: 1%; color: black;">&#160;</td> <td style="text-align: left; width: 1%; color: black;">$</td> <td style="text-align: right; width: 10%; color: black;">689,645</td> <td style="text-align: left; width: 1%; color: black;">&#160;</td> <td style="width: 1%; color: black;">&#160;</td> <td style="text-align: left; width: 1%; color: black;">$</td> <td style="text-align: right; width: 10%; color: black;">654,677</td> <td style="text-align: left; width: 1%; color: black;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; color: black;">Component parts</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">7,799,890</td> <td style="text-align: left; color: black;">&#160;</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">7,495,333</td> <td style="text-align: left; color: black;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; color: black;">Finished goods</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">2,849,782</td> <td style="text-align: left; color: black;">&#160;</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">3,178,507</td> <td style="text-align: left; color: black;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt; color: black;">Reserve for obsolete and excess inventory</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; color: black;">(1,289,733</td> <td style="text-align: left; padding-bottom: 1pt; color: black;">)</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; color: black;">(1,327,291</td> <td style="text-align: left; padding-bottom: 1pt; color: black;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: right; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt; color: black;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; color: black;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; color: black;">10,049,584</td> <td style="text-align: left; padding-bottom: 2.5pt; color: black;">&#160;</td> <td style="padding-bottom: 2.5pt; color: black;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; color: black;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; color: black;">10,001,226</td> <td style="text-align: left; padding-bottom: 2.5pt; color: black;">&#160;</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>3. Earnings per share</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,386, respectively. The number of diluted shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,834, respectively. The number of basic shares outstanding for the six months ended December 31, 2012 and 2011 was 8,112,490 and 8,124,386, respectively. The number of diluted shares outstanding for the six months ended December 31, 2012 and 2011 was 8,112,490 and 8,124,386, respectively.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>4. Commitments and Contingencies</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Legal Claims</b></p> <p style="text-align: justify; text-indent: 0.4in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.</p> <p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient and that it is not reasonably possible at this time that any additional liabilities will result from the resolution of these matters that would have a material adverse effect on the Company&#8217;s results of operations, financial position, or cash flows.</p> <p style="text-align: justify; background-color: white; text-indent: 0.4in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><u>Stuyvesant Falls Power Litigation</u>. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (&#8220;Niagara&#8221;) and other parties, which provides electrical power to the Company&#8217;s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company&#8217;s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara&#8217;s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara&#8217;s claims. Among other things, Niagara seeks approximately $469,000, which it alleges represents the value of electricity provided prior to the commencement of litigation going back to 2003. The Company has posted a $250,000 bond which Niagara could draw against for electricity provided and not collected since the December 2010 temporary restraining order in the event Niagara prevails in its lawsuit. The amount of the bond exceeds the cumulative invoiced electricity charges generated by Niagara since the issuance of the temporary restraining order. As of December 31, 2012, the Company has not recorded a provision for this matter as management intends to vigorously defend this litigation and believes it is not probable that the Company will be required to pay for electricity as Niagara claims. The Company believes, however, that any liability it may incur should it not prevail in the litigation would not have a material adverse effect on its financial condition, its result of operations, or its cash flows.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <div style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Employment Contract</b></div> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In March 2007, the Company entered into a three year employment contract with its chief executive officer. The contract is subject to annual renewals after the initial term. The contract was amended and restated in December 2009 without extending its term. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with &#8220;good reason.&#8221; &#8220;Good Reason&#8221; generally includes changes in the scope of his duties or location of employment but also includes (i) the Company&#8217;s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a &#8220;Change of Control&#8221; as defined in the Agreement.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font style="font-family:times new roman,times"><b>5. </b></font><b><font size="2">Financing</font></b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank &amp; Trust (the &#8220;Credit Agreement&#8221;) pursuant to which the Company obtained a secured revolving credit facility with borrowing availability of up to $7,500,000 (the &#8220;Credit Facility&#8221;). The Company&#8217;s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.</font></p> <p style="text-align: justify; text-indent: 31.5pt; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">The Credit Facility was amended on November 12, 2012 extending the maturity date to November 12, 2013, reducing the borrowing availability from $7,500,000 to $5,000,000, and removing all financial covenants. The Credit Facility will be available on a revolving basis until it expires on November 12, 2013, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank &amp; Trust. Such advances will bear interest at a rate equal to 3.50% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">Under the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company&#8217;s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company&#8217;s obligations under the Credit Facility.</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">The 30-day LIBOR rate was 0.21% on December 31, 2012.</font></p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">&#160;</font></p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><font size="2">At December 31, 2012 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.</font></p> <p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>6. Baralyme&#174; Agreement</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A reconciliation of deferred revenue resulting from the agreement with Abbott Laboratories (&#8220;Abbott&#8221;), with the amounts received under the agreement, and amounts recognized as net sales is as follows:</p> <p style="text-align: justify; text-indent: 0.4in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6">Three&#160;Months&#160;ended</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6">Six&#160;Months&#160;ended</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">December&#160;31,</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">December&#160;31,</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 40%;">Beginning balance</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">-</td> <td style="text-align: left; width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">630,850</td> <td style="text-align: left; width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">114,700</td> <td style="text-align: left; width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">802,900</td> <td style="text-align: left; width: 1%;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Revenue recognized</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">as net sales</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(172,050</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(114,700</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(344,100</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">458,800</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">458,800</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Less - Current portion</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">of deferred revenue</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(458,800</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(458,800</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <p style="text-indent: 0.4in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In addition to the provisions of the agreement relating to the withdrawal of the Baralyme&#174; product, Abbott agreed to pay Allied up to $2,150,000 in product development costs to pursue development of a new carbon dioxide absorption product for use in connection with inhalation anesthetics that does not contain potassium hydroxide and does not produce a significant exothermic reaction with currently available inhalation agents. As of December 31, 2012, $2,150,000 has been received as a result of product development activities.</p> <p style="text-align: justify; text-indent: 0.4in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Basis of Presentation</b></p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the &#8220;Company&#8221;) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2012.</p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Recently Issued Accounting Pronouncements</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">We have reviewed accounting pronouncements and interpretations thereof issued by the FASB, AICPA and the SEC that have effective dates during the periods reported and in future periods. Management does not believe that any of those pronouncements will have a material impact on the Company&#8217;s present or future financial statements.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>Fair Value of Financial Instruments</b></p><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p><p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Inventories are comprised as follows:</p> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: right;">&#160;</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2">December&#160;31,&#160;2012</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center; color: black;" colspan="2">June&#160;30,&#160;2012</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: right;">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 74%; color: black;">Work-in progress</td> <td style="width: 1%; color: black;">&#160;</td> <td style="text-align: left; width: 1%; color: black;">$</td> <td style="text-align: right; width: 10%; color: black;">689,645</td> <td style="text-align: left; width: 1%; color: black;">&#160;</td> <td style="width: 1%; color: black;">&#160;</td> <td style="text-align: left; width: 1%; color: black;">$</td> <td style="text-align: right; width: 10%; color: black;">654,677</td> <td style="text-align: left; width: 1%; color: black;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; color: black;">Component parts</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">7,799,890</td> <td style="text-align: left; color: black;">&#160;</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">7,495,333</td> <td style="text-align: left; color: black;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; color: black;">Finished goods</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">2,849,782</td> <td style="text-align: left; color: black;">&#160;</td> <td style="color: black;">&#160;</td> <td style="text-align: left; color: black;">&#160;</td> <td style="text-align: right; color: black;">3,178,507</td> <td style="text-align: left; color: black;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt; color: black;">Reserve for obsolete and excess inventory</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; color: black;">(1,289,733</td> <td style="text-align: left; padding-bottom: 1pt; color: black;">)</td> <td style="padding-bottom: 1pt; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left; color: black;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; color: black;">(1,327,291</td> <td style="text-align: left; padding-bottom: 1pt; color: black;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: right; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt; color: black;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; color: black;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; color: black;">10,049,584</td> <td style="text-align: left; padding-bottom: 2.5pt; color: black;">&#160;</td> <td style="padding-bottom: 2.5pt; color: black;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left; color: black;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; color: black;">10,001,226</td> <td style="text-align: left; padding-bottom: 2.5pt; color: black;">&#160;</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>&#160;</b></p> 654677 689645 7495333 7799890 3178507 2849782 1327291 1289733 469000 250000 7500000 0.0350 0.0400 0.0021 802900 630850 458800 114700 0 0 -172050 -344100 0 -114700 0 0 2150000 2150000 <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">A reconciliation of deferred revenue resulting from the agreement with Abbott Laboratories (&#8220;Abbott&#8221;), with the amounts received under the agreement, and amounts recognized as net sales is as follows:</p> <p style="text-align: justify; text-indent: 0.4in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6">Three&#160;Months&#160;ended</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6">Six&#160;Months&#160;ended</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">December&#160;31,</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">December&#160;31,</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 40%;">Beginning balance</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">-</td> <td style="text-align: left; width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">630,850</td> <td style="text-align: left; width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">114,700</td> <td style="text-align: left; width: 1%;">&#160;</td> <td style="width: 1%;">&#160;</td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">802,900</td> <td style="text-align: left; width: 1%;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Revenue recognized</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">as net sales</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(172,050</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(114,700</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(344,100</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">458,800</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">458,800</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Less - Current portion</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">of deferred revenue</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(458,800</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right;">(458,800</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> 0 -240952 <p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>7. Share Repurchases</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On November 21, 2012 the Company&#8217;s Board of Directors approved the purchase of up to 100,000 shares of the Company&#8217;s common stock. This authority terminates on February 19<sup>th</sup>, 2013. Pursuant to this authorization, the Company repurchased 94,139 shares of stock at an average price of $2.54 for an aggregate total purchase price of $240,952.</p> <p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>8. Subsequent Events</b></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p> <p style="text-align: justify; text-indent: 0.5in; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s product liability insurer, Medmarc Insurance Group, demutualized and was acquired by ProAssurance Corporation on January 1, 2013. As a policyholder of a mutual insurance company, Allied was entitled to receive a portion of the proceeds received by Medmarc. In January 2013 the Company received a cash payment of approximately $516,000 and will reflect a gain of this amount in the quarter ended March 31, 2013.</p> 2.54 100000 94139 240952 516000 2013-11-12 5000000 EX-101.SCH 9 aphi-20121231.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:definitionLink link:calculationLink 002 - Statement - STATEMENT OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - BALANCE SHEET link:presentationLink link:definitionLink link:calculationLink 004 - Statement - BALANCE SHEET [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 005 - Statement - STATEMENT OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Summary of Significant Accounting and Reporting Policies link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Earnings per share link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Financing link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Baralyme Agreement link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Share Repurchases link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Baralyme Agreement (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Earnings per share (Details Textual) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Financing (Details Textual) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Baralyme Agreement (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Baralyme Agreement (Details Textual) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Share Repurchases (Details Textual) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 aphi-20121231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 aphi-20121231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 aphi-20121231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 aphi-20121231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies
 6 Months Ended
Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block]

4. Commitments and Contingencies

 

Legal Claims

 

The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company intends to continue to conduct business in such a manner as to avert any FDA action seeking to interrupt or suspend manufacturing or require any recall or modification of products.

 

The Company has recognized the costs and associated liabilities only for those investigations, claims and legal proceedings for which, in its view, it is probable that liabilities have been incurred and the related amounts are estimable. Based upon information currently available, management believes that existing accrued liabilities are sufficient and that it is not reasonably possible at this time that any additional liabilities will result from the resolution of these matters that would have a material adverse effect on the Company’s results of operations, financial position, or cash flows.

 

Stuyvesant Falls Power Litigation. The Company is currently involved in litigation with Niagara Mohawk Power Corporation d/b/a National Grid (“Niagara”) and other parties, which provides electrical power to the Company’s facility in Stuyvesant Falls, New York. In fiscal year 2011, Niagara began sending invoices to the Company for electricity used at the Company’s Stuyvesant Falls plant. The Company maintains in its defense of the lawsuit that it is entitled to a certain amount of free electricity based on covenants running with the land which have been honored for more than a century. Niagara’s attempts to collect such invoices were stopped in December 2010 by a temporary restraining order, although a court has not yet ruled on the merits of all of Niagara’s claims. Among other things, Niagara seeks approximately $469,000, which it alleges represents the value of electricity provided prior to the commencement of litigation going back to 2003. The Company has posted a $250,000 bond which Niagara could draw against for electricity provided and not collected since the December 2010 temporary restraining order in the event Niagara prevails in its lawsuit. The amount of the bond exceeds the cumulative invoiced electricity charges generated by Niagara since the issuance of the temporary restraining order. As of December 31, 2012, the Company has not recorded a provision for this matter as management intends to vigorously defend this litigation and believes it is not probable that the Company will be required to pay for electricity as Niagara claims. The Company believes, however, that any liability it may incur should it not prevail in the litigation would not have a material adverse effect on its financial condition, its result of operations, or its cash flows.

 

Employment Contract

 

In March 2007, the Company entered into a three year employment contract with its chief executive officer. The contract is subject to annual renewals after the initial term. The contract was amended and restated in December 2009 without extending its term. The contract includes termination without cause and change of control provisions, under which the chief executive officer is entitled to receive specified severance payments generally equal to two times ending annual salary if the Company terminates his employment without cause or he voluntarily terminates his employment with “good reason.” “Good Reason” generally includes changes in the scope of his duties or location of employment but also includes (i) the Company’s written election not to renew the Employment Agreement and (ii) certain voluntary resignations by the chief executive officer following a “Change of Control” as defined in the Agreement.
EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W M8C,Y9#5B8F8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC M:65S7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9I M;F%N8VEN9U]$971A:6QS7U1E>'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E7U)E<'5R8VAA#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I!8W1I=F53:&5E M=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF M72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U M;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T M7V-C9&1D86-E7S,Y-C1?-#8Y.5]B9C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^04Q,245$($A%04Q42$-!4D4@4%)/1%5# M5%,@24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@ M("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^4VUA;&QE3QS M<&%N/CPO6UB;VP\+W1D/@T*("`@("`@("`\=&0@8VQA2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^9F%L'0^1&5C(#,Q+`T*"0DR,#$R/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B M8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV M-%\T-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2P@<&QA;G0@86YD(&5Q=6EP;65N="P@ M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#8R."PY,S4\ M6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA3H\+W-T3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S3H\+W-T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!S=&]C:RP@870@ M8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E? M8F8W,U\Q.64W8C,Y9#5B8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO8V-D9&1A8V5?,SDV-%\T-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#DW,2D\ M6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'!E;F1I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B8F8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV-%\T M-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6EN9R!U;F%U9&ET960@ M9FEN86YC:6%L('-T871E;65N=',@;V8@06QL:65D($AE86QT:&-A28C.#(R,3LI(&AA=F4@ M8F5E;B!P2!A M8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A;&QY(&%C8V5P=&5D(&EN('1H M92!5;FET960@4W1A=&5S(&]F($%M97)I8V$@9F]R(&-O;7!L971E(&9I;F%N M8VEA;"!S=&%T96UE;G1S+B!);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT M+"!A;&P@861J=7-T;65N=',L(&-O;G-I2!O9B!N;W)M86P@ M2!O=&AE M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[ M)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E M;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE2!T:&4@1D%30BP@04E#4$$@86YD('1H92!314,@ M=&AA="!H879E(&5F9F5C=&EV92!D871E28C.#(Q M-SMS(&9I;F%N8VEA;"!I;G-T6%B;&4N(%1H92!C M87)R>6EN9R!A;6]U;G1S(&9O&EM871E('1H96ER(&9A:7(@ M=F%L=64@9'5E('1O('1H92!S:&]R="!M871U2!O9B!T:&5S92!I;G-T M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B8F8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV-%\T M-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W9E'0M86QI M9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L M86-K.R<^)#PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z M(&)L86-K.R<^)B,Q-C`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`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS M1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE3L@=&5X="UI;F1E;G0Z M(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE2X@5&AE(&YU;6)E2X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B8F8-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV-%\T-CDY M7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@=&5X="UI;F1E;G0Z M(#`N-&EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE#L@9F]N=#H@,3!P="!T:6UE2!C;W5R6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UEF5D('1H92!C;W-T2!A M=F%I;&%B;&4L(&UA;F%G96UE;G0@8F5L:65V97,@=&AA="!E>&ES=&EN9R!A M8V-R=65D(&QI86)I;&ET:65S(&%R92!S=69F:6-I96YT(&%N9"!T:&%T(&ET M(&ES(&YO="!R96%S;VYA8FQY('!O2!A9&1I=&EO;F%L(&QI86)I;&ET:65S('=I;&P@28C M.#(Q-SMS(')E6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE2!I;G9O;'9E9"!I;B!L:71I9V%T:6]N('=I M=&@@3FEA9V%R82!-;VAA=VL@4&]W97(@0V]R<&]R871I;VX@9"]B+V$@3F%T M:6]N86P@1W)I9"`H)B,X,C(P.TYI86=A28C.#(Q-SMS(&9A8VEL:71Y(&EN(%-T=7EV97-A;G0@1F%L M;',L($YE=R!9;W)K+B!);B!F:7-C86P@>65A2!M86EN=&%I;G,@:6X@:71S(&1E M9F5N2!A('1E;7!O2!R97-T M2`D-#8Y+#`P,"P@=VAI8V@@:70@86QL96=E2!R97-T2!I="!M M87D@:6YC=7(@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE2!E;G1E M6UE;G0@8V]N=')A8W0@=VET M:"!I=',@8VAI968@97AE8W5T:79E(&]F9FEC97(N(%1H92!C;VYT'1E;F1I;F<@:71S('1E6UE;G1S(&=E;F5R M86QL>2!E<75A;"!T;R!T=V\@=&EM97,@96YD:6YG(&%N;G5A;"!S86QA6UE;G0@=VET:"`F(S@R,C`[9V]O9"!R96%S;VXN)B,X,C(Q.R`F(S@R M,C`[1V]O9"!296%S;VXF(S@R,C$[(&=E;F5R86QL>2!I;F-L=61E6UE;G0@8G5T(&%L6UE;G0@06=R965M96YT(&%N9"`H:6DI(&-E2!T:&4@8VAI968@97AE8W5T:79E(&]F9FEC97(@ M9F]L;&]W:6YG(&$@)B,X,C(P.T-H86YG92!O9B!#;VYT7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE3IT:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M2!I2!T;R!A($QO86X@86YD(%-E8W5R:71Y($%G2!O8G1A:6YE9"!A('-E8W5R960@ M2!W:71H(&)O6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`S M,2XU<'0[(&UA#L@9F]N=#H@,3!P="!T:6UEF4],T0R/B8C,38P.SPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T M97AT+6EN9&5N=#H@,"XU:6X[(&UA#L@9F]N=#H@,3!P M="!T:6UEF4] M,T0R/E1H92!#2!D871E('1O($YO M=F5M8F5R(#$R+"`R,#$S+"!R961U8VEN9R!T:&4@8F]R2!F3L@=&5X="UI M;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!S=6)J96-T('1O(&-U2!B;W)R;W=I M;F<@8V]N9&ET:6]N2X@ M06UO;F<@;W1H97(@=&AI;F=S+"!S=6-H(&-O=F5N86YT28C.#(Q-SMS(&%B:6QI='D@=&\@:6YC=7(@8V5R=&%I;B!A M9&1I=&EO;F%L(&1E8G0[(&UA:V4@7!E(&EN8VQU9&EN M9RP@=VET:&]U="!L:6UI=&%T:6]N.B!T:&4@9F%I;'5R92!T;R!P87D@<')I M;F-I<&%L+"!I;G1E2!O9B!U;FEN2!T;R!B92!I;B!F M=6QL(&9O#L@9F]N=#H@,3!P="!T:6UEF4],T0R/B8C,38P.SPO9F]N=#X\+W`^ M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N M=#H@,"XU:6X[(&UA#L@9F]N=#H@,3!P="!T:6UEF4],T0R/E1H92`S M,"UD87D@3$E"3U(@6QE/3-$)W1E>'0M:6YD96YT.B`P+C5I M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B8F8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV-%\T M-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6UE M("!!9W)E96UE;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L M87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0@0FQO8VM= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T M97AT+6%L:6=N.B!J=7-T:69Y.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E"8C,38P.TUO;G1H'0M M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$ M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE M/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)V)A8VMGF5D/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI M9VXZ(')I9VAT.R<^*#$Q-"PW,#`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`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^#0H\=&0@6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E M>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^#0H\=&0@#L@9F]N=#H@,3!P="!T:6UE6UE)B,Q-S0[('!R;V1U8W0L($%B8F]T="!A9W)E960@=&\@ M<&%Y($%L;&EE9"!U<"!T;R`D,BPQ-3`L,#`P(&EN('!R;V1U8W0@9&5V96QO M<&UE;G0@8V]S=',@=&\@<'5R#L@9F]N=#H@ M,3!P="!T:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'`@3L@8F%C:V=R;W5N9"UC M;VQO#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;CL@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2!T97)M:6YA=&5S(&]N M($9E8G)U87)Y(#$Y/'-U<#YT:#POF%T:6]N+"!T:&4@0V]M<&%N>2!R97!U3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B M8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV M-%\T-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!-961M87)C+B!);B!*86YU87)Y(#(P,3,@ M=&AE($-O;7!A;GD@6UE;G0@;V8@87!P2`D-3$V+#`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`P+C5I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E28C.#(Q-SMS('!R97-E;G0@;W(@9G5T=7)E(&9I;F%N8VEA;"!S=&%T M96UE;G1S+CPO<#X\2!497AT($)L;V-K73PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M#L@9F]N M=#H@,3!P="!T:6UE6%B;&4@87!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2P@0W5R6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)#PO=&0^ M#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8V]L;W(Z(&)L86-K.R<^)B,Q M-C`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`@("`\=&%B;&4@8VQA M'0^/'`@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`P+C1I;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`Y,"4[(&)O6QE/3-$)W9E M6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`T,"4[)SY"96=I M;FYI;F<@8F%L86YC93PO=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`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`\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^ M#0H\=&0@'0M86QI9VXZ(')I9VAT.R<^-#4X+#@P,#PO=&0^ M#0H\=&0@'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^#0H\=&0@ M'0M86QI9VXZ(')I9VAT.R<^-#4X+#@P,#PO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY,97-S("T@0W5R M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V)O'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)W!A M9&1I;F6QE/3-$ M)V)O6QE/3-$ M)V)A8VMG6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X- M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^#0H\=&0@6QE/3-$)V)O6QE/3-$)V)O3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q M.64W8C,Y9#5B8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D M9&1A8V5?,SDV-%\T-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y9#5B M8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D9&1A8V5?,SDV M-%\T-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'1087)T7V-C9&1D86-E7S,Y-C1?-#8Y.5]B9C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6UE("!!9W)E96UE;G0@*$1E=&%I;',@5&5X='5A;"D@*$)A6UE(%M- M96UB97)=+"!54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@@8V]L3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q M.64W8C,Y9#5B8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V-D M9&1A8V5?,SDV-%\T-CDY7V)F-S-?,3EE-V(S.60U8F)F+U=O'0O:'1M;#L@8VAAF5D('1O(&)E(%)E<'5R8VAA'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M M;6EC&UL/@T*+2TM M+2TM/5].97AT4&%R=%]C8V1D9&%C95\S.38T7S0V.3E?8F8W,U\Q.64W8C,Y )9#5B8F8M+0T* ` end XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Earnings per share
 6 Months Ended
Dec. 31, 2012
Earnings Per Share [Abstract]  
Earnings Per Share [Text Block]

3. Earnings per share

 

Basic earnings per share are based on the weighted average number of shares of all common stock outstanding during the period. Diluted earnings per share are based on the sum of the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The number of basic shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,386, respectively. The number of diluted shares outstanding for the three months ended December 31, 2012 and 2011 were 8,100,593 and 8,124,834, respectively. The number of basic shares outstanding for the six months ended December 31, 2012 and 2011 was 8,112,490 and 8,124,386, respectively. The number of diluted shares outstanding for the six months ended December 31, 2012 and 2011 was 8,112,490 and 8,124,386, respectively.
XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENT OF OPERATIONS (USD $)
 3 Months Ended 6 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Net sales $ 9,921,422 $ 10,681,395 $ 19,208,513 $ 22,076,403
Cost of sales 7,815,489 7,946,458 15,123,605 16,935,449
Gross profit 2,105,933 2,734,937 4,084,908 5,140,954
Selling, general and administrative expenses 2,857,065 2,693,894 5,495,640 5,327,983
Income (Loss) from operations (751,132) 41,043 (1,410,732) (187,029)
Other (income) expenses:        
Interest income (2,821) (7,297) (7,047) (16,292)
Interest expense 0 0 0 336
Other, net 7,645 11,743 15,226 26,149
Nonoperating income (expense) 4,824 4,446 8,179 10,193
Income (loss) before provision for (benefit from) income taxes (755,956) 36,597 (1,418,911) (197,222)
Provision for (benefit from) income taxes (287,263) 13,907 (539,186) (74,944)
Net income (loss) $ (468,693) $ 22,690 $ (879,725) $ (122,278)
Basic earnings (loss) per share (In dollars per share) $ (0.06) $ 0.00 $ (0.11) $ (0.02)
Diluted earnings (loss) per share (In dollars per share) $ (0.06) $ 0.00 $ (0.11) $ (0.02)
Weighted average shares outstanding - basic (in shares) 8,100,593 8,124,386 8,112,490 8,124,386
Weighted average shares outstanding - diluted (in shares) 8,100,593 8,124,834 8,112,490 8,124,386
XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting and Reporting Policies
 6 Months Ended
Dec. 31, 2012
Accounting Policies [Abstract]  
Significant Accounting Policies [Text Block]

1. Summary of Significant Accounting and Reporting Policies

 

Basis of Presentation

 

The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2012.

 

Recently Issued Accounting Pronouncements

 

We have reviewed accounting pronouncements and interpretations thereof issued by the FASB, AICPA and the SEC that have effective dates during the periods reported and in future periods. Management does not believe that any of those pronouncements will have a material impact on the Company’s present or future financial statements.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
XML 20 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Baralyme Agreement (Details Textual) (Baralyme [Member], USD $)
 6 Months Ended
Dec. 31, 2012
Baralyme [Member]
  
Abbott agreed to pay Allied $ 2,150,000
New product development costs $ 2,150,000
XML 21 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Subsequent Events (Details Textual) (USD $)
 1 Months Ended
Jan. 31, 2013
Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds $ 516,000
XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 23 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories
 6 Months Ended
Dec. 31, 2012
Inventory, Net [Abstract]  
Inventory Disclosure [Text Block]

2. Inventories

 

Inventories are comprised as follows:

 

    December 31, 2012     June 30, 2012  
             
Work-in progress   $ 689,645     $ 654,677  
Component parts     7,799,890       7,495,333  
Finished goods     2,849,782       3,178,507  
Reserve for obsolete and excess inventory     (1,289,733 )     (1,327,291 )
    $ 10,049,584     $ 10,001,226  
XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
BALANCE SHEET (USD $)
Dec. 31, 2012
Jun. 30, 2012
Current assets:    
Cash and cash equivalents $ 4,586,331 $ 5,284,543
Accounts receivable, net of allowances of $300,000 3,551,587 4,843,593
Inventories, net 10,049,584 10,001,226
Income tax receivable 583,706 46,042
Other current assets 590,082 400,677
Total current assets 19,361,290 20,576,081
Property, plant and equipment, net 9,628,935 9,603,556
Other assets, net 1,137,908 1,167,432
Total assets 30,128,133 31,347,069
Current liabilities:    
Accounts payable 1,693,881 1,797,144
Other accrued liabilities 1,961,826 1,855,579
Deferred income taxes 793,990 802,961
Deferred revenue 0 114,700
Total current liabilities 4,449,697 4,570,384
Commitments and contingencies      
Stockholders' equity:    
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding 0 0
Common stock; $0.01 par value; 30,000,000 shares authorized; 10,427,878 shares issued at December 31, 2012 and June 30, 2012; 8,030,247 and 8,124,386 shares outstanding at December 31, 2012 and June 30, 2012, respectively 104,279 104,279
Additional paid-in capital 48,563,230 48,540,802
Accumulated deficit (2,016,693) (1,136,968)
Less treasury stock, at cost; 2,397,631 and 2,303,492 shares at December 31, 2012 and June 30, 2012, respectively (20,972,380) (20,731,428)
Total stockholders' equity 25,678,436 26,776,685
Total liabilities and stockholders' equity 30,128,133 31,347,069
Series A Preferred Stock [Member]
    
Stockholders' equity:    
Preferred stock; $0.01 par value; 1,500,000 shares authorized; no shares issued and outstanding $ 0 $ 0
XML 25 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories (Details) (USD $)
Dec. 31, 2012
Jun. 30, 2012
Work-in progress $ 689,645 $ 654,677
Component parts 7,799,890 7,495,333
Finished goods 2,849,782 3,178,507
Reserve for obsolete and excess inventory (1,289,733) (1,327,291)
Inventories, net $ 10,049,584 $ 10,001,226
XML 26 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
DOCUMENT AND ENTITY INFORMATION
 6 Months Ended
Dec. 31, 2012
Jan. 31, 2013
Entity Registrant Name ALLIED HEALTHCARE PRODUCTS INC  
Entity Central Index Key 0000874710  
Current Fiscal Year End Date --06-30  
Entity Filer Category Smaller Reporting Company  
Trading Symbol ahpi  
Entity Common Stock, Shares Outstanding   8,030,247
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Dec. 31, 2012  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2013  
XML 27 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Earnings per share (Details Textual)
 3 Months Ended 6 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Weighted average shares outstanding - basic (in shares) 8,100,593 8,124,386 8,112,490 8,124,386
Weighted average shares outstanding - diluted (in shares) 8,100,593 8,124,834 8,112,490 8,124,386
ZIP 28 0001144204-13-007330-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-007330-xbrl.zip M4$L#!!0````(`!9Q2T([7,-T["X```^/`0`1`!P`87!H:2TR,#$R,3(S,2YX M;6Q55`D``[Q!&5&\01E1=7@+``$$)0X```0Y`0``[%WY<^,VLOX]5?D?N-ZW MJ=TJ'01OVC.SI?$QXV0.K^W)4>^]FJ)(R$*&(A4>MI57M7_[ZP9)B90HB;1( M6;/);B61B:,_?&@T&D`3?/'/QXDKW-,@9+[W\HCTQ".!>K;O,._NY=&GVXNN M)O&>Z(NDN^L:.@P`T>EVY-+6DH$-9>1E(*,E.'^UQ M>7Y,*2G`O'L:1N5%DK220I[%[+"\#$_"(J18)&1V>0%(*,L>38,U^2&EI$`< M=N\L:SHO,[+"(>_9-*&D%8_N!OWY^1TJ-0Y+U.[CD.OM-1T)7-N/4U79/";Z MT\"?TB!B-,R//EY!-)M"Z9!-IN[\V3B@HY='..J[V=CN/8;.43^S4*>^%]'' M2+BA=H2&IF`X[#21@8JG&3\/PL\?1Y^)WOW@WW=1QX\6^<&2L6BV^)LY^`3L M6B#PUA8;E]%_>OG#T2L1_F?HBD[$%_WEPEAAOUP"<,%\)R>1C^H('B"T+G0I MT1>E%ZG9DT7Y?J')53B0Q>[WL8>\DH/E`'5:Z\IBBQS_#!Y9^/D& M)-!P<`4N``5GT.$I[^ED2(/],)>.&7J'\+('#H@$/YC9+$JP"`Z#]&29EGI6 MQVL;=?1JGF5]ZU[T2P7EN,YA.LSN32?5PU;Q'295_/]6'B22.IF'S0-8/*D% M7.)O2PYUO<&#C.P3YZQ9\4P;`ISU;@/^'ZMCE%=1AV;AEEZ+5%51.O?]7_R;_<_'CU5OZ2,]433=^N::_L5<_?[K\-S[^Y8'=VXJBV*JJVK?_ M-WZEO7A[_D)Y\X94<^?,*^LVJH$%:KH%]%O;ODTSC6X M*!:3MO&(>G3N\NFQH&(OT&E,_,5K>L?"*("Q_L&:4"%5SFL\25R[7AR\>W=Y M?B:\/1^\NWU[.K@^%ZZN/YY].KV]$2X_G+[HKZL=(2W23@$5&/I+SZ&//]!9 M-='Y<;^VJDS.*3\7CRY8:%ON+]0*SI/164U4-]GX2^2LJZK8I`OFTN`4'M_Y M0<4&W4PL%PH)UW3J!Q$&I)SZDZGES?+M*]2;B;P-+`QPN9E-AKY;39@UGK*D MWD+AI7[Q)Q/?XTX2'W#AQSC"R0#SEXI9G><$5$">)S4M@D-M!BT-7QZ)1Z\, M418E12_TX`:A&;PL@.9V-JW8A43L_BN1DB^;U3>`!PX^O'"M\I:M5#B")M"D MQD+I98A7W.C74K>%)U)$7*AJ64ZBCTF6"W@65I/U+ZDH8Z6:2([6XX)%U63%E?0,A57D=F'>50B2*:JK*SS#J] M+Q%1-66YX79NEJF(AF**QE:9-]1U8>)/0G5=Z/B!`_XS]R0C=D_/'Z?4"\OG MU5I=#6/2,'.T5Y/;$-):"B)+NFG(SX2TEEH9JBYJZD%PNAFIJI@J3-*[(/TX MQ?4BE+GT;']"WX$R[ZR4"A&57$>7B'@*@CK*UB6&+DIFXQCJJ%%75PF1I99Y MV(*!0%_H-4!<\H!G='23]$N0"4N9W>>DKBZ9N1EIG9PG8ZFG'9ID2BV"J:4F MDB&1O1&S365%I78G)<^:FM#$O/A"U76EUM((6=8:$URG]]MJ;A-2/T9C&GSP M/;]H,IKJ:4+TPBRQ4=J.N&JM?#627^.TBJO66@>6@\]"U[8%CR1I3\'5GF8I MBI)#U`*86JMFD9ARJVCJ*)%B2,H>J=D,QB"Z61/,PFNY"/P)"F5>#`52M\;W MPM=TY`BJ36$-054U%:@U)SI:-+FKPG6K9@4663&"NC<".6#S1J<),$O"8SYX<7 M*J\GM9Y%!GNL&XW(K=7WBF9H!3^HJ?9ND6OH,`6I%>2>6X$'5B*\H@$_OGUM MA^%"B5]U1(K2C1CIA:4:1&>6I(F4HP_439W1B>#>[!W[FC'V(, M&/TX6@DL>8J5*@]H(9(BYR?$6@B:A;Y>&0\>^GJ=70-=Q"/,@X"^7K770`?: M\QY,T]#345$M@.L)VF[(RE;PZS`T#;\EC=\7_):T_GG8;TSSJ\`_M<+QP'/P M/^>_Q>S>3]T7+C\HVVU4M=-OG!FDHDP\@M22L);A1IQ16* M)JE$UI3G1)J[LF'CZ;MD*&K^".,9.=VRZZL:FBR3'9`.;'ZS5WA-;0K9ARY& MPJ41Q0U0J1B*7+`(F^0U@:LB<;*J$C4_;*KBPJ-3#V].6Q>26(\?,)B012KL M5RP$/$5PU=,=451,U5"J")[OQ"W(:4(U-%%9V4%>$K,3CJJQ-H:LBV4;1NN` M\).P01C2*&QPH(BBIN?T<57(TR%4)<(414.J"J%I`B11U371R-FRW457C@R6 M-2+E)_ZUHJ^2:^]F5Z[E16!HTO%;8SHLKF5"-&WJ6IA.@L?0,>)MY6>#)$"7`M M0&V4UPBPJN$_IFSFYY[:P-(W6.H@VA)FHQJ&6(*H*&@W*)7M/%BXEJ'4CZW; MCJ(5%594793S+OMF_6A%6Q5%,;5\-,QF#,6++9I:H(MY1V1%0"/RGW@CR;.@ MKJ_`;HBFCDCP:WBVT.9.502%63)5E\,DC;CB>QBS?J7WH/Z!AO MAKFGBQ@#6.E\',$DW<@L)VNF9A0\ICH06D)?];4JD6C:TA[?4]'?!ORZB%FC MHU@2=9DH4H[?53%/!U&9)5.79$.L"H(_'?NN0X,05]=1^:4--9G0=%W3C/PK M<"MBG@ZB*A-X88R2?R]C,XBIO0I@`^>?5=!^#`=?T'_,C( MA1^<^?$P&L7NZH9W$SSB'2AYPUM)<+-0*S.Z*]2B.W)E!1\#[OXX?"QG,2!/ M8753J!!9YP^M`]`6Y"9\O0-N:.U8H$."_!7U37**/HBCL1^PW]=$9VT:+Z5' M^41=&MZ;A38-;V?^2QLE/4.;JD=//`OE#:K\'BB_#,.X*0W?`BH1U22@=@C> M4S.JJ_'>`1TPKQ5O5VM,:=?$4C4"[5EH;KY!C2ERF]`.B>O<)L\SN.@5I#<( M=D>?]>E@VW'BDB5:?OK=(+(!9-7'5G/(FG0)^':QH1L;4*W:_2<@JN$3-H*H M\6EH)*X;=+\0=>G37!VVQ_Y\]W?N]2DW0YK]]5A+8`EZ:* M*:1;;M%6A3+PEHJO;R/9I."F+X?R^]BEOL]=Y()[(A+EU1L%5L"S"W M75$AZ8JI2DW"S$+I60.C7B6FLIG$G+0F86T[9)?S=QCOA*IJ7'\=VG39S%\3 M65%L.TBWA-W+NJ9MZ>#:4/FY^_Q*R`U!P+7F:U.4Y(U(R\2V`G1;3*RIY&]J M;@+H4I3OSF3*ABSJI(K5224V#6^;613EY3M==L&W%#*Y^^PB*PK)+\"WBFP: MWS;^EB)7=\175-C?0O2?%G;!CMA],RQK*NA#;KA7%]T:X&TV%-Q+>5?`8!MP&SB\]0?V;S$+ MZ-H7AW9FV"22F;\PO;KHU@!O694KFI2/Z'D:X#7]DESQVZP.=Y+$>;Y5CO+%GV7#OKL.2QI1 MI:WO]I=+;Q'U-CTV#8E(NZ.^87<>&S$;#4KBOD&W7/GX\4H:W@*LU^ZZ(.R5 M;RA]YT8G4R&,9BY]>32Q@COF'0OB-()_'D^$$10[%@C^';$):)M''X3`GUA> M)WG0$4*`.SHY^NXN.L&ZAOB#](2;>`*US01_).3@"@N\@N4YPN*C9!E\K*,_ MS&KK3_'7M]^T@O([:S(]^2O1Q),]"L7[=4)DY2J@(70WWY;<@_QB6\LDH'YT M+1LR2'Y++3<:VWA^FG[4%6J&@=(3_@Z.HI"TT9`D\23] MQ-W\"3GYAS"V[JDPI-03I@&=0B6.P#R.)'!P0U)X8-%8P(KPVZ1!S+]F&$+C M`N'"#R8"?NN-*ZWC"YX?02[;C1UHB^LBQJ0@Y)XD^]D\)PMMU\:CH)I`/6PJ0LY[I+O@K@\G4ZC!"#6^\GC]/"CW(20"?!I6QP<,NG2 MB):RUP-^>!7^E'D("PI#OUAW/+G#P5L.=C?/WD&C`0K*H?F>R\>OAVURH0'X M&C0?N8L"27Z'8L,\:M,PQ$&/L`"J[FG5P?I.PY/6'N?(*$,':CA'+H M/>&WV`HB"K^APY'Q3``#7*"30`!^-B4C?[FTCXN'>1WP$!,PXRB&1L^H%?0$ MT$4P[#EE"\=^[$(?8746YQ\:^&OL)9^VG&M(J:)BCP-,Z*'(7Y\+45'(D!&0 M]?&2RA+])!0&GA=#Z<1*0G_,%?&'>6.P'0+UL*+O8X\*LM@1T++WVK1D6"*K M#G]W'_@=2\>IJI2:',RWT<*5VI^FS"YNN7D1Z$UZ,)Z;A\"4>/#;3OJG@BEN M!>CAV.>?:#),`WK/Z`-P5;!6>:ZXQC-P+`(8YI`(.+^:MO.2S9=7!LZ=Q MTKS+4M;YBZYF"Q*R*119LL&U[V0#"!5X?N"`*CQ_/DTV7_E\!&626[X$:Y*D M\DF^5D6"-07M?F2HQZBYT'%\,K[GO>?`/^D,!=,=3"R0#09;E(X-G!%SSMJ6FTVJ0S^*_,E)/J]3-OD&Z.N4MC=RRLJF,+I) M_=">:72"C?0#D.E:]I<:=:5D957QXEBA$,+@;]NQ?;7LTLNT3H4XOI8915_Y6IB$_^<$7\&S0<[T#MS/< M0$-F84OKJ4VD2T>@LAOK_*^*526Z-Z]++*U,,\R.IJC-H:O4XJ^<,U7I:+J^ M%\XJ#X*',8MHO2&PBG(5&OKBOH?+KJD51)O&06,=V4!%:3>NUJ1W=-/L&*:X M#T1?"2.*J79D66X/4;N&O`JX"_SV\Q@<\SO\^OS7WF52QU#,CFYL\H3^6$HL M=XAN=%2QGDT^&$-8-G"_P`]_YUT MH(Z@M3KR=]*1P-G1:UJZBH3]XT_.RSF7);TCF60_G.]OIDF;O(Q4ZJG3738L MDO*-]AFO4G#\>.C2:OJQR5FN*6*M9A"Q(\(DIAK*3IJQ&U]_:/9%L(>2MG?V M"T.TS_^2[RJ4;%]O^EK9(>QQRSTA@X5G90)_+Y,W]+FWNO=UI)E\5HNN MD,`WR(?XDF!VQ/>0?BQ(L)*O!0D>_UP0GHPDK[/B+PR:L/D;O=`0[%L_]P+Q MRKEE3\@^65<%0!A/LH"&2E@*.-#M*CR@B["R;2#QZ&DA8,@9R\3D2F9Q!]$X MH%0`2=$X3.,/LIUD029)#`+'@\%\T!1HI]$AHMA139D_A[\DI2,;6@S-'"^/(<'K%F'Q/&8$V@P5!#/(*\R1P$"6EH M)*\GH#8/J`S`@CD\Q"!*PQ:G:&) M`&7PD"C9&QTARW:/>ZUCK.Z>V*>.(@&2&(,`!X("R#CST M(0E`965EY5&5^>7*LY#G*7X30=DAT3@DH!R4C6&42&TFDB1"Q`CX0V`4'-#%/TFL.68A$Q1;#K@Z+RSV M"'5:Y[^@CX0$33E'AD`=K&P6A85\6]FC![-G;X0?X+.VD>JJ$L'DYO'N9)*K MX+8F!=IPP"0;C3";)4PE7?`2SPFSRC`E/PIAC+DUBY+$IYP;6*L)_!W7)T\W M$QJUO#`$99MQQJHU@H55&:P1&'^\,58Q,(ZCR;B]KO\ M_ED4SR)>0,M].W@KK`LAQ>R7V'>M-T8RO/Q`(1D>99H3I/$&S M&G?8;IC$EX7H/.=9Y0&N"B]#KAXG41BA=AR128Q)M80T9@@6%,*#A>6E6:/2 MF,Y2:=<#I(/MMV8KA4$0),YF+'4Z1(!%<:A&P<)/@(S%:)23-(8)LKUVO1@+ M!\!89&/T"-#E2,GPH&J<>Z`>LR"/:+%4(=5Q,_RGC&"V,0?6*<0M8RF9H$W! MPN0"@GY%8J8VPL9YW3LZL1V(Y23?8'5@%&],!1S(Q&-\P=N0X0AZ@@L.'.X[3+8H2<@&4*)DOZW7G$(^T@)V17E@U MF2&IZKB7E9'"]F'H&F"A. M]3=RG(HY@'R0("W%LW9!1RA11#\H)@8R+Q&D2/HYL(79LJ(C:W@)AC]\XX\C M,&()2!GI`Y=?,X0!UT6[%;ES4'1Z3,+(ZE-MB:P%@F%F8EFI`4U:3N3&,(5, MC6F#AHP3_SCUI[%WIP%U[]YD%CZTW061%0A3D<+,81!"R$U4/*L MSV+!!S@7,6A"4)[]XKZE=#TR1V15^5R/"YQRM@TEV]ALDC1-?`_4^ITWS&0] M&'CN7BRSZ=7CQ;A<<&45N%_>K0#U)T:I%\L:/I!B^!/\/%WX!)Z5B2D?J>'> M1_TDTB7[Z9P0;5&&84:J_!DT0\N?E%5@_#?82]KMP[>'`KP;/M2=J",`>C,* MP,P;0J2-9@65">GBF80Q,(H2067<)#,3$:#6]D>%1543PY@/"">9THY9@,08$AYY$&-^.`.;:"*#^9,"@; M9.B`)%'^N3?^WU2IS68,P M++WS(\ZERRBLI>IS#V:GE-B%>!Q#X3E'=%\CP?[=-58]HSNEY=RF`D77NH!` MCC1^NV^3UK=9+WWB@D@\G/T@PN^\M?`?Z[<8)KAV=R%.GV4Q>L>D M%7(%KVB.!KC]R<%-D$X/M2">)!"2,7]7Q^9$W""*8[GG^92,_P:;/9OA&*_[ M]J'#0Q1>H<,0FA0L**\:I+7;YO2#9F^5K+/I0(&URW=0 M1UY+YOX2G1RHND27ZABCI1>Z>$7I9D/UP@KII@-60[)1S@_IU(!.#MB5FT:T M:_",P@QJY&&-E/#%^W(!,R@SP!-R]Y5^\B10W6=^*<=%7IJ7O#L+_WOSL5KE?880*<)C4;^=)% M!*O![D1>X)U?*('&N8GHJOH>38@@,7BEI*B3-(B8KXW`N4:6`#MQ];7WV3TX M='["861^J=0.7:?E0K3[]7=.)J MG/?B<98_7'U6K?05HX-D<6X(\TLD%]QB7)?O9MRFONRY.G`#+\7'TT,\S*(( MDKOEH@I"#8M(!0FX\ZJ_!>T%1&S0#U("T7N.R3DB5]1`Y!HF0L+C$`L%1!0! MWBLF[ZGZ'9-Q<=/BD;47CR6T#N*R#-5-+W-*W2^_!ZG!I"HY@KR]5O8_1B"= M!"](\/]AR5WR5G(NKK?L\N-T`$IZ`R(9@8=4\CK=,X0+3^1&RMF62@;O]N8S M3X9V\'M;JXW`ARB'W)QWC/P"]@"Q(.3YG@3Y$8&M59MMC3R.))D32M7?3B`> M!`W^G@T:!+4@0YCQ92RVB:E#G[@5,:R)AH,39GP6H"?K1D.NYH?UB:,D::FI MT\)HMA,EJ`(&($JAH5TEGYDH^`X#>V4A\)6$OA&Q*8>\ M'Y)DA<.Y>:_]7M]&*XKQ_D+!ARR.5#RY8M"@T%O`#%HTN?#DP&,8$_0YHG@H MZR;H@!4T"AU)"2FPAKRRQT(7X-+-Q;P-/HV0Z"M\KJ;%SCC)1[<"B4_8U%=X M!!((J=P,O9K/`'Y)_I#]%7WFCKCCL M_*R\^`2:;I0DOG>@!R;^>*+_/L,S(GD!SW,)Q.W?;;UZ@<=G8_G%.8-A,;,B M0MH*/#F4]#:E[Z2$9I6V7BNT:;R'/8052[X>!1;.0:?]$[K62[=#FRQ"P^\B ML:=I2?9H\;(-[XM`+8->'N-:F/;#SHVE=BP"`M,T=H_-,#0M\J_P74XU0G]* M_VK5$IJ=,TK/"\MZ>4BL[CV>+NXMZ4R=#AYA'A0XQZ"EI#CU>^^-,Z2GE:FZ M!V$^I=O?<$A^J3RG=^7Z8X!.^/!\24FITRH'2[L7;+A/!UA68GT%LP:*AE%U MS-P:_KMY%F;G%E_Y=/*BQ37,A#!BGM`UGU29>WB'[:5XJ8)W$ M517V,YA>LWJ/9E?79`R?%9Y90\IC``>2GG(//&4N6/;`SPWY!C'`,]`*7N0@ M7KL`X2Q\94MHLHY\O;7+V!N"M3V>61]U'?OX<#,4K^=ESGW8Z=C MG^QM[OO`>-J/)J:9[0*BM<.2UF!]FBDU4ZI_V`=V)>BI;_I\4QTGO@1.-U-J MIO0,M_C**-J\(:B8SL,=$VRX1IN#^=&W-_.SGLH1R\/P[DV[W[&=#4.4E4S8 M%%[R:7-NBP"GX1QRKMOK(=S6OCCWT!BX+U=[-)IW>][U#H_MX[HVP8ODX$Z\ M^^__>N'<>RCY^Q'A[E?,5&Y99PRG8U%+80F\\\PCCV9*S91>4LA;DL3W@G1X MXSWL$(74:@!?4OS62-WCE;J'C'WKZ2*Q(\OOZ5QP[VWN5KT*:M@&#?,:YC7, M>Z;,6]$]A']>55[VS"#0O^15Z@I_)87$-83Q+D'#J=>&G$P3#%(%Z MMJ2\22*`VZHJASZG011/@\#W7(5CT[';$GR3&Z82G+D+(4,0S22.7,+XJ(1V MX17^AG6R--VAB`>(L.M'=PC$+@9)%'/MJ/HD%HIGC,.^6/3KAQ,1**1(+X%) M@>V5%=)NY"42TY-JF*U9E(HD0>B)R=R-Y7"AFS_(`R(D(R)\R>;KEG='9;93 M?XCX9\;@)7#8!8+&U-M]-9ZFP4"$TR0H6EW'A#`N!L)C&7L-P/F=9'-?V\0L M'+RO*M"L(<16,LGE:*'K_9S_O4L=85V5@40@KLJ5@1)`\QZHYYYYMQ^"KAT. MN3Z5(7-$!JH)090UL@\A-TX5$H34'?_P$-9XB/`%5[+;@&U]"8<'RV!8Q8)P MPNK*,9L):8;Q`(B2V"4<`UT8B'"_<281-%"#?([B*Y^E.7#"[R&QYSHEM$5D"*(V#P41 M1T`-V-6QC'L$ZLTU]7XHZRQS/%V;88Q<7&X)2X+X(!)[G_H.P/,AS@G!.%%I M$0A3_@(_[Q*Z`FA7+TD4/(=`:(;8,L$P[&);`>2>>V!=,@`M?%?AW]/KX=SZ M3R9B`EF0>!5J`)_P(%UJ/G&C@8D7WV;\"/4-!`R1_7<(T`%Q2PF7)/%,89-` MO`0"+%QI-OZ=A0M@$:6"*G&@MK1U*<7WJWQ=!R%\+\,V)'4I5E+]4Y= MZO:;-V0S^P71O?POC[=G[&&+$'0C3"UE\HHDW6?T M,$_AW$AH$X8ITKACGT^O/X!#^.7LZE2#?EQ_.F,OBX9C/!79P05 M#_(O47T)D07QD=2?#ZSS'"!<^V,2A#M'WB8M@?U3%N9"L&:+:-H^[,7J7AU2 MKY%>87)*U6_9+MQT3YG[\3/HU#\0*O]R]%F-]X7,E?'^#W1OD#[K#X7EKTFT M#!K+=MJ^79VJ2*_F%C\%*3CPW"^!YW?T%TU>.0\)(]V*&/> M18#7YG8)-YM:WFU2%:1B[/=^*I.0?T7Q]Q8?0([!GZM*T\\+`K?=055%AANV M]*XH>G1*/W9T?&(?]0[KHV[#8M`GR;/#GGW4[S\(S_9Y4;Q,Y3)IZ+M&(67G MB3BMV@>U+60-'UK9JKYO]T].[..3S6Z7MJ3HB7"D=W)H=[O=_5'TT*`,R\1! MI.$G$$98V'#FR0MQQS[NG=C]XRI/Z&4)<==N]X_M0V,V.%Q M;R?)V(U?+YK[#NC#SM&#%CP);S" M)@1)4GH,?9K\>3GZL^NT?LU"/HC&'@S\S._7'U]9KC?TIR)(\`#U9X@O(;S, MB2L?:#=2C#/Q2E*.3XYZAYN0?7[VQ"#YAS]CYZ9V?_"F[4I_3_4,EP;VC$\>I!X,9OX[SY$ MH+%I#5G\A?O@P_ MR@Y'F^Z]\CGTM(AL-'K5.E"NU/4,T\`NPS]$[*.'@-^IB62GTU[%]I5#5W3+ M6$N9MBM%^MCIG#C.RLS;K0>_]F;W#W[4=8X/:Q]E\=A$=O;-M6JZ6O?LJ$VHNXA"6:I1@YI935(^3'VT;+MX15K( MJ)[))&]*]:0N1NYOT0?O"MNUKN/^R6Q];'+&942K<6R>BA=347%ZGZ8GV*72,YCW6/OJSUD/S;-G)IF3DTSIWJ);)HY M/>;F1B]MOL]=LWJ/9I=79,Q?%:IS@TICR%OL&GF]!R:^C3-G%[F MW)MF3H\??;294C.E'S*EIIE3(SS-E)[UE)IF3@\)D-N`"V_/NZ:94]/,Z<$Y MUS1S>B8KV6C>[7G7-'-JI.])2]^:[;":9DY-,-5,Z=E/J6GFU%C`)\6[IIE3 M(W7/3^J:9DXE"_ITN\(TS&N8US#OR3%O!;#(RFJF^\IJS(J<*S&G0OW/4?S- MFV7Q<"(2K.F.IM,HO$[7*\*I*`%;J'N\?[C:B;NG<*[3_E#2>UU2ROM;%T@,OT#BR9A&;,@(1NHQUYB5XC+T+J(;KC]5$>VGUK9%.%# M)&*7.E;YL3=,HSAAH'FLQZ*&#I*O^`@W`FL[W,0J0<[K1F1EWQZ2T,'T0:80 M!Q_+M+)T$A$N?8H]MD+NCA-:G[U!G&$?FO8)\BS)B('IA)@I?Z*9=`^L*VPO MAJVZ"/`^_^A?LF.-00[VH9`3<*V3GMWNGAAT$V$6-9NP!/A^8HRM)OPA3?8U M*+>>[$QCB?$X]L:$O!^E(LBY8CS>IM5L#2SP:)]Y\,I.`3HI`\ MP;UX#'M13\+B631[<567"=7@+?#%@'!'L#T#&+G8MLX]%P8=8O^-+*8N5[_` MNLUL4/S3+,V`Z+]D7Y5;[!HWS'M47<71::)>.HOB613+XL[0^E6$O+_4+CK% MCG,S:NHPB0(LO*0>?3P$4T/?D5V_;-71"P?U$!8FX$:!LGJ3/A:K4E+9K'#H M>:Y1WPDDRLE1CRM%$M*SL&E55SSJD8$=,'03P;P)1C"W7A^VCT@7$3>P*TSL MC0)08_#F&'L`$BFH(1CW1O9M4@VFN`?3.=`S47WZNJ6M,5;N3D8CX6V.RB3? MYNX5:H8K+V8#5;:+ST#NHBGB/C!\396IASV.^DBIE*JQ"FJE^.`5@J:+Z46& MMN%R1(\GIU)[F(V5$R@9=UTJ5Z-&;2(:6,N^X`3>.VBQJ%VI%5(6'^9:\3#ZTS4V MD:.^DXSC!-HH2B>&?^K=6R/D=1 MBCW>K&O92K35PND'?OC]W4C^[2O\8-W1K]+Y#.P#3(&TPROYVSA"JS%)T]F[ MMV]O;V\/[@9Q*_"_T`3&J<>:_>_KS[6*M# MGXJQ:L(26S?N8BBQ[;'$_N&UL550)``.\01E1O$$9 M475X"P`!!"4.```$.0$``-UP-T=614LG.1__ZDQP;L&/+"AR.G.&!8'97N_N35JM=.1\^+2:^-0/& M,26GC=;>?L,"XE(/D_O3QI=!QSYJ?/KXYQ\?_K+M[V=W/>N"NN$$2&!="9H1 M!L^:XV!LM7_;7S',@5E?5[(L(6KO_=Z1)3YV&/;0\JW5@2$+$5M:^T=OK8/] MUJ'X<')X9??- M@_W]PV9"V%A1GBPX3E'/#Q/:5O/[5:_OCF&";$QX@(C[R"7%Y/&UCH^/F]%_ M!2G')SSB[U$7!9&G2O6R"BGD7W9"9LM'=NO`/FSM+;C7D#Y@U(<[&%G1\"?! M<@JG#8XG4U^J'3T;,QB=-M!TC`5_ZZ!UL.)^TQ\X@_95^WIPT[FY;=\Y@^[- M=;]A28%?[KHIK9'O"_3&4[SGTDE34C3SN9M2)1?Y;NA'MO>$`BG58!$`\5;-B#?O(!WX',R`A7(-*RRQE%C6' MI95&S$VDB8]KD*5G;$S1Y.%D$DFS<0"3A'_$Z*389PHD%$RF@Z*R M-\;GH!@?NWJ`;J;`A.WDOBOVK`GTA(4*9/*HFQ^W!HA"^2PP*>ST5DJE80I$ MA"?WET"$1;Z8.HXWP03S0-HW@_9B"H2#*GKI":@'6+K>T%Q150)Y30E-&UJ. M73%/M;IWR0QX('/3E19=$@`33Q2J%[)L<:*50I"=;L5VFQN-NLTY MG0?X>KQY18^;N(G$9L0+]4PD6NHC?!%'/8#-L51W0VEFZC;B>+;Z>4&-Z34#\;$XC_U1I'+A!K50X]/YA8D')J=C,!TQM=7DLK!XG>28C0O927;1-D9F/0]HJO>RX:K\_9#B/ MDT4G,4C1UP&)7#MC2-Z9!$ETR-+=('.(S0!I1LQJ*A-E9O5]Y2())GW4UB MT1-Z8^$H,,^\&E8/HR'V<8!!8T/((:Y6VR3WO$5+N0$X7C MVSCZ(&48:H5.UEB]H].6]DEY&2>@[L\Q]8667&9:P5)OU\QG-0,JI5E9X!1K MR:!]:2.8=@.8/$K-#>DUVA-/;I:>._W/G=[-MV?=@'UD?NT+L(\C55P0D%54 MQ,?B(#?#0OVSY1<.7I<\7'5RW`#/H@FA;C7K"JFZX/'<;OD6"TZ;0Y)=CAFC M3>QB7,"4@8LC?XC//D1N)IXSH2S`OZ/GRO1#@[WF*.JYR,361W^,&)PA8?`Y MG=-[5J;B:;^?P3#DE!O(?XX'< M^(*"EH0=!%=UP^'(<)BC9MRC_66-=TT!.P=ROIMBC(\-QSC3+'O6=IOP[ARR M:\YYJ$.8G49EV@,;@9KEW3E0UYR3@&I4=:DLS#RI<[\@)#^5LG-`*QR60&Y4 MS:G`!ZLW(U]8R,X34O&M,K24UZKX@#KNKQ`S*+QYI;ICIB]DNV_%;`CDVJVT M#9Q57ANO_+7,_'<3;H%AZF77J0+MC<1L$>_GF)O3\-`.@)H-XQUT1^X2,N_> M4('V'4P0<5\8R?.$[";8N>[2O'A4T)-_04?^29WF`@*$?:[=C\]A?95N?,XX M=7EC:!LZ?J/L9Y>(6>>"LK%>P+#5?#G/T84O.F4,-;&9'N7J#PKWP^G45T?' M`@;C02DRU,0F^(.:'?G%/V/PHN_4TEDI:0;C02DRU,R7`V-='>_?&UL550)``.\01E1O$$9475X M"P`!!"4.```$.0$``.U=W7?:.!9_WW/V?V`SKTL(=#K3]DQW#@'2R=DD<`)M M9Y]\%%N`ML:FDIV$^>M7LC%@(\F?(+GKTX<2T)5_]UY9NA_2U6^_OZ[LUC/$ M!+G.QXONY=5%"SJF:R%G\?'B\^RF_>[B]W_]_6^__:/=_O/Z\:XU=$U_!1VO M=4_;S!&T6B_(6[9&?[6_(/@"<>M+V%>+=G7Y]O)=BWZ\P<@"FW^V;N`3]@'> MM*[>_;/5N^J^H1\^O.E]^/E=:W+?:K?9=J.%%V/+#*T&QUB]OHK;=SI_W=U-S"5>@C1SB`'3=]^_?=X)?:5."/I"`_LXU@1=(*A572]B"_=6.FK795^UNK_VF>_E* MK!TNVL;R=H\Y[.!M)_SQ@HD+8!.[-GR$\];VX^?'VV,RY'@="ZTZVS8=8-OT M20S#!V^SAA\O"%JM;1A]M\1P+F0Q>CY#_I9A_HGUUBF!AGZ&#ALT;0O.@6][ M%6([[KLBI.X*(.,5XN3U M7@:MXWK]2E^9;8!5, M41>M)'<,%7U5Z9R]7*-+TUUU`MZDG90$.)WU9Z/[T<-L?#.>C![[L]OQPS0S M,CYU24C7_;O^PV`T_6,TFF5&$B.J$,`$8"KY)?20">Q":.(]5*>N07_ZQ\W= M^&LA;>V)2P*Z=9XI=RY&D`RA!Y!-,L/AD)8$,P+8H681F4`\75*Q;[N=P5?/ MSZ&]E&Y*@ARXJQ7RV/M,Z`L]<.D;[2RH1;<7P_9!V269H\N2X&^00XTSVGO8 M;VZD(OJR;RS`P-ZL8'^!(61RR#L6A1V<"%C>(9G63]EIA0WS1[CVL;FD)B\I MB#*EF[(@_2<"O_N4^1&;.`J#E'<3@*26*'(06U_O**(85MH,.A:T(K2LSU(+ M>.!3N6;L(3;S8ES,-5T"LV4.R%-@N_BDO0!@W6&2ZD#;(]$W@>S:5]VMV_+3 M]FMCZ@$O&$&4,WA+/Y+H*39X@G;P;$/)#&W0T.@F==G' M<R`C+XU<,$^['^W70*MCQ<>]F%!)1%H7B[@UW_# MC53FB;;&F]H(_1AY)/7>F:4^\#&SWF\0H<;[?R#`(\<:4E8$@APE MX"/QOU$RZ&^0#?&`(EFX6#[D8RV-MS40.A]W).^?SRSO&08LKCS=K)Y<6R#I M6!OCEQK(.(DXDNY;-5,X==9<9^JYYK?`7B9CWV,A;P91/I]+"(U?:Z"'3&Q$ MROGES,J);/09[5:@AL,FQKL:"#P!.!+MKV<6;9]BL!B.&QN(AGBLC?&^!L)- M(HZD^T[1P)U`C%Q+;I]PVQK=JQJ(6P@]DOM[17(/[:40U@W]CN=/2]L;W9-X MJB>2/Q?^WBE2J@1FM&97P:ZUT:V#/RH!OQ._P"GMQ.-9)XAP\1-!36BK"6WI M$MHJH21@0_((GZ'CPP?HR;04;ZE]F$N,N^HH5W'I#USBC>>?7-=BN:TIQ,_( MA&3JVI9$$6(B[:-@F5BH.AQ67#V?L$O(!+MS)'LQ#EII'PKC8ZXZ`E9B.H)T M^746GZ`#,;#IV.A;*RI)%J3VT#,Y6:GZJ!:<16.UY"! MI\A4GX$=K:YU=3B"E] M04JT5!K]*Z64)!OZ6-%C;PFQD#?9XB,E5!LZ+*&K=+;T,;&+J$W"FLI@8PF- M23G2QSK?VSDWE/MP*Z9/(6\-(=65 M142H9.V`VPSKV\F>JC8X6FHZ/JE,]/$F=@QL17--/2&Y.RZ@,+HJ@R.E5*^`PNBJC)-4J*0#?JK>9E!<35\A6BPIJOXS97(!'WPFCO'\ M:%-/VON5JQ^CJS*H4D*EN;FL>E]#Y8K>#LHLF]@*]F1T:QJ?*!G]H\8GRN0+ZD=(=,&3,5\M7"9^''T8P\,"'B?32[P"RA_H^\^>@9V4"+!&P",-]3N_@)L7V:Z M9:)7NA=#J`/!/)>1(7W>*--T?0KQ$9J0PJ5&SP/TMNS*7BP)F=)=&3GUE<*' M/F]:5,ME(]\@>]A,Z=Z+G'I(X-8G-WR0O-J/D2R9G\/V2C=46B;PK1!*Y/@G/"6;A4V\SL4%8 M^H9:'&MF6\K7"!F9_B>ULG*ASQ)R\`ZSW0YYIJQ]>[5;!W+M2!;!UV<%"=&E M3E=J]P;D]Q0/=P&H7QKN$'A"-I4:S.&PBXG4[@?(HPPY#_HL'Y'O,P$;9N-E M=_KB!&KW`*0(6^[U'3.BDU^.?6@=LR?7#Y]&;4Z_J(K$O.CCE@^W\5+J+^52 ME91.;5:^D+I2^='''(N@;H_C9M=5G,#HJG3J2RGIF!%]3+-<;Q%GJ/54.O>% MM,)G0A\[3E+[6!;9%U,9/97NOT#<@G"^G`MMK(4@7;=T;8J&,$?8VV2PM<5$ M1J\N40`Y#_ILB8XG5M/28IS61D^M_R\5LRA"P^5"FY?FH$Y>:IXRT=3HJ8T, M%-`&CP5][.B^9:'PT1.`K%MG`-;(`_8!:)G?DTIL]-0&#PKH*QM3^IC5U&'S M5[Y-IVXKB`!2H&L,EVQ/T3/CI[960Q'=YN=0'PM] MAB$@/MYDFCB/&QL]M44;"JB+SX0^%OHQ4[FL/J.GMM1J`8WPF=`GM'K@9+#: M4GGTDT9J]'2OW9J'DY0S<><]DQ&_2*HYH)$5<7-`HSF@T1S0:`YH-`?6%P<COZ1E/N2$M2FWF#"S5>)(H=3^!I[L?.@3=CM(CA18MS)0 MZW^33TYF],F0']U:EFG!DE#I?^M/1B;TJ1MV!#1UI1)0U.>8B80!?0J%Y;SQ M,`M9?,XM!FJHG*BD.+;1R%#DG3-Y]`;5VMLVI8*(`J7FFP7H97)W=[6T6Q;XP` M.,O7"6HYV.'_;E+%/*6]%+]J2W'=18UEY6//IF[Z(AF_BM'4BC5 M%@,[\W2>)@E]TG\4(XN4P"$,_S]@>7O@(X,MF+T3M87(SCH*<@E%GX3C,>Q< MVV>RD*M-8N732U;=\KG4QF([!AP5/)2?HI;2J4UPG4:/"?;T\;AX4'-7ALS2 M@]K4V*FT*F!4'\.+PS@[F;=?>M)*AF7K0&U:[33:%?&ILY65J`!5:$7=TJI- MRIUV.3U@46<3*5'8)IW3FF MX`2S^NSQRA[CKR0SJ?@JNVJS7CEXUL>J$N!F5CZI*B4MZ4QM(;T*6;9G.W(G:XGL%E<77?#ZFM8EH9)=!)6^TVKI^E2H\ M']/Z1$`$N&^0`QRSHKE;9: M7.G$:HL+%E2.?.Z6,ZO[G,WAO9(W5VW)PDH5G8]I?>9L_G5D$XB1:R6]2(G. M\W2CNC1BCH,#.;G2)P)VGFOW%-=,+*M(#CLI4:_3GSXX2&\-H0>039JS!\W9 M@Q_@[,'N_KZO+OYVZ]"%TH32W>E\@MJ<(1#"UV?M#V+".YQ3?[VVY98=GT#I MR8'<]T[QX.L3)=NAHX8C(DMH?7)=*]-;$B-0ND^_T%N2A*^/L[N#>+`[+8M" M#IK7IAB1`+P^=FV12V[K4D8H`5JY*3H"V*&V,8FJ06SMT1GMRV^JGS9FZ0]A MEGZ%:+'TH-5_AA@LX(//WN?Q_*A.P#4@R)3H,%<_M3%B\W*ECVTK0#Y$MD^_ MS5,#(V=/M;&&\_.58B:??D627+847YR:H$FS.NFS.A%H7B[<9_I^H%`_]$-2 M+?0KXPXN@#VB@]K;".IOWA#+RX]+E!M,MWL+.'>@-@, MP8K:0&3J^M0F2DN.I=+6)MZ3A9,3'H"_=ATKK);77['3!*+AGFRG?4A'A%JY M!;W;CQ#:RXVYW)C+VIG+%2AI:D('8.1FO<;FL'T-#.HT_-JLLA&NSPY90Q/- MZ724>FN*D$:;RVR2TA8H1\+'CZH@W6ZW*:TI_2ZX8;/Z>#[`T$+>#3#9*:[- M/7A%*W]U[6+LOH3GQ.@O*9<(9N^F-MGDG$SI$ZT>PB?OUB%TT62/@'I3]U3P M=-AE5E^>3K5W?RIAL8H=(`*_4XQKCVCL#./+3-(IS=6)]A?C%&))GWTA<>0L M'4FF:PR!-7:^T*6=F=&/>69380^UN3XG.S_RC2;LWSENV048V)L5["\P#%AL M=C\WD8DF,M%$)NKA^#:1"X=0HAQ+#M_C/= MA9-R15H::8W"":F,Z!14B($=^/0/:?$3/D&-@@$"^/H<]4A`?'`=,Z]6]C3: MN_Q9.$CQ\-7YAU(Y MA4)[AR(=O_)MEL'IJ7W!+](8K8W1JI'16I627//;?I#3UW&!P2I^1G1_3SV; M"/>-9>&H4OW6YFAM62[UB3PF.+&&/D;.(JR2EGJ'>3IQ;0[49F*EBOBCP`A( M/G^"D0FCX@TB.T!*I'U@/A,+^L0792,D[=!1*JWV)G(>3I3'':?^$X'??&UL550)``.\ M01E1O$$9475X"P`!!"4.```$.0$``-U=_V_X?B4'`EKE>O6FF?I'6\_>N/I*1=2?PBR+42; M>O&G%Z\1_7B512'>S=`5661;G.W0V>L9>GEV_HI^>//JY9MO7Z/;C^CDA#TG MCI+?%S@GB,J5Y#\^6Q7%YLWIZ9A,SL?EWJXPLY3+$67;*^$\3\H`+$K+V7Y_01Y3M_WOU]3/$B'Z^N]ZWPEO8 MYJ?;_.0!XTW92(P7)*Z;>G;Z$YI`NN^9]N=_;DKW@3U6%+';E=^WVBJ9J(PN M)+PE692&[Y+C1.UP.Y7YI3 MZJ7)<7UZX!Q1UD*4T[HC#SW(QA'V^0-]?DLR\E20)&3NK_R6<6I\>>D#V1C` MAZ8T:#46L\$@S=IZXLTJHKJIY$[/]4Q(7^YD4]P8G9^?U#*SZ^C*V$7* MG@#]RDF<6^]XDKI`L?[5UY#5OG<`?-)1E%S3C[D)1@_$$#AMBJI!`"-#G`X> ML,-%!D&N``HE>KN(L$5P3H(7#^GC:4BB$KST0Q>S]*O?2L]^1QXBYM"3XA-> MR[RJDM0!7C5B=E]]->P>Z!`C=(W6T05V@=4^,-1([4'"M#B]I):1X?B:1B-/ M_TUV6J!V:9TB5114\>8K0L0I$26%`^MX,KO%JP(4(F#EB)@*L9?;+*,/O(KR M`,?_0W#V+@G?4N^N`*V2W!%N->)V85"1HI(6,6(:\(2(D4/`=R+17:&X#RA- M(/>@9%KO>Q7%)+ND3WM(,[WO;5,Z];Q=(14^C).AF@[.Z8XBKEM_*X6!Z&UE M&)@*G_<99GMOGW?K12KT=R5\F\81)KN"=5]O]3LJ"2!@.$Q"5\B3ON`FYF1O M=^*Y:+I>I\GG(@U^_[S"].W<;`NV3_0R!XB'RN M$"E[M4WL2=[K5"B;T^>$[%E7,5:YVS:-(YQU!>N^R/WOB!%`(&V8A*ZP)GW! M3;#)WN[4/FV?@J()Y.6TCKU<5U"E.RD)0LD2-=DO^FKR6GKXW"8-Z`6 MNHN1DA(U-N3!$M8F%=YE+D$/9+H)!7J\.,R+P3')[\@C2;;D$]$AO$OI,B-& M$%+(+6$4J"*9(4HT.I"+1I+Q`$GIMRAG5&"Y.H`B%HWD]U'?]@SQ['C09"*Y M)0F91%(SW"S?IVF8SY/P,\D>HX#DG],XU-B^ALFA&]"*+NPH4V)T MLT2$\2DN&8>I1YN(X2GD9:1(_DW=.&)+GV6(=9`RZ#!E.5A-EE MR3A#%2N?/+294<4-%&0FB\(5?*F<4P7Y=JLK/GGBGG M-)2S\H9"A&?C"MVY^)L-80(D#^72TPV4SD6M"8"8H8]%!:,J8)F"/V470C-VLG^`<3P5WZ&8U)=IV*VA[=>9!/ M:9*VQ:A\F<'^2#^O0^]BHD@71#_G)^^[O!'GK48L7/%"&?$Q2MT4*Y*AYZ4> MW^S'WC>01F&,LJZ)F$+,Y3;B(\D+MK]3RG.=T)&$?J/=1U2P.-U(5(HMNM:: MM!J"9ZBFAMM)M)"^_`F5!@`UGQY/8K<;GGIPBSN>6F2[M,KRP?V+&EU*IS;8 M%5()A:G6(HSMS5A2,M6JBQ<9\*\EE>DV,?+U=,4"'S49K,4#)!>H=IJ.R1R&8AL@\"VSF^ M$45V<N18AL#?Q*Q[$^,?$]E[$]!*\N'6%0^-W6P5&G[;8N)NCM8@J+0@'*P&;+G%=4K,GDK][ M*C*<9F&4X&S':W11=6A/%;3+8JZ0P>K+=$]UG@D^5>?IE]?9$]'AD>CP3%0^ MM#84_M@9:CVXK`DW0^UG3[>D9#1+==N;FXR<%/@)$9PEE!)L3P@&0^7>TJ($ MRB9+'R->?I_^B9XO2$*64<$W<+ZIQXN"/1AJ0>'K[2'W)R,F=>7RTQ53^G'7 M(R&5L1J*+\J7W#N*B1S.1R"9T`I<4])ZV0T]KZB!5B7,9;]HV-NT#LG*:9N( M?OLU^-91WX%[EZ>T6;F[4AFLP^"?%$;)06TZET%^1T#9R:7V='1>%%FTV!:L MZ#0-R-`M9G7Z8!R+B?118;A/4#B6-PY[[>52'3+!QHW)Z1VZ,Y7`0D&TBHX5I2@+HB4#D*;N*6*VA?35@M?_3+8O"%-H(.G/B-H@\F=&?R-1`\K M^N`Y?8GX@7S:KA5C6X(W M4XV2`PT5>#`<45^ML=:S>[_-M0_+A@;;`V2`&\UNEE=10L."",>W:1[U7,)I MQ0YQZYE>'?6E8M0&]XRHYO2@LME@Q5)+Q4!N4#,`H?).M7X$`EC598SSG([/ MK%3[_"DRNBY0X(&P'XG@0MT;1L('+49$H43)X.W#6/!4+S@(_E5P48)>@16' MA<`:`KQ-US@2+MYM%B@2B5T6_I*)V@?JDA`,UA8RIWTR.RU%I82%4()*A0F7 M96NRB.3S6]HDR3(Z*V.R?"1LIJ;SUQHNIP5J=,*+M3,8-=I3UY`I&>"\]S%* MS(W5<%OUHQ=,8JF//B2YLX5YGI,BKRZB,P@`Y/0.\:\26+CW@M/-4'U'(/R4 MWE3R6F+,Z4%/U6O1T86U#AH.)R@X7\V3D/WS[I_;Z!''5)I\7ESB+-O1B/L7 M'&]UQU+,^%U.8PP5$F!$&?@V*O_08)VA>8%J;L39P:8[0W4+V`=R8`4J'SK^ M*\+=5S35^9P-O_*!!AA9X?QM,2T7Y"%*V(83F]"6PDRDX[ND]QC/)!H2^KU2 M-Z>3=!O7*,S;+?RBP^E+$*1;*L<="0B5:1&SZMC5$*2;Q>C87$YF].(+KL;'9V=@;CU\=^/1X< M[C,Q&&%BUV\M;JLC);3MG?[>B1:9XRI(#?%DE8_XS]/<-F%1[,A`R(B=M`,K M03!02-=%C;J8E!4RZ@`2X#00:1BQUGID]!`G@3H"J\\!D;;;!1X0+>5G1S0)'`Q'%QGM;B@P;9$F+717BZHLH+[W36KP!+[9C)&[16K4`+ M[7@AL'F9G3'$=5ZQ1FIOTBHU,F,#6M\V7=<&6\_N7\?V8O%:(B8/;+RPJ3$D M!5MC-UI;=VY$MQFK[U+L;FE'%O,D9`M`&Y:.H(_!M&P.3:Q'?,DA9TX^0YR! MK^OM64#CMJ,5V>P5(0=%P"([_]6P6!0?'5PS=+%?$K_`,5L*@UL0GT"[=V4" ML$(UEY[7Q*UU';&!3P.)?%C9$9O@IT$/$_^T!-:'0`=2\"C(0&I<20U=;M0+ M@6VCH&'B`D5!HNUI`B'!\%S'0KU!D/OH1QGVP$8[RN`!/KRQ%,U]/*,/9)Q# M_T.$%U$<%1&QR'73,#DT$:WH71`TB'U*?;/2H18[/C"!)L'U8Z<+\E[@N$^0 MN,4[MCAOGAK180!(BA!$5NZW5Y3PBV36DF]*2MCTAN,[VJ.$!CG`5:D,4G0[ MMOXHCNV5#WH M)<:J1;P[>WU;G=2XQT]6-JOG=._((TFV!A-@!0.`L0HB*_%247IBG>9R9R4EM'WV"OR! MY#DZV0?4K+0JJZ:0+E$XM2I&M[NOA0'/0_A)^5.1N4@I1X&2I*L0-=H>Z'E%A0I@=/+I/+FF40 M^HYGRZB=II+)A!738%IU*F;U"=[K/-_"%?:SE3UG9#^@_SA[<7:.-CA#CXSE M!W0^^U-Y**^NZX>WQ2K-HC](^`-*TOK;B"O+4X`:A?^@,LZ&OS8/#F"/HX97 MZ65C*.131IG2EXF)9"I'YK!61KI>IXF1WQ5(75;`$,44%OHXB5?NUEQJE:-] MQ;VLRM.>G\V^??G=[/5WK[L>MT!O2<#+":%7YS/$7CYWP_^U30AKE'_S`WH] M.Z-_O/SV._[CZ]GYRV]GKU[_65:MU:S)&0W%\PT)BNB1Q#N@4AR#L.*!CQ^J M@$?>?:@J_OAUE:,4BF3(O:3#C>4PY)50<7R+H_`ZN<2;B`*Z(9=NA[F?V>56 MLXDJPI[SG@DQ+G2=H(IOAII8`]M_'JC4AG*=1`D*2CY(1S7*^XD4[\'.X;^T2*F^4]?M+Y M1\044M=5Y*C0L4I'GQ`WHY>W7V:O;M M]R_WZT=%>\6&K^'0#^=0@[D++<]K+8&J"'[E.EJ,Z,?;F%<#\A`U_!A/C2&G M1=SWW\W^_*I"E@1_@U>$70[(ZI&J.^8JARG(%!&KU!#8E)!!J2`P8ZV1$F7F M4R[)_?`G:056;*/1T#>A+88W(]'!1Z\A4L(F+:D\LM+#@>3*SI/0RC_WLL+D MT:K4T&35\O%=XLL]2+(UU:9T+'%')W^\HU.5@%)TM0:D2=C568^))\";5<3M M^_QE9=WLF]\J5_AY14A13D)6I(@"'&O2<@T9'5BVL0J*$0!Q)M3B`LS'_=K4 M"=-@RZI_8;;YY4@?"#.VLY3:B*W,Q.'.8'W%Q%6:O4VWBV*YC<4[#G0;@F8- MN-P'-%5)6#>O&1'E1#4KDEQE`;;?-UBU'"U3?AJ^>^D(OWL\3.,89["7C]LA M4M@EL($C5&(_-?V;C-]C&_)%E5N2\=O0-69FV`!8^K]&I=X49LJ+;C)4+ MAXCR(]Z`'R<$CE*O6D;<9[$V38Q=@56N'X(:FQTN]7G;/:"$,C8N0S[?9PL; M&YG`"&9<$A5ZC:KD00:6)1LZ#%/L*8F8+%&K.Q'D3+3=DL@B5=5PP1F00 M6;:-QYL(^2@E?(R-#:"DL0CPJ%B0I30PRSLU;)!VJT^X)!CR(-P]S@]O`QTQWXE7L6XXROG3WAK MX@IZW1AD8-O*LR_%T;@P&374Z;&]L'UG0DI"+\Y6]WIF9:=NCP^@PO"LO)NEI%%4]4A%4D-%W!Y7Z`>5>'"A%U'NK.(3*9@0MUGZ&(4DO-C]G)/P M.KFAW@P7U-',V2F],M&ZWU:.:,RA!1VE:A>.K$H"1V'=#+K8H>>L)72=?(/V MC:%#:Q[8W"BJ<[67W/B8(:!TKRO>LX,6/#X>RUT3/1K(+FNZ_6.;%\R-Y/?I M'6%=%,6$"GXH`'&?CF?:DSS.:=VX2;I+K.^U?PP[OKI_$*^NTBJXPG[^^AP) M0#<6*<$C5)P<)U8\'9V@Y:<,&#*04W*RAAU]\+H;\]L%L]S(5E!1W& M!YR$YG.%G#8E.4?&#E_CF.1WI-AF"?OS<+Q.8H[#VG-U;GJ`PF)R9-64XAPE M+YW`VD-5@^7PL6\2Y*#U)/JSLY9AK3]NZI]S_;.&_G@Z_8U.9H_8`728W)9+ ME\6*["](*[<*$'EB9DJ_II;[P*YH>,!1DA=U#),F^8RSIT*#L*5IC1DK;CS(>KF4$QW32P`[95CF- M7/R2D75'P+(W:7,+VBMI'/._OWD!=K9]J.]K'7D?Z/C<7XY;1HWW^.E="=0+ MBKME9')+KHH3X+IZIR_`:KOQ:-.#1Q*]6Z M0*N9T?.:_1MV+\AAW;5JPH-%UT%Z7J[H7RQ!-&FNC>9T0E'.!1HEHD#72>UQ MVK4\:Y!"&J%591DC=E##,RJ]HC`YCZK*'*G87"PB`U7C=SH-8)V!>=T;"V.! M=`#7R2,-!=,LTB8XZOE`3;ZM@*&M-YC\L?$^3:83V6@2/4;71ZVN'_V:EZ$^ MZN@W`.N4)#;<[XU$`X9U0U680HZ=BLA;`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`;LX:)BNS`ZCO39A,\4XJ+N!?R"'QH$N"H-7U.EE M/$>8J'`YC[U].JQ!7N9)4T=XF\918%A)7,WDLAZX3G1%FCL;V6IJ#\+L"55P M6B"[%T1"F>L^!#FL1!L])-$R"MARO2#5/7DJ+F)];&S8@,M*M:8J"954#XQ( M"C?&C#@WW.4S$,HYK1EK!4BAAJP-&EVFG)B] M&!"FU@/$!C204MJ"&D_N;.(=SM@5C2R\X=7,#7R]DL6A+6C$[N*G)F6K$.65 MCA[X_:GD=XG]/NAT<=^#&SC,FPP":AY`U.O,5?KFOV^+6,^LT&;`L&_+-/G7C@CEJ/1CP_-#6.ROM'3"/PJ_+"SL6 MA=5PJ6!P>CV'0F2QBL>B\&NA00H4PDV&'!4'&,9U;E5` MB@=CQ332PR&]U\GK$>/^^J6JP(^E8^_C!;B"2:>(LFA3Q>2;ZW>E$<1-1[V` M4]UUU(O2N6`,V+P85ATIY84,&PXXAZ@;D#_/+'X8-A5>E\CQ#C,(]PN%)6T M'DSG)Q+?:;Y?#W"$##\=:NK_7"+_`N=1?K/LI!ONRO^;S-H-&W!H%<8J=4'& M&=F9T@/KK$PQW:%?JW\]F,0/U"\]5C^7=F4'RZZ566'2Y6G4+PV1LC2A'P/" MMS5LK;<:\=$F?=+9[1G/XR`MGO0\"L_N;/<*1]DO M.-Z2FV5U_!3'UPD=O+<-(34&:\;OT$I-%>K"E/$ASLA&RCTK:O#Z:*">J.O2 M-JT@VS5(&[PZC-."%0FW,15JGSA]65Y`=L]NBC$Z\67:A,LXSEPM(3"J6!DZ M&R=#*G;T*V_`!P,<0\?T2!V=1H26$!4B1#M\@NWM7.SF64;?$A^D!VWT]+8$ MM^MCH&3?;LF,E59IM#)K;Y_X8IY3*+X8HCC@[I$IM'NVD@QQ#7#F[6]I]OMU M0J?9`(;>9VD.=M6/H?SL]Y,H886*'J@T M@)?Y6'8XO\^>=[E&>I!C>%*4*P_@R2#NSC3Y_3-[63YO-YM87Y1,P>#0-)4B MRV\1:AAH33N591I"W5B!RW2]21,VU=S@#+:FC1XG77!K00(P[M!(,LKI]/9] MFH9&XTZ;`6+YLY#+SO(D",%N'+( MD:$;P"KGX3^V>7FZPL0FF^00%MD65UTAH$$'CFM0F6UO##22^8[D)'LD:)EF M*%WD]`$%X4>2R!.;0/&Z[KP9+^Q2`G&E58KXMK7)G`0O'M+'TY!$I3G2#UTK MI%_]]H&^D?A=4D3%;OX4R8Q/1N7`YN3"=2'`*5!)@GYE1,Y7+T83U`4J-:^\ M!J/Z?4^%P?)!;],UCA(%`%LDCM#7$4NH!E"]RY(`!';#)'2%-]GK;8)-\FX' MY(Q^BO`#SO!'LEZ03((F"9&KW-"N:,+N>_D[^K6D@$NAE/9A*VU2UH'NIHT? M:%!S.(&[>XO7^('DG]/MPZK@&X::.60_K\,)I8DBPDA">1J'KFG05[&ADF]6 M;A5#S3<=JN1R&F<,N>Z19J$UWF^)>%\S=)75%Y/H'/E^"0""GF! ME`25-*@D`LE_]T/2,`UXB@,NHE28$5F(>D/GI%V!#E`KSK5%* M`7B'`U64L-M',A)&Q14.V'WNNX_X*5IOUQ=IEJ5?J%>XQ!OZ2Z%+W+)JQN7P M9:>>X/8I.[\^AS>`ZA9FJ&H#[1M!=2M@HQJXIDX'NR-@*XQ[]IAU6TOBD$GV M$1?;C(4@N-#-'#5,CBM**$67EF4X4#.\E?2(,4"6E9A(!=>U)?0@DI67T"(( MR@*NDX+0%U[<45$^%VR)]I;0=T]G(`^$?7?'4D@^1@FS7F,+L6H4S((L5>^% M9]T>8LPS5#:)#FWR[Q%OE6*Y;-SEW-M-O=0M@,PF=4KVF69Z++;F9WZGYN:GZ,3^PT4\9 M\+9][5LZ`6;G#/EBDC]C?R\\]0.]'IL0)^P[6>%:*VM3PIU[D%I-.[W?DX,* MLD5B\A`EK,`Z6F#Z0S"^J.4"+!W"L^+K$?==TIO[TR\L;40C*>"9#;5WD-D4 MF/7O_PG2AR3Z@X3F[D!DA?,/,C7ZSP/5]>,.;##9L4[8D0SE%""I3C M&.YR;)\UL4L[G%X30.>DM/H>;Z4R>3#W]8FJ7QY&-?=;#1XXA]42O-]3'7D>M1*"0](*<8;CW9KH4ZD[5,Y2"KO"B84& M2P)E-K4;5!G+"9=))WW-[3PZV3L>@*S+-,FCD&2\Y^9\^^4^O2"W.)*M1?2R MN,*<7FSQQ':#&I7DZ#Y%%P0Q#A!/;*?!?+%(BZ+>'RM2MHN&YG$<3;!H8F1, M0U[`08L%H8I$@+FK!O!OF5\_]H>PF6:2P_B]G$X.TFC M$UI6U+*>8C3($:<',4-K\3>5^&%#_&`2\8WLT$I^]CV*RK@N9`5:*B78&C[; ML4\:^@E&RNHW,:*,Q#Q7(4C7&YSLX&RWWUS:YZ3Z;,5AW<(B#7X_5+J_965R M\/K3E@WI-TM>!S^?;XM5FK%5/N9@#L2Z+8)A[;JL<#BP`X22@*R]QOT'J&IQ MALHVV?YWV2HZ-%O-`!HM@Q5#=-T=J:P[2E/7=(?3NHECF(A03'$$^P#S$F&9 MH5$F:)2RFKL"&3.->SKSSXGS%ZY\2;7'&X6T[30,9WA'BIG^K35;?>]]J566*3NOV#5?U M"JIZD(@UCNK6X;(RIN^6Q7C=XC:-8B33$=,MQK$;=U[D,EVOH[(2WCP)#X54 M])6)=5P.+5\OO*3$;TW-JQBVZ*&L=)@*@4X%EQ9E`*.NK?1CR.4\%!>\A/_G M@"28CNF*K"8]O=/YIEQ@<496T5&W7%$"IA89=;>_G9__Y^KQKG6#W7`._:!US]I,$!RW7E$P:_6^G_^& MX"LDK=_BOEJLJXL/%Q];[&.?H#%8_J/5A\\D!&39>O?Q'ZW.N_9[]N'S^\[G M'SZVAO>M\W/^.Q[R?W\&%+887S[]+MV?B76`RO>R\>_?^ M'Z!@>>M/,)E' M/)^U>+^_/MXFF`>>QY0X6Z`+%\\O>8M+92>7Q1@O>]AZ=!?S#L/7:? M;@RE/7 M=7?T2_]N\"V7MK;$11D*YW,V@PPF(S3UV?SC`F:GKHM#9JC^=(@]Y")(]5G4 MZZX@T[?^"U,))B:<[=(4_/D>(#Y#0X>0C&;,.K1YV",LR,@UGL]1P*<6RN:6 M:QP)F:TV)G)1]5&0O3[RV=+`NM-F9DM1=`H`!'C+.>Q."80A&Q@`Y.42T9JTY#E[U>T3?`M"@XU!1C>'F\^3/U3*])[N MLJS9/N[7F%,9?=F#P]06I1T7&=V4O+3E95+=C1&3(F_5 M(R3^(1].00#'W%?]Q'W5]H\1C-77=^`92IC>=7P_)?J*B2[_V3H&AVSZ0Y@Y ML_E835$?E>=1`$A0@.L=^B/Q_80#X.7B>(?R2+P^P'RRW=`=2Z:04)A/IEO* M$GD-]ODT%N16@FR66A!(V0P6A9CN&!L)!MET!OTQ'*]9Y!T4BF%%<4;L)G[$ MXY$]3+)F;OZ-H^J\^TP#`MQ@W9''44;=.]JTSKMX[M;B<26'2,830)\C08?T M?`K`XI+S?@F]@*Z_B="\I*QT56+RT44Q3IW9\C;Z'U"\-Q<`:.%B9C2+Z<,8J0,A;Q M@G?$5V,&;@()6:U9"N8CSE\@><;;,6=)C6P0P5OVD>JHTQMA73FRVCW"*N+7ZP0.8BX:>K*GSOAK:2F@A MJ3$%ZU)]'4/FUXQMYH;POU9`QXKA]Y$'R37C9(J)VNP3+9T?:R%V M,>=KB;\_LL2?".#'Z*/E_!E[$EDGVC@_U4+*:9[7\OW!SE2.YW/LCP+L_AX% M;>@@#/@9_S@ZR%'-ZPI"YV,M-*$%9*V>#T=6SWI__L2ZE2ABMXGSJ18B3[&\ M%NZ/1Q9NE_$PYGST/2`S\T0;I_VN%O+=8WHMX9\LF>\F^J?8K0C;.FT[SG%> MB]YC?BWYCY8D'^^>8K;Z[#N1+ZML[[0KXL]J:D`(8*V%3U:UP/>P^CK8M';: M]?!1%>QO'2:Q`B[3L+,MR-'EVY]Q@_U7+K]3 M6/,4UJR/_H`'Z2-\@7X('Z!JPDBUK$&(4\YY(U1WC6DPF'S%>,P3BDV@13E1#:*G6B#D851#Y0:[![3'5>U7@BD=$CQ!JA&YTZH&P5%.9 MM#4(6YM@D4>NZS1N>7(XC5*:8YRW/EOSV3=*MUE,8CE&KJ4SL;H5B!JQ35[C MR5Z&4RUMQ^4+Z70/2?%ML3A+^,@K;3"#1"H8U:*K)+1](%!`U=G`2MMB6QW& M>92N$(O=N%,!?2LQE;:=MK@-V^XK^TQN\3VCD(%=;3RQ3Z_@!!,8MWL";Y#V MWIC0&'3D`[*,=C=,2BZC9%B\2$X:Z_K!?M7V24NA=>2@4BG-:["\P5B!7XGU MBGF]ZL"-A,)IVPW!%384(:)FN`H/,-!R[A/MG+;=L%R192:-0YY.4Y^E)7WG M]@I0Y"J4*6SOM.W&X0HH58I'GLE3IS&Z=Z4:>6$`5:5Z**=Q#) MDX;JI.1O$$UG#%&7<0&F\"&#8[N>O:`Y2R18-?9.B^(:T5\B]8@U*L30"%6.(*]KU1VN.8X@WD.^;"NS3:14EG/`Q)J2I9BH M4#1#O05S:RN2$V:>6_NAO"0^JPKL4@H#NKIQK+&A$[:O7MK7!YDJ9?PW8C1> M`SKCA>_8'[T_0O0"/,A+X077@)`E=[&2M2@J$A.=4\KRDADJSLKD1CVQE=ALH4`R@O MJ]K>519=%:;`VPT6F:Z,:=Y+RWFP>%@^)/P<(5@./1!7\F,[O`5W!-0KHXK, M=B:4B2^3A:,9VYV=>8>G:9E,M-OVMO.63-0J!5#>133;2!+;3CS)4 MI8X.[$-I2O2'A(S1/=&HM2NFL9U.E%?!GDFDZ64?E@M9.QW:,2:DD60Q1B*,1`W:GM'5FYD.JJ=.Q'7_*H4L1 MB&9X/=WQ&,5L#P$:W_K78('82K\#6.7C9A(['=M!JAS:UH/5#">(.?;A//1X M48\H.LY`,NYGT*?H!6XO@3[`8#!A_J`ZX&'2D].Q7?8JCV688RSN3U6A],H3 M@8"&9*DUY>\W=CJV*V#E4+881G&/J@KZW!>(T4[;Z=A^%2*'/L4PRCNMKT2\ M@Y=$-=%M%JGSOG+O4^B<,DFQ'*R2P?$O+`XC`\%TX MFD$8)'K.>CDSD_!T"U'GV4P=,4HGMM/]PPR:T_W#:BCU=/_P=/_P=/^P%NH] MW3^L>63/\_`KWU+T,;G!X7,P";W]6SRJ@(Y6!W6ZH:@+J!$#.#DYL2WE@$3" M&D>AC'6)*.V#&%D'U:M>K\CJU@34C`D@"3>NX-,-@QDFZ+NR,)J:L'K%[#45 M+@#2C!B^".8MI:&QDF.BZKWX:J3@#8AF7(430=2K799!:?O&8U$]IZ`T(XE\ MYXPQQXJM06W[:J2)UC7A-"-)9N^U<*VE6D%E^QIE3DV+8)06M*^6AC/7:`E% MG6Y2*B`TH^[P'D"]Q5E%5J14)\<]YN)HSNE^1 MK>6?]N5N7GR+V?"0X!?$IL&KY:\4CF_]S?N<73=`+W$FC,;[E<:=5>4<]D[C M0K;'\"E$N;4DUG\#5"*5VQ_\+XP<[Z1-^A"[V7135XMM"?<+E M30V'^#G+1\-EFMB!Q-.,\Z<;R)AU4:1?]MF#D:+]<7>.28"^1]\K3$^'W/+A M\Z'4+S8V38$T8II;OU`%Q_R*!?1IEK6("6Q7U#VJ?4A%8'LZD60<1Z`I8T20 MCL'SMX''BUL&(?'Y7S?)&Z*M3*'^;!?B/8J1%)50,T[*UV4OS%_MS*"T70;X MR`M1EBR:MW8OM`_KA&9":79ISN[V,V2LC4 M(;=]OF^H5EW;$`,MO-6MPE7,?;#K*NWJ`C=*.MN'_PVBFU7W5Z\#VTD'!S(.&=1FE&60+Y2K2JRY M=A,K6MLY"P?>2NR@;,)3"_M`4S4>C4PA16N[UO2!3$&`L@GE(+)FP9TZ"066 MC9U>;->L/LK:D<);7B$)>X:B?Q162O:`[V58)8BY2T;+ M2CE1=&:[DG8).2<9Z&P?TY1T7PDL5R'$KOM'B`B4OJ6CNKJDW8GMZMLY52VV M&S/8C8A^ZX"(D[8_OYP42OJ&TVL>WZXCE5JUYSU'`;D52D+[=29@W;5V-;2-';+YE> MU`@$@$J+L"\B`V,\DJ#1-E"YJDI%;>"G\D+KL0WT_%V7]4A72,/Y')#E8#)" M4Q]-D,O=\O@\B2$=8@]%KQ+9>7ERAP.=FQU2(AL72E7B?&*:NO+4FW:]#BQ? M0%6*7#*ZM($=;H=^G*&UF_1T]/.R^*>7;).KE=&YW]S"F-FP<8.HZV$:$J@S M4E1DEL>'1+#2\SHED+J/AQX@/AOJ=%/VZSV>-)@ MIR>Y>Y[N,.N1*UE[HY&@R8O*HM4$-M^O4D@H9;F9&&IOK>$SA7^$K,\>#U$< MW2])_[Y.@4$)B8U8<(H5K?"OC,9IVRXZ*!>L+.*KQ%+6V/"J>71R.D+)B^`* M4$0'DQ1/R_C_.F-(KX,:'J%H`VM(DM/K#E*"??;1C5P0:FH1IEU9K@J:QS9R M0&Q&FGX?(!*=S`\FJX`-\&Y])JYP![S"-K3H+9<)S6,0NK@.F"A[]//6J(KN MZ=15;W?JSN`X])AY;!BZ#@FWQDB*6IM5S2YJ=1IK`*KN[MU>;,_.^&EXA.]J MV24$^--(PH7"?5D]-2;VIP&T[F-O9]6Z@0%`WFG9:O"+#89+T.FEAM-+#973 MW\:&OV'R^ZW/?$P7*LOQBPEJ].*"%$!9^K18,2,J";(!.`H7"T]]74Q,8/F5 M!1-M2@$T(PZR0<:\?429#_,5X['6\$P05.6Y>Y/AF0907I$2FZ6/5N!VBMGJ M*'.G>?4>M,]699+]IM2VVV[^-#?8U7N+/EMU,=OE5:!+W8ZTDZR^\LVXYQDR M#*?4]<:[:N9)ZB=W[>2N54]_WR":SMB:UV5<@"E\".?/D`PF>V_;\D-E5Z%: MHWYJY-R9XFJR4=P@+V3?FCS[;-A3C?Q$Z7R;Q95 M>0-%H7LQQ2^78XAB;;(/:26RKYP[YF%Z/2:`8-E]0Z*]DJ!5Q3=)8HZERCFL M@&,>;O`<(-'S>>DFEG8B$I'MRS7%:PE"E23E/R`P!03<0[Z,R1+Q$XTLK=4B MJ23E)F3U`'G$-?*R*A*M-?>RFO(V+'],;+OP+6_`G.T9Z0B';`^954$ID[9Z M$5SI*V@Z6"POZY()\@K[XUM*0\C?GPV%U9R%[:H7HQ6_E2G@N_8.R^9J=NR> MV/).ZGM1NY[^ANFU["H[%B7H;N1"'Q"$)0Z'LGW%78\LWFN^ZUN!^=6G"^BB M"9O>I(Y-)DU58JYI#4D4JH!14=`'+G\B M:7D/WM`\G%]A0O!K_`H3^Y=`=:'(I)NJ^&\)94HV^&:P&K'2\OW&]L[4/0A" MPL,33&@9>SPQ4?7<.:FVE2":,=R3$&_]`#*U!(\,8B2H\1`2EVMI"OEWC_PZ MPCWRN;UK*]^DT^JYDYK&80BRM.0\TU5>XO[+P6QA#/@#BR#TI+$!HTX,;S`>^+^Q'2O?%CV:S/S2'IS*O?^F.=)5B$K+ M^]LJG_]GZR:DI3M93;L*6=(TRGB5,7%[11Q.D6<3A&GJLVK^@_; MIQ]XKT_<:)_SL@:=]1>44M`V?[AXZJ/OVQUHMC[W2&L5*LJ$4MXK>O8NY.4? MJW4*[*0Y+RU:(WKJRI[V5A5]])6X(JA!Z"830#,N5:;@/6#?-=7IEJ96$1DY MAO+N7J:F6;M!&$N7+T^QF%,LYACYAT."QZ$;2$(JZ285CZ((V*VTU*5!D/U& MEJ(>(HG*95YZ9*/D7-O5%*^^C9!L92E,(9:J0/)[W/ZY@TH5B4S4\4:"9-!< M8Y\BQE@L2[XY&C_A*S@$2!1AR"*I7F1!G+:NAE#-Z>T!OJYG#+9=\?""`[W& M5%BZ)X.B>F$#L9Z4"&I_T2#]NDM>EZ1*K_?\&=T)PY=]JNI"5&.)K[8+HF2\ M(?K#[N];.V;3[Y2`>;*"23<,9ICP^#M?-;>-58<2A?JMRJ%P0MLRRRB&LXE& M-+X)"7]?(CY3BT2@;RD"XJH<+IN;@QA,17V#-.]#@ERX>6E=MHM0$57%@5,H M3@O$`=\UJ<@HS;I>GDE;/5<6[9Y_U/SQQ5JY)QH"/'DH M)P^E-OJ[@?.0SUGH>R3[J^6M3T,"?!?VH@H_(^CR"V4(TK@RQ5?"RX<`.HMJ M[$-EW?+"?=?(4RD#ZY%?RKGD0)[9&LW^\G]02P,$%`````@`%G%+0B'(-:/T M!P``$#\``!$`'`!A<&AI+3(P,3(Q,C,Q+GAS9%54"0`#O$$94;Q!&5%U>`L` M`00E#@``!#D!``#M6VUOXS82_GY`_P//G_:`RHJ339L8FRV[M=W2+U8+[0LQVDO=[HONS)GGN',0W$X=,:??GCV/?1( M1$@YN^KTNB<=1)C#7\,'OIGI_V/%VAVCRQ+S1,Z&^)C)+%8$SG!/@D#[)"KSD;*H&_;3T]/7>QY M,.\FH%V'^S;8.>V=GO7`;X\HST9<^+=DA2-/7G5^B["GW>P@")2%?1QL:"-K M6KV@^736Y6(-*B<]^^O]W5Q[FMKU*/NUH/V\%%ZJ?V8K\1*')%574E=F@+SR MN1T+,U6OQN[7.S"<-TIKE"D+)6;.UHF*TTF(OJ$9HP6*4BO"`FI M8P:`P*`."R!?`A(:ET9+#&Z%,A`[)@&)81:7!((X>UX<+!S][JRP(RWR''B8 M8VZ!D@181U,EP^T$)0.4>S!B76$+V^OP)!P%E M*ZZ&U3[H*Q<7`$#JXP"P2_FO'Y8K`8*CJFH^EL M^*`IF,=4FT5FCD^!V#G001*2,RR:CM`6W3)RKP=W@\G-U@.+\<79;!A6'&/>I0$B9D M-],UT_^=.MYHZ'@\C`11_,?6$%^AG#VT-8@P<]$#";C0GU+[+5N@,924#*JG M;!7R`V:JOR]3G8.TC+TA%@Q>GG!&Q'P#*32FL#)JYO&BS&.*0P%`@I&6\3VB#*[W$'W,[O:C MD29G+#-`RWJZQP-Z+3P9K0?1YG]1DE6$SC[TRCRD0H0S:,D9UGH3#.!+. M!H=915`>-?-Y6CG[%0[E@&UC,UJ&Y+<(8AFJDSFKKTJC9C;/JI54BD,QL'5L M-JE+7U/+UM>TO8]O5=.B#^G3WUJV=KG2=(&7GJ'(38;-*W!>4^JB#S&T;916 M3KD\L;N$9GHKES;#0=A6FG-OVBV1F'K55S<=-Y-;=TU#'Q)LVU@M7\T2&A;D M64;I5VM[=,QL-[C,9:2CQ%3;R*^YO14YWG_;*^N;%^6PRU_KUR>[SL4\%!=C ME]#(_.GNJV+K6:XUO?]/+U MW43_'ATS^]4K:OG"_W_N2Y=](_?U.F;N#9?2TM<#_W/:H_381I#554>UBUEI4]@O$%+WV?=2%66YIMU*+UR9A63BU$32 M_%+?A`5&.)2=$HH:.W6^8[]!/$#XH?$4U^A=1>/AY:'1`(1X[RX0>*\/#:2T M%=XV'#MMAH*G;8L4""`2+B1BQC;-7;V'<8?G'7>TF1J(^F2E.$L-6;U3ZZS7 M?0[=V+$#YL\B.G#^%'?8_.9^SH8SIP`UY7F#R6J[*G?,J>)%!M)/ M1\Q>[5UM,OT6%3]:6P.'.E#NA6TR?8I1#\=,7>Z0;31W"M)/A\V^KT.[23+R MA"B@5$:Z5$FP]]TQ'C1,A;G9Y;$SUS<9-_4F;V6X-7*8<[5=YDW>BA2C'@[; MC?4MT(UH**..6!ASX_9A3G`V>8T?]=WNKS\SM2WCFB0_3M&^U/=^#Y:A%/JU M5)BR)KZX^'803K:N.%)$J/K46E'N4NPN--?94S3;?$"(+K:B&V!KH MOI_`9H(_4O7SIA$7MSQ:RE7D)7^N5=]IS[%'P@K?)^EKGLH_KBX]KC MSJ\U<>1TXD#BWZST93K^RJ4Z/IH)Q6LL\#WQET3D(BB-%[QVN8\I^X_E#\[< M<1A&Q!WX:F/DTT5%],=M"T<0]VWVQ2U9RC'<9(5.XV,FB8";S0/45#,B'/7] MT)I,6?*KQ7SB/PR7+"&L7Q"+#^(AOFJ_2;R0Y-S(D8-G6DI]V]$_>;>[LN]2 M\%!EWO$>MV_URU]U/!UON%/^E,V=_J&BLKO+@O?D]`V'=7!);%#_@<5=\&LR MP]3-15"K]=^PZR?D*7USR"/Q>*!D-SR4^4U1IW1TD-F6_L,.?`DGV_84=&=0 MBI-B^WQ\6M;KO>%JOB8F.Z[XH4[_'5!+`0(>`Q0````(`!9Q2T([7,-T["X` M``^/`0`1`!@```````$```"D@0````!A<&AI+3(P,3(Q,C,Q+GAM;%54!0`# MO$$9475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!9Q2T+H*6#R$`<``#%4 M```5`!@```````$```"D@3`L``00E#@``!#D!``!02P$"'@,4````"``6<4M",7\[KTX1``"A M$`$`%0`8```````!````I(&6-@``87!H:2TR,#$R,3(S,5]D968N>&UL550% M``.\01E1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`%G%+0OP1QUF-)0`` MS2("`!4`&````````0```*2!,T@``&%P:&DM,C`Q,C$R,S%?;&%B+GAM;%54 M!0`#O$$9475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`!9Q2T(MV9X-.!4` M`/UM`0`5`!@```````$```"D@0]N``!A<&AI+3(P,3(Q,C,Q7W!R92YX;6Q5 M5`4``[Q!&5%U>`L``00E#@``!#D!``!02P$"'@,4````"``6<4M"(<@UH_0' M```0/P``$0`8```````!````I(&6@P``87!H:2TR,#$R,3(S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``U8L````` ` end XML 29 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
BALANCE SHEET [Parenthetical] (USD $)
Dec. 31, 2012
Jun. 30, 2012
Allowances for accounts receivable (in dollars) $ 300,000 $ 300,000
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,500,000 1,500,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 30,000,000 30,000,000
Common stock, shares issued 10,427,878 10,427,878
Common stock, shares outstanding 8,030,247 8,124,386
Treasury stock, at cost 2,397,631 2,303,492
Series A Preferred Stock [Member]
    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 200,000 200,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 30 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share Repurchases
 6 Months Ended
Dec. 31, 2012
Share Repurchases [Abstract]  
Share Repurchases [Text Block]

7. Share Repurchases

 

On November 21, 2012 the Company’s Board of Directors approved the purchase of up to 100,000 shares of the Company’s common stock. This authority terminates on February 19th, 2013. Pursuant to this authorization, the Company repurchased 94,139 shares of stock at an average price of $2.54 for an aggregate total purchase price of $240,952.
XML 31 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Baralyme Agreement
 6 Months Ended
Dec. 31, 2012
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue Disclosure [Text Block]

6. Baralyme® Agreement

 

A reconciliation of deferred revenue resulting from the agreement with Abbott Laboratories (“Abbott”), with the amounts received under the agreement, and amounts recognized as net sales is as follows:

 

    Three Months ended     Six Months ended  
    December 31,     December 31,  
    2012     2011     2012     2011  
                         
Beginning balance   $ -     $ 630,850     $ 114,700     $ 802,900  
                                 
Revenue recognized                                
as net sales     0       (172,050 )     (114,700 )     (344,100 )
      0       458,800       0       458,800  
Less - Current portion                                
of deferred revenue     0       (458,800 )     0       (458,800 )
    $ 0     $ 0     $ 0     $ 0  

 

In addition to the provisions of the agreement relating to the withdrawal of the Baralyme® product, Abbott agreed to pay Allied up to $2,150,000 in product development costs to pursue development of a new carbon dioxide absorption product for use in connection with inhalation anesthetics that does not contain potassium hydroxide and does not produce a significant exothermic reaction with currently available inhalation agents. As of December 31, 2012, $2,150,000 has been received as a result of product development activities.

 
XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share Repurchases (Details Textual) (USD $)
 1 Months Ended
Nov. 30, 2012
Nov. 21, 2012
Stock Repurchase Program, Number of Shares Authorized to be Repurchased   100,000
Stock Repurchased During Period, Shares 94,139  
Stock Repurchased Price Per Share $ 2.54  
Stock Repurchased During Period, Value $ 240,952  
XML 33 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitments and Contingencies (Details Textual) (Niagara [Member], USD $)
 6 Months Ended
Dec. 31, 2012
Niagara [Member]
  
Loss Contingency, Damages Sought, Value $ 469,000
Bond Issued Amount $ 250,000
XML 34 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Inventories (Tables)
 6 Months Ended
Dec. 31, 2012
Inventory, Net [Abstract]  
Schedule of Inventory, Current [Table Text Block]

Inventories are comprised as follows:

 

    December 31, 2012     June 30, 2012  
             
Work-in progress   $ 689,645     $ 654,677  
Component parts     7,799,890       7,495,333  
Finished goods     2,849,782       3,178,507  
Reserve for obsolete and excess inventory     (1,289,733 )     (1,327,291 )
    $ 10,049,584     $ 10,001,226  

 
XML 35 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Subsequent Events
 6 Months Ended
Dec. 31, 2012
Subsequent Events [Abstract]  
Subsequent Events [Text Block]

8. Subsequent Events

 

The Company’s product liability insurer, Medmarc Insurance Group, demutualized and was acquired by ProAssurance Corporation on January 1, 2013. As a policyholder of a mutual insurance company, Allied was entitled to receive a portion of the proceeds received by Medmarc. In January 2013 the Company received a cash payment of approximately $516,000 and will reflect a gain of this amount in the quarter ended March 31, 2013.
XML 36 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting and Reporting Policies (Policies)
 6 Months Ended
Dec. 31, 2012
Accounting Policies [Abstract]  
Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

 

The accompanying unaudited financial statements of Allied Healthcare Products, Inc. (the “Company”) have been prepared in accordance with the instructions for Form 10-Q and do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments considered necessary for a fair presentation, have been included. Operating results for any quarter are not necessarily indicative of the results for any other quarter or for the full year. These statements should be read in conjunction with the financial statements and notes to the financial statements thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2012.
New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

 

We have reviewed accounting pronouncements and interpretations thereof issued by the FASB, AICPA and the SEC that have effective dates during the periods reported and in future periods. Management does not believe that any of those pronouncements will have a material impact on the Company’s present or future financial statements.
Fair Value Of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts receivable and accounts payable. The carrying amounts for cash, accounts receivable and accounts payable approximate their fair value due to the short maturity of these instruments.
XML 37 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Baralyme Agreement (Tables)
 6 Months Ended
Dec. 31, 2012
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

A reconciliation of deferred revenue resulting from the agreement with Abbott Laboratories (“Abbott”), with the amounts received under the agreement, and amounts recognized as net sales is as follows:

 

    Three Months ended     Six Months ended  
    December 31,     December 31,  
    2012     2011     2012     2011  
                         
Beginning balance   $ -     $ 630,850     $ 114,700     $ 802,900  
                                 
Revenue recognized                                
as net sales     0       (172,050 )     (114,700 )     (344,100 )
      0       458,800       0       458,800  
Less - Current portion                                
of deferred revenue     0       (458,800 )     0       (458,800 )
    $ 0     $ 0     $ 0     $ 0  
XML 38 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Baralyme Agreement (Details) (USD $)
 3 Months Ended 6 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Jun. 30, 2012
Beginning balance $ 0 $ 630,850 $ 114,700 $ 802,900  
Revenue recognized as net sales 0 (172,050) (114,700) (344,100)  
Ending balance 0 458,800 0 458,800  
Less - Current portion of deferred revenue 0 (458,800) 0 (458,800) (114,700)
Noncurrent portion of deferred revenue $ 0 $ 0 $ 0 $ 0  
XML 39 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
STATEMENT OF CASH FLOWS (USD $)
 6 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Cash flows from operating activities:    
Net loss $ (879,725) $ (122,278)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 650,379 627,378
Stock based compensation 22,428 21,695
Provision for doubtful accounts and sales returns and allowances 17,054 17,030
Deferred taxes (8,971) (8,678)
Changes in operating assets and liabilities:    
Accounts receivable 1,274,952 1,138,044
Inventories (48,358) (519,444)
Income tax receivable (537,664) (73,929)
Other current assets (189,405) (290,234)
Accounts payable (103,263) 383,071
Deferred revenue (114,700) (344,100)
Other accrued liabilities 106,246 (177,084)
Net cash provided by operating activities 188,973 651,471
Cash flows from investing activities:    
Capital expenditures (646,233) (912,994)
Net cash used in investing activities (646,233) (912,994)
Cash flows from financing activities:    
Purchases of treasury stock (240,952) 0
Net cash used in financing activities (240,952) 0
Net increase (decrease) in cash and cash equivalents (698,212) (261,523)
Cash and cash equivalents at beginning of period 5,284,543 6,512,887
Cash and cash equivalents at end of period $ 4,586,331 $ 6,251,364
XML 40 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Financing
 6 Months Ended
Dec. 31, 2012
Debt Disclosure [Abstract]  
Debt Disclosure [Text Block]

5. Financing

 

The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the “Credit Agreement”) pursuant to which the Company obtained a secured revolving credit facility with borrowing availability of up to $7,500,000 (the “Credit Facility”). The Company’s obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement.

 

The Credit Facility was amended on November 12, 2012 extending the maturity date to November 12, 2013, reducing the borrowing availability from $7,500,000 to $5,000,000, and removing all financial covenants. The Credit Facility will be available on a revolving basis until it expires on November 12, 2013, at which time all amounts outstanding under the Credit Facility will be due and payable. Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to 3.50% in excess of the 30-day LIBOR rate. Advances may be prepaid in whole or in part without premium or penalty.

 

Under the Credit Agreement, advances are generally subject to customary borrowing conditions. The Credit Agreement also contains covenants with which the Company must comply during the term of the Credit Facility. Among other things, such covenants restrict the Company’s ability to incur certain additional debt; make specified restricted payments, dividends and capital expenditures; authorize or issue capital stock; enter into certain transactions with affiliates; consolidate or merge with or acquire another business; sell certain of its assets or dissolve or wind up the Company. The Credit Agreement also contains certain events of default that are customary for financings of this type including, without limitation: the failure to pay principal, interest, fees or other amounts when due; the breach of specified representations or warranties contained in the loan documents; cross-default with certain other indebtedness of the Company; the entry of uninsured judgments that are not bonded or stayed; failure to comply with the observance or performance of specified agreements contained in the loan documents; commencement of bankruptcy or other insolvency proceedings; and the failure of any of the loan documents entered into in connection with the Credit Facility to be in full force and effect. After an event of default, and upon the continuation thereof, the principal amount of all loans made under the Credit Facility would bear interest at a rate per annum equal to 4.00% above the otherwise applicable interest rate (provided, that the interest rate may not exceed the highest rate permissible under law), and the lender would have the option to accelerate maturity and payment of the Company’s obligations under the Credit Facility.

 

The 30-day LIBOR rate was 0.21% on December 31, 2012.

 

At December 31, 2012 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.
XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 20 110 1 false 3 0 false 4 false false R1.htm 001 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://www.alliedhpi.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION false false R2.htm 002 - Statement - STATEMENT OF OPERATIONS Sheet http://www.alliedhpi.com/role/STATEMENTOFOPERATIONS STATEMENT OF OPERATIONS true false R3.htm 003 - Statement - BALANCE SHEET Sheet http://www.alliedhpi.com/role/BALANCESHEET BALANCE SHEET false false R4.htm 004 - Statement - BALANCE SHEET [Parenthetical] Sheet http://www.alliedhpi.com/role/BALANCESHEETParenthetical BALANCE SHEET [Parenthetical] false false R5.htm 005 - Statement - STATEMENT OF CASH FLOWS Sheet http://www.alliedhpi.com/role/STATEMENTOFCASHFLOWS STATEMENT OF CASH FLOWS false false R6.htm 006 - Disclosure - Summary of Significant Accounting and Reporting Policies Sheet http://www.alliedhpi.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting and Reporting Policies false false R7.htm 007 - Disclosure - Inventories Sheet http://www.alliedhpi.com/role/Inventories Inventories false false R8.htm 008 - Disclosure - Earnings per share Sheet http://www.alliedhpi.com/role/EarningsPerShare Earnings per share false false R9.htm 009 - Disclosure - Commitments and Contingencies Sheet http://www.alliedhpi.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R10.htm 010 - Disclosure - Financing Sheet http://www.alliedhpi.com/role/Financing Financing false false R11.htm 011 - Disclosure - Baralyme Agreement Sheet http://www.alliedhpi.com/role/BaralymeAgreement Baralyme Agreement false false R12.htm 012 - Disclosure - Share Repurchases Sheet http://www.alliedhpi.com/role/ShareRepurchases Share Repurchases false false R13.htm 013 - Disclosure - Subsequent Events Sheet http://www.alliedhpi.com/role/SubsequentEvents Subsequent Events false false R14.htm 014 - Disclosure - Summary of Significant Accounting and Reporting Policies (Policies) Sheet http://www.alliedhpi.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting and Reporting Policies (Policies) false false R15.htm 015 - Disclosure - Inventories (Tables) Sheet http://www.alliedhpi.com/role/InventoriesTables Inventories (Tables) false false R16.htm 016 - Disclosure - Baralyme Agreement (Tables) Sheet http://www.alliedhpi.com/role/BaralymeAgreementTables Baralyme Agreement (Tables) false false R17.htm 017 - Disclosure - Inventories (Details) Sheet http://www.alliedhpi.com/role/InventoriesDetails Inventories (Details) false false R18.htm 018 - Disclosure - Earnings per share (Details Textual) Sheet http://www.alliedhpi.com/role/EarningsPerShareDetailsTextual Earnings per share (Details Textual) false false R19.htm 019 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.alliedhpi.com/role/CommitmentsAndContingenciesDetailsTextuals Commitments and Contingencies (Details Textual) false false R20.htm 020 - Disclosure - Financing (Details Textual) Sheet http://www.alliedhpi.com/role/FinancingDetailTextuals Financing (Details Textual) false false R21.htm 021 - Disclosure - Baralyme Agreement (Details) Sheet http://www.alliedhpi.com/role/BaralymeAgreementDetails Baralyme Agreement (Details) false false R22.htm 022 - Disclosure - Baralyme Agreement (Details Textual) Sheet http://www.alliedhpi.com/role/BaralymeAgreementDetailsTextual Baralyme Agreement (Details Textual) false false R23.htm 023 - Disclosure - Share Repurchases (Details Textual) Sheet http://www.alliedhpi.com/role/ShareRepurchasesDetailsTextual Share Repurchases (Details Textual) false false R24.htm 024 - Disclosure - Subsequent Events (Details Textual) Sheet http://www.alliedhpi.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) false false All Reports Book All Reports Element us-gaap_PaymentsForRepurchaseOfCommonStock had a mix of decimals attribute values: -3 0. Process Flow-Through: 002 - Statement - STATEMENT OF OPERATIONS Process Flow-Through: 003 - Statement - BALANCE SHEET Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: 004 - Statement - BALANCE SHEET [Parenthetical] Process Flow-Through: 005 - Statement - STATEMENT OF CASH FLOWS aphi-20121231.xml aphi-20121231.xsd aphi-20121231_cal.xml aphi-20121231_def.xml aphi-20121231_lab.xml aphi-20121231_pre.xml true true XML 42 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Financing (Details Textual) (USD $)
 6 Months Ended
Dec. 31, 2012
Nov. 17, 2009
Line Of Credit Facility, Maximum Borrowing Capacity $ 5,000,000 $ 7,500,000
Debt Instrument, Maturity Date Nov. 12, 2013  
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum 3.50%  
Debt Instrument Interest Rate Percentage On Default 4.00%  
Debt Instrument, Basis Spread On Variable Rate 0.21%